<SEC-DOCUMENT>0001437749-22-022258.txt : 20220913
<SEC-HEADER>0001437749-22-022258.hdr.sgml : 20220913
<ACCEPTANCE-DATETIME>20220913084534
ACCESSION NUMBER:		0001437749-22-022258
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		29
CONFORMED PERIOD OF REPORT:	20220909
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220913
DATE AS OF CHANGE:		20220913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33678
		FILM NUMBER:		221239794

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nby20220909_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:nby="http://www.nby.com/20220909"><head>
	<title>nby20220909_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 9/13/2022 2:15:03 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0001389545</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="nby-20220909.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-09-09</xbrli:startDate>
<xbrli:endDate>2022-09-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d) of the</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of earliest event reported: </b><ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September<b> </b>9, 2022</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName">NovaBay Pharmaceuticals, Inc.</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact Name of Registrant as Specified in Charter)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber">001-33678</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber">68-0454536</ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or Other Jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of Incorporation)</b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission File Number)</b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1">2000 Powell Street, Suite 1150</ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown">Emeryville</ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode">94608</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of Principal Executive Offices) (Zip Code)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode">510</ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber">899-8800</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Registrant</b>&#8217;<b>s telephone number, including area code)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:16.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Title of Each Class</span></b></div>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:11.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Trading Symbol(s)</span></b></div>
			</td>
			<td style="vertical-align:top;width:0.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:16.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Name of Each Exchange On Which</span></b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Registered</span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:16.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.01 per share</div>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&#xa0;</td>
			<td style="vertical-align:top;width:11.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:TradingSymbol">NBY</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:0.7%;">&#xa0;</td>
			<td style="vertical-align:top;width:16.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE</ix:nonNumeric> American</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter). Emerging growth company&#xa0;<ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#9744;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&#xa0;1.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Entry into a Material Definitive Agreement.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On September 9, 2022, NovaBay Pharmaceuticals, Inc. (the &#8220;<i>Company</i>&#8221;) entered into written agreements relating to the following two private financing transactions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">Warrant Reprice Transactions</span>. Warrant reprice transactions with certain existing Company warrant holders to amend previously issued common stock, par value $0.01 per share (&#8220;<i>Common Stock</i>&#8221;), purchase warrants to reduce the exercise price, provide for an initial cash exercise by certain warrant holders and the issuance of a new common stock purchase warrant to such exercising holders, as well as provide for other terms as described in further detail under the heading &#8220;Warrant Reprice Transactions, Initial Exercise and Issuance of New Warrants&#8221;&#xa0;below (the &#8220;<i>Warrant Reprice Transactions</i>&#8221;).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">Private Placement</span>. A private placement transaction with institutional accredited investors to sell Company units (&#8220;<i>Units</i>&#8221;) that will consist of (i)&#xa0;a newly designated Series C Non-Voting Convertible Preferred Stock, par value $0.01 per share (&#8220;<i>Series C Preferred Stock</i>&#8221;), (ii) a new short-term Series A-1 warrant to purchase common stock (&#8220;<i>Short-Term Warrants</i>&#8221;), and (iii) a new long-term Series A-2 warrant to purchase common stock (&#8220;<i>Long-Term Warrants</i>&#8221;&#xa0;and, together with the Short-Term Warrants, the &#8220;<i>2022 Warrants</i>&#8221;), as described in further detail under the heading &#8220;2022 Private Placement&#8221;&#xa0;below (the &#8220;<i>2022 Private Placement</i>&#8221;).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrant Reprice Transactions, Initial Exercise and Issuance of New Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As previously disclosed in the Company&#8217;s Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the &#8220;<i>Commission</i>&#8221;) on July 21, 2020 and November 1, 2021, respectively, the Company issued (i) Common Stock purchase warrants to a limited number of accredited investors (the &#8220;<i>2020 Investors</i>&#8221;) in connection with the Company&#8217;s prior warrant reprice transaction that closed on July 23, 2020 (the &#8220;<i>2020 Original Warrants</i>&#8221;), and (ii) Common Stock purchase warrants to a limited number of accredited investors (the &#8220;<i>2021</i> <i>Investors</i>&#8221;) in connection with the Company&#8217;s private placement financing transaction that closed on November 2, 2021 (the &#8220;<i>2021 Original Warrants</i>&#8221;). The 2020 Original Warrants have an aggregate of 6,898,566 underlying shares of Common Stock that are currently exercisable at $1.65 per share. The 2021 Original Warrants have an aggregate of 37,500,000 underlying shares of Common Stock that are currently exercisable at $0.53 per share.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"><span style="text-decoration: underline;">Reprice Letter Agreements </span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By letter agreement, dated September 9, 2022, the Company provided the 2020 Investors holding 2020 Original Warrants (the &#8220;<i>2020 Reprice Letter Agreement</i>&#8221;) and the 2021 Investors holding 2021 Original Warrants (the &#8220;<i>2021 Reprice Letter Agreement</i>&#8221; and together with the 2020 Reprice Letter Agreement, the &#8220;<i>Reprice Letter Agreements</i>&#8221;) with an opportunity to amend their respective warrants to reduce their exercise price and, in the case of the 2021 Original Warrants, extend the term of those warrants, in exchange for such warrant holders agreeing to certain limits on future warrant exercises for a period of time and entering into voting commitments on the terms set forth below. As further described below, the Reprice Letter Agreements also provided the 2020 Investors and the 2021 Investors with the opportunity to make a cash exercise of their respective warrants at the reduced exercise price and to receive a new Common Stock purchase warrant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to entering into the Reprice Letter Agreements, each of the 2020 Investors who participated in the Warrant Reprice Transaction (the &#8220;<i>2020 Participants</i>&#8221;) and each of the 2021 Investors who participated in the Warrant Reprice Transaction (the &#8220;<i>2021 Participants</i>&#8221; and together with the 2020 Participants, the &#8220;<i>Participants</i>&#8221;) also signed and delivered a voting commitment letter (the &#8220;<i>Participant Voting Commitment</i>&#8221;) to support the Reverse Stock Split Approval and the Company Guide Approval (each as defined and discussed below), and entered into a Leak-Out Agreement, dated September 9, 2022 (the &#8220;<i>Leak-Out Agreement</i>&#8221;), which limits the Participant&#8217;s trading in Common Stock until and including September 13, 2022. The Reprice Letter Agreements became effective and the Warrant Reprice Transactions were completed, which resulted in the Company receiving gross proceeds of $2,065,500 from the Initial Exercise, as discussed further below.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="text-decoration: underline;">Amended Warrants</span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result of the completion of the Warrant Reprice Transactions and pursuant to the Reprice Letter Agreements, the 2020 Original Warrants held by the 2020 Participants have been amended (&#8220;<i>Amended 2020 Warrants</i>&#8221;) and the 2021 Original Warrants held by the 2021 Participants have each been amended (&#8220;<i>Amended 2021 Warrants</i>&#8221;) to provide for, among other terms, the following:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline;">Reduced Exercise Price</span></i>: The exercise price of the Amended 2020 Warrants and the Amended 2021 Warrants being reduced to $0.18 (the &#8220;<i>Reduced Exercise Price</i>&#8221;).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline;">Limitation on Future Exercise</span></i>: The Amended 2020 Warrants and the Amended 2021 Warrants being subject to a new restriction on the holder&#8217;s ability to exercise their warrant subsequent to the Initial Exercise (as defined below) until the later to occur of (i) six months and (ii) the date on which the Reverse Stock Split Approval and any Company Guide Approval have been obtained at a meeting of Company stockholders and such approvals become effective, including under the laws of the State of Delaware as applicable (the &#8220;<i>Stockholder Approval Date</i>&#8221;).<b>&#xa0;&#xa0;</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline;">Termination Date</span></i>: The Termination Date of the 2021 Original Warrants being extended to September 11, 2028. The Termination Date of the 2020 Original Warrants remains the same and was not extended.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline;">New Warrants and Resale Registration </span></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the Reprice Letter Agreements, (i) the 2020 Participants had the opportunity (but were not required) to elect to make a cash exercise of a portion of their Amended 2020 Warrants at the Reduced Exercise Price, which resulted in the exercise of an aggregate of 2,100,000 shares of Common Stock ( the &#8220;<i>2020 Initial Exercise</i>&#8221;) and (ii) the 2021 Participants all agreed to exercise an aggregate of 9,375,000 shares, or 25% of the shares of Common Stock underlying their respective Amended 2021 Warrants, at the Reduced Exercise Price (the &#8220;<i>2021 Initial Exercise</i>&#8221; and, together with the 2020 Initial Exercise, the &#8220;<i>Initial Exercise</i>&#8221;). The Company received $2,065,500 in aggregate gross proceeds from the Initial Exercise. In exchange, the 2021 Participants and the 2020 Participants that elected to participate in the Initial Exercise received a New Warrant (as described below). The 2020 Participants that did not make a 2020 Initial Exercise did not receive a New Warrant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company issued to each 2021 Participant and each 2020 Participant that participated in the 2020 Initial Exercise a New Warrant to purchase a number of shares of Common Stock equal to 100% of the shares of Common Stock received by such Participant in its Initial Exercise. The form of New Warrants issued to all 2021 Participants (the &#8220;<i>New 2021 Participant Warrants</i>&#8221;) is substantially similar to the 2021 Original Warrants, and the form of New Warrants being issued to the 2020 Participants that elected to make a 2020 Initial Exercise (the &#8220;<i>New 2020 Participant Warrants</i>&#8221; and, together with the New 2021 Participant Warrants, the &#8220;<i>New Warrants</i>&#8221;) is substantially similar to the 2020 Original Warrants. All of the New Warrants will be initially exercisable on the <i>later to occur</i> of (i) the six month anniversary of the date of issuance and (ii) the Stockholder Approval Date. In addition, the New Warrants will have a term of exercise of six (6) years and an exercise price equal to $0.18. The New Warrants are also subject to a provision prohibiting the exercise thereof to the extent that, after giving effect to such exercise, the holder of such Warrant (together with the holder&#8217;s affiliates, and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates), would beneficially own in excess of 4.99% or 9.99% of outstanding Common Stock. The New Warrants do not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of the Company.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the Reprice Letter Agreements, the Company agreed to prepare and file a registration statement with the Commission that will cover the resale of all of the Common Stock underlying the New Warrants (the&#xa0;&#8220;<i>New Warrant Shares</i>&#8221;) within 30 days of the Stockholder Approval Date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline;">Stockholder Approval and Other Commitments</span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reverse Stock Split Approval</i>. Pursuant to the Reprice Letter Agreements, within 75 days of closing the Warrant Reprice Transactions, the Company must call a special meeting to seek stockholder approval of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split (the &#8220;<i>Reverse Stock Split</i>&#8221;) of the outstanding shares of Common Stock, which Reverse Stock Split will have a ratio of not less than 1-for-10 and not more than 1-for-35 (each 10 to 35 shares, as the case may be, of Common Stock will be combined to become one share of Common Stock without change to the number of authorized shares of Common Stock of the Company) (the &#8220;<i>Reverse</i>&#xa0;<i>Stock</i>&#xa0;<i>Split</i>&#xa0;<i>Approval</i>&#8221;). If the Reverse Stock Split Approval is not initially obtained at such stockholder meeting, then the Company will be required to call a stockholder meeting every four months thereafter to seek the Reverse Stock Split Approval until it is obtained.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Company Guide Approval</i>. In addition, the Reprice Letter Agreements require the Company to seek such stockholder approvals as may be required to comply with the continued listing rules of the NYSE American Company Guide, including pursuant to Section 713, of the NYSE American Company Guide (the &#8220;<i>Company Guide Approval</i>&#8221;).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Voting Commitments</i>. At the time the Participants entered into their respective Reprice Letter Agreements, each Participant also entered into a Participant Voting Commitment that provides for such Participant to vote its shares of Common Stock in favor of the Reverse Stock Split Approval and the Company Guide Approval. The Reprice Letter Agreements also required the Company to obtain similar voting commitments from the Company&#8217;s executive officers, directors, more than 10% stockholders and certain other significant stockholders to vote in favor of the Reverse Stock Split Approval and the Company Guide Approval (the &#8220;<i>Additional Voting Commitments</i>&#8221;).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The foregoing summaries of the material terms of the Amended Warrants, the New Warrants, the Reprice Letter Agreements, the Participant Voting Commitments, the Additional Voting Commitments, and the Leak-Out Agreements are not complete and are qualified in their entirety by reference to the full text thereof, copies of which are filed herewith as Exhibits 4.1, 4.2, 4.3, 4.4, 10.1, 10.2, 10.5, 10.6, and 10.7, respectively, and incorporated by reference herein.<b> </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Anti-Dilution Adjustment to Series B Preferred Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Certificate of Designation of Preferences, Rights and Limitations for the Company&#8217;s outstanding Series B Non-Voting Convertible Preferred Stock (the &#8220;<i>Series B Preferred Stock</i>&#8221;), par value $0.01 per share (the&#xa0;&#8220;<i>Series B Certificate of Designation</i>&#8221;) provides for anti-dilution protections in the event that the Company grants any right to reprice any Company security or issue a new Company security that would entitle the holder to acquire Common Stock at an effective price per share that is lower than the conversion price of the Series B Preferred Stock, which is referred to as &#8220;full-ratchet&#8221; anti-dilution protection. As a result of the consummation of the Warrant Reprice Transactions that resulted in the Amended Warrants being exercisable at the Reduced Exercise Price and the issuance of New Warrants at the same exercise price, this anti-dilution protection in the Series B Certificate of Designation was triggered. Accordingly, the conversion price of each share of Preferred Stock, which was $0.40 into 2,500 shares of Common Stock, has automatically adjusted downward to now be $0.18 into 5,556 shares of Common Stock. The adjusted conversion price of the Series B Preferred Stock is the same as the Reduced Exercise Price and the exercise price of the New Warrants. Therefore, based on the 11,620 shares of Preferred Stock currently outstanding there will be an additional 35,510,720 shares of Common Stock issuable upon conversion.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2022 Private Placement </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On September 9, 2022, the Company entered into a Securities Purchase Agreement (the &#8220;<i>Securities Purchase Agreement</i>&#8221;) with each of the purchasers named therein (the &#8220;<i>2022 Purchasers</i>&#8221;) that provides for the Company to sell in a private placement Units, with each Unit consisting of (i) one share of Series C Preferred Stock, (ii)&#xa0;one Long-Term Warrant, and (iii) one Short-Term Warrant. The Company expects to close the 2022 Private Placement in the fourth quarter of 2022 after the Stockholder Approval Date (the &#8220;<i>2022 Private Placement Closing Date</i>&#8221;), for gross proceeds of $3,250,000, subject to satisfaction of the closing conditions in the Securities Purchase Agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company intends to use the net proceeds from the 2022 Private Placement for working capital and general corporate purposes, and has agreed to not use such proceeds for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), for the redemption of any Common Stock, for the settlement of any outstanding litigation, or in violation of the Foreign Corrupt Practices Act of 1977, as amended, or the regulations promulgated by the Office of Foreign Assets Control of the U.S. Treasury Department.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><span style="text-decoration: underline;">Securities Purchase Agreement</span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Securities Purchase Agreement entered into by the Company and the Purchasers contains representations, warranties, and covenants of the Company and each of the Purchasers, as well as indemnification rights and other obligations of the parties.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The closing of the 2022 Private Placement will not occur until on or after the Stockholder Approval Date, and is conditioned upon the Company obtaining the Reverse Stock Split Approval and any Company Guide Approval, and the amendment to the Company&#8217;s certificate of incorporation to effect the Reverse Stock Split has been filed with and accepted by the Secretary of State of Delaware. These closing conditions are in addition to other customary closing conditions, including the accuracy of the representations and warranties in the Securities Purchase Agreement, the compliance by the parties with the covenants in the Securities Purchase Agreement, material adverse effect occurred with respect to the Company, and no suspension in the trading of the Common Stock. The parties were also provided with customary termination rights, including the right of the Company or any Purchaser to terminate the Securities Purchase Agreement if the consummation of the 2022 Private Placement has not occurred on or before the fifth (5<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) trading day following the date the Reverse Stock Split Approval and the Company Guide Approval are received and effective.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="text-decoration: underline;">Description of Series C Preferred Stock</span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series C Preferred Stock to be issued in the 2022 Private Placement are set forth in the Company&#8217;s form of Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Preferred Stock (the &#8220;<i>Series C Certificate of Designation</i>&#8221;), which form is attached as&#xa0;Exhibit 3.1&#xa0;to this Current Report on Form 8-K. The Series C Certificate of Designation&#xa0;will be filed with the Delaware Secretary of State prior to the closing of the 2022 Private Placement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Voting Rights</i></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The holders of shares of the Series C Preferred Stock generally will have no voting rights, except as required by law, and except that the consent of the majority of holders of the outstanding Series C Preferred Stock would be required to: (i) alter or change adversely the powers, preferences or rights given to the Series C Preferred Stock or alter or amend the Series C Certificate of Designation, (ii)&#xa0;amend the Certificate of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of the Series C Preferred Stock, (iii) increase the number of authorized shares of Series C Preferred Stock, and (iv) enter into any agreement with respect to any of the foregoing.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Dividends</i></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Holders of the Series C Preferred Stock will be entitled to receive, and the Company will be required to pay, dividends on shares of the Series C Preferred Stock equal (on an as if converted to Common Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. The Series C Preferred Stock will not be entitled to any other dividends.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Conversion and Limitations</i></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each share of Series C Preferred Stock that the Company issues in the Private Placement will be convertible at a current conversion price of $0.18 into 5,556 shares of Common Stock, or an aggregate of 18,057,000 shares of Common Stock (as the same may be adjusted for the Reverse Stock Split), subject to certain limitations upon conversion. The conversion price for the Series C Preferred Stock and the number of shares of Common Stock issuable upon conversion will be adjusted to reflect the Reverse Stock Split. Pursuant to the Series C Certificate of Designation, the Series C Preferred Stock will be subject to another limitation upon conversion of the Preferred Stock to the extent that, after giving effect to such conversion, the holder of such Series C Preferred Stock (together with the holder&#8217;s affiliates, and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates), would beneficially own in excess of 4.99% or 9.99% of the outstanding Common Stock. <b> </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Dilution Protection</i></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event the Company, at any time after the 2022 Private Placement Closing Date and while at least one share of Series C Preferred Stock is outstanding: (i) pays a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon conversion of the Series C Preferred Stock or payment of a dividend on the Series C Preferred Stock); (ii) subdivides outstanding shares of Common Stock into a larger number of shares; (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the conversion price of the Series C Preferred Stock will be adjusted as provided in the Series C Certificate of Designation. Any adjustment made pursuant to the Series C Certificate of Designation will become effective immediately after the effective date of the applicable event described in subsections (i)&#xa0;through (iv) above. In addition, if the Company at any time while the Series C Preferred Stock is outstanding, but prior to the Ratchet Termination Date (as defined in the Series C Certificate of Designation) sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or any securities of the Company or any of its subsidiaries that would entitle the holder thereof to acquire Common Stock at an effective price per share that is lower than the then conversion price of the Series C Preferred Stock, then the conversion price of the Series C Preferred Stock will be reduced to such lower price, which is referred to as a &#8220;full-ratchet&#8221; anti-dilution protection. This full-ratchet anti-dilution protection is subject to termination as provided in the Series C Certificate of Designation upon the earlier of: (a) the Common Stock achieving an average trading price of 250% of the conversion price during any 10 days during a 30-consecutive trading day period and (b) 75% of the Series C Preferred Stock issued on the original issue date has been converted. The holders of Series C Preferred Stock will not have any preemptive rights as a result of their ownership of Series C Preferred Stock.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Liquidation Preference</i></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of Series C Preferred Stock will be entitled to receive the same amount that a holder of Common Stock would receive if the Series C Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="text-decoration: underline;">Description of 2022 Warrants</span></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The terms of the 2022 Warrants to be issued in the Private Placement shall be as set forth in the form of Long-Term Warrant and Short-Term Warrant attached as Exhibits 4.5 and 4.6 to this Current Report on Form 8-K. The 2022 Warrants will have an exercise price equal to $0.18, subject to customary anti-dilution adjustments as provided in the 2022 Warrants. The Long-Term Warrants will be immediately exercisable for a period of six (6) years after the date of issuance and the Short-Term Warrants will be immediately exercisable for a period of eighteen (18) months after the date of issuance. The 2022 Warrants will be exercisable for an aggregate of 36,111,114 shares of Common Stock. The exercise price for the 2022 Warrants and the number of shares of Common Stock underlying the 2022 Warrants will be adjusted at the time of issuance to reflect the Reverse Stock Split.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2022 Warrants are subject to a provision prohibiting the exercise of such 2022 Warrants to the extent that, after giving effect to such exercise, the holder of such 2022 Warrant (together with the holder&#8217;s affiliates, and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates), would beneficially own in excess of 4.99% or 9.99% of the outstanding Common Stock.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2022 Warrants will not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of the Company.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="text-decoration: underline;">Registration Rights Agreement</span></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Securities Purchase Agreement and at the closing of the 2022 Private Placement, the Company will enter into a registration rights agreement (the &#8220;<i>Registration Rights Agreement</i>&#8221;) with the 2022 Purchasers to register the Common Stock underlying the Series C Preferred Stock (the &#8220;<i>Series C Preferred Stock Conversion Shares</i>&#8221;) and the Common Stock underlying the 2022 Warrants (the &#8220;<i>2022 Warrant Shares</i>&#8221; and, together with the Series C Preferred Stock Conversion Shares the &#8220;<i>2022 Underlying Shares</i>&#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company will be required to file an initial registration statement with the Commission covering the resale of the 2022 Underlying Shares no later than 30 days after the Stockholder Approval Date and to use best efforts to have the registration statement declared effective as promptly as practical thereafter.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The foregoing summaries of the material terms of the Securities Purchase Agreement, the Series C Certificate Designation, the Long-Term Warrants, the Short-Term Warrants, and the Registration Rights Agreement are not complete and are qualified in their entirety by reference to the full text thereof, copies of which are filed herewith as Exhibits&#xa0;10.3, 3.1, 4.5, 4.6, and 10.4, respectively, and incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Private Placement Exemption</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None of the issuance of the New Warrants and the New Warrants Shares in the Warrant Reprice Transactions, and the Units, the Series C Preferred Stock, the 2022 Warrants, or the 2022 Underlying Shares in the 2022 Private Placement (collectively, the &#8220;<i>2022 Securities</i>&#8221;), have been or will be registered at the time of issuance by the Company under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company is relying on the private placement exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the&#xa0;&#8220;<i>Securities Act</i>&#8221;), and by Rule 506 of Regulation D promulgated thereunder, and in reliance on similar exemptions under applicable state laws. No form of general solicitation or general advertising was conducted in connection with the issuance either in the Warrant Reprice Transaction or the 2022 Private Placement. The 2022 Securities issued in each of these private placement transactions contain (or will contain, where applicable) restrictive legends preventing the sale, transfer, or other disposition of such securities, unless registered under the Securities Act, or pursuant to an exemption therefrom. The disclosure contained in this Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, and is made only as required under applicable rules for filing current reports with the Commission.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Placement Agent</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ladenburg Thalmann &amp; Co. Inc. (&#8220;<i>Ladenburg</i>&#8221;) agreed to serve as the Company&#8217;s exclusive warrant solicitation agent for the Warrant Reprice Transaction and as the Company&#8217;s exclusive placement agent in connection with the 2022 Private Placement, in exchange for a fee equal to 8% of the total gross proceeds to the Company from the Warrant Reprice Transactions and the 2022 Private Placement, subject to certain exclusions. The Company also agreed to reimburse Ladenburg for certain related expenses in an amount not to exceed $50,000 in the aggregate.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional Matters</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The documents entered into in connection with the Warrant Reprice Transactions and the 2022 Private Placement described above and/or attached as an exhibit to this Current Report on Form 8-K (collectively, the &#8220;<i>Transaction Documents</i>&#8221;) contain representations and warranties of the parties to such agreements that may be subject to limitations, qualifications or exceptions agreed upon by the parties, and may be subject to a contractual standard of materiality that differs from the materiality standard that applies to reports and documents filed with the Commission. In particular, in your review of the representations and warranties contained in the Transaction Documents and described in the foregoing summary, it is important to bear in mind that the representations and warranties were negotiated in connection with separate transactions and with the principal purpose of allocating contractual risk between the parties in such transactions. The representations and warranties, other provisions of the Transaction Documents or any description of these provisions should not be read alone, but instead should be read only in conjunction with the information provided elsewhere in this Current Report on Form 8-K and in the other reports, statements and filings that the Company publicly files with the Commission.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&#xa0;3.02</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Unregistered Sales of Equity Securities.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information disclosed in Item 1.01 of this Current Report on Form 8-K regarding the repricing of the 2020 and 2021 Warrants, and the issuance of the New Warrants, along with the New Warrant Shares issuable upon the exercise thereof, and the Private Placement of Units (including the Series C Preferred Stock, the 2022 Warrants, and the 2022 Underlying Shares), is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&#xa0;8.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Other Events</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On September 9, 2022, the Company issued a press release relating to the matters set forth herein, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cautionary Language Concerning Forward-Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This Current Report on Form 8-K contains forward looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of the Company, as well as the Warrant Reprice Transactions and 2022 Private Placement. This Current Report on Form 8-K contains forward-looking statements that are based upon management&#8217;s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the Company&#8217;s current product offerings and marketing efforts, the financial and business impact and effect of the completed Warrant Reprice Transactions, the expected completion of and impact of the 2022 Private Placement, our partnerships, and any future revenue that may result from selling the Company&#8217;s products, as well as the Company&#8217;s expected future financial results. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Other risks relating to the Company&#8217;s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this Current Report on Form 8-K, are detailed in the Company&#8217;s latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the Commission, especially under the heading &#8220;Risk Factors.&#8221; The forward-looking statements in this Current Report on Form 8-K speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&#xa0;9.01.</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits. </b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<span style="text-decoration: underline;">Exhibits</span>.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit No.</b></td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 88%; border-bottom: 1px solid rgb(0, 0, 0);"><b>Description</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.1</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422212.htm" style="-sec-extract:exhibit;">Form of Certificate of Designation for the Series C Preferred Stock</a>**</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.1</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422213.htm" style="-sec-extract:exhibit;">Form of Amended 2020 Common Stock Warrant</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.2</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422214.htm" style="-sec-extract:exhibit;">Form of Amended 2021 Common Stock Warrant</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.3</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422215.htm" style="-sec-extract:exhibit;">Form of New Common Stock Warrant for 2020 Participants</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.4</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422216.htm" style="-sec-extract:exhibit;">Form of New Common Stock Warrant for 2021 Participants</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.5</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422217.htm" style="-sec-extract:exhibit;">Form of Series A-1 Long-Term Common Stock Warrant</a>**</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.6</div>
			</td>
			<td style="vertical-align: top; width: 4%;">&#xa0;</td>
			<td style="vertical-align: top; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422218.htm" style="-sec-extract:exhibit;">Form of Series A-2 Short-Term Common Stock Warrant</a>**</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.1</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422219.htm" style="-sec-extract:exhibit;">Form of 2020 Reprice Letter Agreement</a>*</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.2</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422220.htm" style="-sec-extract:exhibit;">Form of 2021 Reprice Letter Agreement</a>*</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.3</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422221.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement</a>*</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.4</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422222.htm" style="-sec-extract:exhibit;">Form of Registration Rights Agreement</a>**</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.5</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422223.htm" style="-sec-extract:exhibit;">Form of Participant Voting Commitment</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.6</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422224.htm" style="-sec-extract:exhibit;">Form of Additional Voting Commitment</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.7</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422225.htm" style="-sec-extract:exhibit;">Form of Leak-Out Agreement</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_422226.htm" style="-sec-extract:exhibit;">Press Release, dated September 9, 2022</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 6%; text-align: right;">104</td>
			<td style="vertical-align: middle; width: 4%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 2%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 88%;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">*</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Certain schedules and exhibits were omitted as well as certain confidential portions of the agreements by means of marking such portions with brackets (due to such confidential portions are not material and would be competitively harmful if publicly disclosed) pursuant to Item 601 of Regulation S-K promulgated by the Commission. The Company agrees to supplementally furnish a copy of any omitted schedule, exhibit or confidential portions to the Commission upon request.</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">**</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These documents are not currently effective and will be entered into and become effective only if the 2022 Private Placement is completed on the Private Placement Closing Date.</td>
		</tr>

</tbody></table>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tbody><tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td colspan="2" valign="top" style="width: 38%; ">
			<div style="margin-top: 0; margin-bottom: 0;"><b>NovaBay Pharmaceuticals, Inc.</b></div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 35%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td align="left" valign="bottom" style="nowrap: nowrap; width: 35%;">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td align="left" style="width: 50%; text-align: left;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 3%; text-align: left" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; BORDER-BOTTOM: #000000 1px solid" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#xa0;</span>Justin Hall</div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 35%; ">
			<div style="margin-top: 0; margin-bottom: 0;">Justin Hall</div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td valign="top" style="width: 35%; ">
			<div style="margin-top: 0; margin-bottom: 0;">Chief Executive Officer and General Counsel</div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: September 13, 2022</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex_422212.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<html><head>
	<title>ex_422212.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 11:24:45 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 3.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATE OF DESIGNATION OF PREFERENCES, </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RIGHTS AND LIMITATIONS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SERIES</b><b> C NON-VOTING </b><b>CONVERTIBLE PREFERRED STOCK</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PURSUANT TO SECTION 151 OF THE</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">DELAWARE GENERAL CORPORATION LAW</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The undersigned, Justin Hall, does hereby certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">1. He is the President and Secretary of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Corporation</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">2. The Corporation is authorized to issue 5,000,000 shares of preferred stock, 15,000 of which have been issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">3. The following resolutions were duly adopted by the board of directors of the Corporation (the &#8220;<u>Board of Directors</u>&#8221;):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">WHEREAS, the Amended and Restated Certificate of Incorporation, as amended of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 5,000,000 shares, $0.01 par value per share, issuable from time to time in one or more series;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">WHEREAS, the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof, of any of them; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a series of the preferred stock, which shall consist of up to 3,250 shares of the preferred stock, which the Corporation has the authority to issue, as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TERMS OF PREFERRED STOCK</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 1</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. For the purposes hereof, the following terms shall have the following meanings:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Alternate Consideration</u>&#8221; shall have the meaning set forth in Section 7(e).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall have the meaning set forth in Section 6(d).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Business Day</u>&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in the State of New York generally are open for use by customers on such day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Buy-In</u>&#8221; shall have the meaning set forth in Section 6(c)(iv).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section 2.1 of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto and all conditions precedent to (i) each Holder&#8217;s obligations to pay the Subscription Amount and (ii) the Corporation&#8217;s obligations to deliver the Securities have been satisfied or waived.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Common Stock</u>&#8221; means the Corporation&#8217;s common stock, par value $0.01 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Conversion Amount</u>&#8221; means the sum of the Stated Value at issue.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Conversion Date</u>&#8221; shall have the meaning set forth in Section 6(a).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Conversion Price</u>&#8221; shall have the meaning set forth in Section 6(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Conversion Shares</u>&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance with the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Conversion Shares Registration Statement</u>&#8221; means the registration statement(s) that registers the resale of all Conversion Shares of the Holders, who shall be named as &#8220;selling stockholders&#8221; therein and meets the requirements set forth in the Registration Rights Agreement.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Effective Date</u>&#8221; means the date that the Conversion Shares Registration Statement filed by the Corporation pursuant to the Registration Rights Agreement is first declared effective by the Commission.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Escrow Agent</u>&#8221; means Continental Stock Transfer &amp; Trust Company with offices at 1 State Street, New York, New York 10004.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Escrow Agreement</u>&#8221; means the escrow agreement entered into prior to the date hereof, by and among the Corporation, the Escrow Agent, and the Placement Agent (as defined in the Purchase Agreement) pursuant to which the Holder shall deposit Subscription Amounts with the Escrow Agent to be applied to the transactions contemplated hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Exempt Issuance</u>&#8221; means the issuance of (a) shares of Common Stock, options, restricted stock units or other equity awards to employees, officers or directors of the Corporation pursuant to any stock or option plan or any other equity award plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose and (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of the Purchase Agreement or in connection with the Warrant Reprice Transactions, provided that such securities have not been amended since the date of the Purchase Agreement and the Warrant Reprice Transaction to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities- (other than in connection with stock splits or combinations or pursuant to anti-dilution adjustments) or to extend the term of such securities.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Fundamental Transaction</u>&#8221; shall have the meaning set forth in Section 7(e).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>GAAP</u>&#8221; means United States generally accepted accounting principles.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: justify; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Holder</u>&#8221; shall have the meaning given such term in Section 2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Liquidation</u>&#8221; shall have the meaning set forth in Section 5.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>New York Courts</u>&#8221; shall have the meaning set forth in Section 8(d).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Notice of Conversion</u>&#8221; shall have the meaning set forth in Section 6(a).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Original Issue Date</u>&#8221; means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Preferred Stock</u>&#8221; shall have the meaning set forth in Section 2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Purchase Agreement</u>&#8221; means the Securities Purchase Agreement, dated as of September 9, 2022, among the Corporation and the original Holders, as amended, modified or supplemented from time to time in accordance with its terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Ratchet Termination Date</u>&#8221; shall have the meaning set forth in Section 7(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Registration Rights Agreement</u>&#8221; means the Registration Rights Agreement, dated as of the date of the Purchase Agreement, among the Corporation and the original Holders, in the form of <u>Exhibit B</u> attached to the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: justify; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Registration Statement</u>&#8221; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale of the Underlying Shares by each Holder as provided for in the Registration Rights Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Securities</u>&#8221; means the Preferred Stock, the Warrants and the Underlying Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Series A-1 Warrants</u>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) of the Purchase Agreement, which Warrants shall be exercisable immediately and have a term of exercise equal to six (6) years from the initial exercise date set forth therein, in the form of <u>Exhibit C</u> attached to the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Series A-2 Warrants</u>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) of the Purchase Agreement, which Warrants shall be exercisable immediately and have a term of exercise equal to eighteen (18) months from the initial exercise date set forth therein, in the form of <u>Exhibit C</u> attached to the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Share Delivery Date</u>&#8221; shall have the meaning set forth in Section 6(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Stated Value</u>&#8221; shall have the meaning set forth in Section 2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Subscription Amount</u>&#8221; shall mean, as to each Holder, the aggregate amount to be paid for the Preferred Stock purchased pursuant to the Purchase Agreement as specified below such Holder&#8217;s name on the signature page of the Purchase Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Corporation as set forth in <u>Section 3.1(a)</u> of the Purchase Agreement and shall, where applicable, also include any direct or indirect subsidiary of the Corporation formed or acquired after the date of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Successor Entity</u>&#8221; shall have the meaning set forth in Section 7(e).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Trading Day</u>&#8221; means a day on which the principal Trading Market is open for business.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Transaction Documents</u>&#8221; means this Certificate of Designation, the Purchase Agreement, the Warrants, the Registration Rights Agreement, the Escrow Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated pursuant to the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Transfer Agent</u>&#8221; means Computershare Trust Company, N.A., the current transfer agent of the Corporation with a mailing address of 462 South 4<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> Street, Suite 1600, Louisville, KY 40202 and any successor transfer agent of the Corporation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Underlying Shares</u>&#8221; means the shares of Common Stock issued and issuable upon conversion of the Preferred Stock and upon exercise of the Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Warrants</u>&#8221; means, collectively, the Series A-1 Warrants and the Series A-2 Warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">&#8220;<u>Warrant Reprice Transactions</u>&#8221; mean, collectively, the two separate warrant reprice transactions contemplated by letter agreements between the Corporation and (i) certain holders of Common Stock purchase warrants issued by the Corporation in connection with the Corporation&#8217;s warrant reprice transaction that closed on July 23, 2020, for the first transaction, and (ii) certain holders of Common Stock purchase warrants issued by the Corporation in connection with the Corporation&#8217;s private placement financing transactions that closed on November 2, 2021, for the second transaction, which transactions provide for those holders participating, among other terms, changes to the terms of the Common Stock purchase warrants that will reduce the exercise price, and, for those participating holders that exercise a portion of their outstanding Common Stock purchase warrants (such exercise, the &#8220;<u>Initial Exercise</u>&#8221;), such participating holders will also receive a new warrant to purchase a number of shares of Common Stock equal to the number of shares of Common Stock received by such investor pursuant to its applicable Initial Exercise (including the registration of the resale of the Common Stock underlying such new warrants).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 2</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation, Amount and Par Value</u>. The series of preferred stock shall be designated as its Series C Non-Voting Convertible Preferred Stock (the &#8220;<u>Preferred Stock</u>&#8221;) and the number of shares so designated shall be up to 3,250 (which shall not be subject to increase without the written consent of all of the holders of the Preferred Stock (each, a &#8220;<u>Holder</u>&#8221; and collectively, the &#8220;<u>Holders</u>&#8221;)). Each share of Preferred Stock shall have a par value of $0.01 per share and a stated value equal to $1,000 (the &#8220;<u>Stated Value</u>&#8221;).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 3</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Dividends</u>. Except for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares of Preferred Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 4</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Voting Rights</u>. Except as otherwise provided herein or as otherwise required by law, the Preferred Stock shall have no voting rights. However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Preferred Stock, after the date hereof (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (c) increase the number of authorized shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 5</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Liquidation</u>. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &#8220;<u>Liquidation</u>&#8221;), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to Common Stock which amounts shall be paid <u>pari</u> <u>passu</u> with all holders of Common Stock. The Corporation shall mail written notice of any such Liquidation, not less than forty-five (45) days prior to the payment date stated therein, to each Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 6</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conversion</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: justify; text-indent: 18pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Conversions at Option of Holder</u>. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <u>Annex A</u> (a &#8220;<u>Notice of Conversion</u>&#8221;). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by email such Notice of Conversion to the Corporation (such date, the &#8220;<u>Conversion Date</u>&#8221;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required.<i> </i>The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing the shares of Preferred Stock to the Corporation, unless all of the shares of Preferred Stock represented thereby are so converted, in which case, such Holder shall deliver the certificate representing such shares of Preferred Stock promptly following the Conversion Date at issue. Shares of Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof (regardless of delivery of the certificate(s)) shall be canceled and shall not be reissued within the same series as the Preferred Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Conversion Price</u>. The conversion price for the Preferred Stock shall equal <b>$[___]<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></b>, subject to adjustment herein (the &#8220;<u>Conversion Price</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: justify; text-indent: 18pt;">c)&nbsp; &nbsp; &nbsp;<u>Mechanics of Conversion</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Conversion Shares Upon Conversion</u>. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &#8220;<u>Share Delivery Date</u>&#8221;), the Corporation shall deliver, or cause to be delivered, to the converting Holder (A) Conversion Shares which, on or after the earlier of (i) the six month anniversary of the Original Issue Date or (ii) the Effective Date, shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Purchase Agreement) representing the number of Conversion Shares being acquired upon the conversion of the Preferred Stock, and (B) a bank check in the amount of accrued and unpaid dividends, if any. On or after the earlier of (i) the six month anniversary of the Original Issue Date or (ii) the Effective Date, the Corporation shall use its best efforts to deliver the Conversion Shares required to be delivered by the Corporation under this Section 6 electronically through the Depository Trust Company or another established clearing corporation performing similar functions. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Corporation&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Conversion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Failure to Deliver Conversion Shares</u>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup>&nbsp;The Conversion Price shall be equivalent to $0.18, as adjusted for the reverse stock split.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Obligation Absolute; Partial Liquidated Damages</u>. The Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares; <u>provided</u>, <u>however</u>, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder. In the event a Holder shall elect to convert any or all of the Stated Value of its Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Preferred Stock of such Holder shall have been sought and obtained, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the Stated Value of Preferred Stock which is subject to the injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall issue Conversion Shares and, if applicable, cash, upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such Conversion Shares pursuant to Section 6(c)(i) by the Share Delivery Date applicable to such conversion, the Corporation shall pay to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value of Preferred Stock being converted, $50 per Trading Day (increasing to $100 per Trading Day on the third Trading Day and increasing to $200 per Trading Day on the sixth Trading Day after such damages begin to accrue) for each Trading Day after the Share Delivery Date until such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a Holder&#8217;s right to pursue actual damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</u>. In addition to any other rights available to the Holder, if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;<u>Buy-In</u>&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the shares of Preferred Stock equal to the number of shares of Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section 6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Preferred Stock with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the Corporation, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver Conversion Shares upon conversion of the shares of Preferred Stock as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>Reservation of Shares Issuable Upon Conversion</u>. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions set forth in the Purchase Agreement) be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable and, if the Conversion Shares Registration Statement is then effective under the Securities Act, shall be registered for public resale in accordance with such Conversion Shares Registration Statement (subject to such Holder&#8217;s compliance with its obligations under the Registration Rights Agreement).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Fractional Shares</u>. No fractional shares or scrip representing fractional Conversion Shares shall be issued upon the conversion of the Preferred Stock. As to any fraction of a share which the Holder would otherwise be entitled to receive upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from converting fractional shares of Preferred Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Taxes and Expenses</u>. The issuance of Conversion Shares on conversion of this Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such Conversion Shares upon conversion in a name of any Person other than that of the Holders of such shares of Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Conversion Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: justify; text-indent: 18pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Beneficial Ownership Limitation</u>.<i> </i>The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the right to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with such Holder&#8217;s Affiliates, and any Persons acting as a group together with such Holder or any of such Holder&#8217;s Affiliates (such Persons, &#8220;Attribution Parties&#8221;)) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Preferred Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Preferred Stock or the Warrants) beneficially owned by such Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(d) applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties) and of how many shares of Preferred Stock are convertible shall be in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&#8217;s good faith determination of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties) and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability to the Holder for any such conversions of Preferred Stock that are not in compliance with the Beneficial Ownership Limitation (other than as a result of a Holder&#8217;s reliance on the number of issued and outstanding shares of Common Stock pursuant to this Section 6(d)). In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request (which may be via email) of a Holder, the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any shares of Preferred Stock, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Stock and Warrants, if any, held by the applicable Holder. A Holder, upon written notice to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 6(d) applicable to its Preferred Stock provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Preferred Stock and Warrants, if any, held by the Holder and the provisions of this Section 6(d) shall continue to apply. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup> day after such notice is delivered to the Corporation and shall only apply to such Holder and no other Holder. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 7</u>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Stock Splits</u>. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Equity Sales</u>. If the Corporation or any Subsidiary, as applicable, at any time while the Preferred Stock is outstanding, but prior to the Ratchet Termination Date as defined below, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price, the &#8220;<u>Base Conversion Price</u>&#8221; and such issuances, collectively, a &#8220;<u>Dilutive Issuance</u>&#8221;) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance, the Conversion Price shall be reduced to equal the Base Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance. If the Corporation enters into a Variable Rate Transaction, despite the prohibition set forth in the Purchase Agreement, the Corporation shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be converted or exercised. The Corporation shall notify the Holders in writing, no later than two (2) Trading Days following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 7(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the &#8220;<u>Dilutive Issuance Notice</u>&#8221;). For purposes of clarification, whether or not the Corporation provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the occurrence of any Dilutive Issuance, the Holders are entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless of whether a Holder accurately refers to the Base Conversion Price in the Notice of Conversion. Notwithstanding the foregoing, no further adjustments to the Conversion Price shall be made pursuant to this Section 7(b) and this Section 7(b) shall be of no further force or effect after the earlier of (a) the Trading Day immediately following the date that (i) the VWAP during any ten (10) of thirty (30) consecutive Trading Days (the &#8220;<u>Measurement Period</u>&#8221;) meets or exceeds 250% of the Conversion Price (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the Original Issue Date), provided that a Registration Statement covering the resale of all Conversion Shares remains effective for each day during such Measurement Period, and (b) 75% of the Preferred Stock issued on the Original Issue Date has been converted (collectively, the &#8220;<u>Ratchet Termination Date</u>&#8221;). The Corporation shall notify the Holders in writing, no later than two (2) Trading Days following the Ratchet Termination Date, that the terms and conditions of this Section 7(b) are no longer in force or effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of such Holder&#8217;s Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (provided, however, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as the Preferred Stock has not been converted and is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Preferred Stock (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder of this Preferred Stock, deliver to the Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the Conversion Price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such Conversion Price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction Documents referring to the &#8220;Corporation&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Corporation herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to the Holders</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Conversion Price</u>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation shall promptly deliver to each Holder a notice as provided below setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Conversion by Holder</u>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to convert the Conversion Amount of this Preferred Stock (or any part hereof) during the 20-day period commencing on the date of such notice through the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><u>Section 8</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 2000 Powell Street, Suite 1150, Emeryville, CA 94608, Attention:<b> </b>Corporate Secretary, e-mail address jhall@novabay.com or such other e-mail address or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 8. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder to the Holders shall be in writing and delivered personally, by email, or sent by a nationally recognized overnight courier service addressed to each Holder at the email address or address of such Holder appearing on the books of the Corporation, or if no such email address or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via email set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Absolute Obligation</u>. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages and accrued dividends, as applicable, on the shares of Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Lost or Mutilated Preferred Stock Certificate</u>. If a Holder&#8217;s Preferred Stock certificate (to the extent issued to a Holder) shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof. All legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, stockholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &#8220;<u>New York Courts</u>&#8221;). The Corporation and each Holder hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding. The Corporation and each Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. The Corporation and each Holder hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If the Corporation or any Holder shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&#8217; fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver</u>. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Next Business Day</u>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Status of Converted or Redeemed Preferred Stock</u>. Shares of Preferred Stock may only be issued pursuant to the Purchase Agreement. If any shares of Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series C Non-Voting Convertible Preferred Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">*********************</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">RESOLVED, FURTHER, that the President and the Secretary of the Corporation be and hereby is authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution and the provisions of Delaware law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">IN WITNESS WHEREOF, the undersigned has executed this Certificate this ___ day of ________ 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 32%;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; padding-left: 9pt;">Name: Justin Hall</td>
			<td style="vertical-align: top; width: 32%;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; padding-left: 9pt;">Title: President &amp; Chief Executive Officer,</td>
			<td style="vertical-align: top; width: 32%;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; padding-left: 9pt;">General Counsel and Secretary</td>
			<td style="vertical-align: top; width: 32%;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ANNEX A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">NOTICE OF CONVERSION</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED STOCK)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The undersigned being the Holder of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Corporation</u>&#8221;) Series C Non-Voting Convertible Preferred Stock (the &#8220;<u>Preferred Stock</u>&#8221;) hereby elects to convert the number of shares of Series C Non-Voting Convertible Preferred Stock indicated below into shares of common stock, par value $0.01 per share (the &#8220;<u>Common Stock</u>&#8221;), of NovaBay Pharmaceuticals, Inc., according to the conditions as set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock (the &#8220;<u>Certificate of Designation</u>&#8221;), as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation in accordance with the Purchase Agreement. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Conversion calculations:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Date to Effect Conversion: _____________________________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Number of shares of Preferred Stock owned prior to Conversion: _______________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Number of shares of Preferred Stock to be Converted: ________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Stated Value of shares of Preferred Stock to be Converted: ____________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Number of shares of Common Stock to be Issued: ___________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Applicable Conversion Price:____________________________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Number of shares of Preferred Stock subsequent to Conversion: ________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Address for Delivery: ______________________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;"><u>or</u></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">DWAC Instructions:</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Broker no: _________</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Account no: ___________</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[HOLDER]</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Name:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Title:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex_422213.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html><head>
	<title>ex_422213.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 12:44:43 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT, DATED AUGUST 8, 2019, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares: [_______]</td>
			<td style="width: 50%; text-align: right;">Original Issue Date: July 23, 2020</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 63pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time (x) on or after the later of (i) the six (6) month anniversary of September 9, 2022 and (ii) the Stockholder Approval Date (as defined in the Reprice Letter Agreement, dated September 9, 2022, between the Holder and the Company, as defined below (the &#8220;<u>Reprice Letter</u>&#8221;)) (the latter of such dates being herein after referred to as the &#8220;<u>Initial Exercise Date</u>&#8221;) and (y) on or prior to 5:00 p.m. (New York City time) on January 23, 2026 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in (x) that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated August 8, 2019, among the Company and the purchasers signatory thereto, and (y) the Reprice Letter.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$0.18</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the later of (x) the six month anniversary of the Closing Date and (y) the Stockholder Approval Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 99pt;text-indent:-27pt;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder's execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:-36pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">d)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Mechanics of Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:36pt;">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. Notwithstanding the foregoing, the provisions of this Section 2(e) shall not apply to any Holder (together with such Holder&#8217;s Attribution Parties and any other Persons acting as a group together) who beneficially owns in excess of the Maximum Percentage of the shares of Common Stock outstanding as of the Issue Date. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the date of the Purchase Agreement and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp; &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<u>Bloomberg</u>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as Exhibit B) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 72pt; text-align: justify;">The Company covenants that, following the Stockholder Approval Date, and during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">********************</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i>(Signature Page Follows)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-align: center;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Name: Justin Hall</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Title: Chief Executive Officer and General Counsel</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>EXHIBIT A</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">&#9744; in lawful money of the United States; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">Broker Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">Broker DTC DWAC #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; _______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">Broker Contact:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">Account #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; _______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(4)&nbsp; &nbsp;<u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[SIGNATURE OF HOLDER]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name of Investing Entity: ________________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Signature of Authorized Signatory of Investing Entity: _________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name of Authorized Signatory: ___________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Title of Authorized Signatory: ____________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Date: ________________________________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ASSIGNMENT FORM</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%; padding-left: 9pt;">Address:</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%; padding-left: 9pt;">Phone Number:</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%; padding-left: 9pt;">Email Address:</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Holder&#8217;s Signature:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>
			</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Holder&#8217;s Address:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ex_422214.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html><head>
	<title>ex_422214.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 12:45:06 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.2</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT, DATED OCTOBER 29, 2021, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares: [_______]</td>
			<td style="width: 50%; text-align: right;">Original Issue Date: November 2, 2021</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time (x) on or after the later of (i) the six (6) month anniversary of September 9, 2022 and (ii) the Stockholder Approval Date (as defined in the Reprice Letter Agreement, dated September 9, 2022, between the Holder and the Company, as defined below (the &#8220;<u>Reprice Letter</u>&#8221;)) (the latter of such dates being herein after referred to as the &#8220;<u>Initial Exercise Date</u>&#8221;) and (y) on or prior to 5:00 p.m. (New York City time) on September 11, 2028 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in (x) that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated October 29, 2021, among the Company and the purchasers signatory thereto, and (y) the Reprice Letter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$0.18</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the later of (x) the six month anniversary of the Closing Date and (y) the Stockholder Approval Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: -36pt; text-align: justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 36pt;">d)&nbsp; &nbsp;&nbsp;<u>Mechanics of Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-align: justify; text-indent: 36pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 36pt;">e)&nbsp; &nbsp;&nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation (other than as a result of a Holder&#8217;s reliance on the number of issued and outstanding shares of Common Stock pursuant to this Section 2(e)). For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be [4.99/9.99]% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the date of the Purchase Agreement and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), as the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp; &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<u>Bloomberg</u>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 36pt;">f)&nbsp; &nbsp; &nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as Exhibit B) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 45pt; text-align: justify;">The Company covenants that following the Stockholder Approval Date, and during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">********************</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i>(Signature Page Follows)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="38%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td align="left" style="text-align: left; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="text-align: left; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name: Justin Hall</p>
			</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title: Chief Executive Officer and General Counsel</p>
			</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>EXHIBIT A</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">&#9744; in lawful money of the United States; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">Broker Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">Broker DTC DWAC #:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">Broker Contact:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt; text-align: justify;">Account #:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(4) <u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[SIGNATURE OF HOLDER]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Name of Investing Entity: _______________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Signature of Authorized Signatory of Investing Entity: _________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Name of Authorized Signatory: ___________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Title of Authorized Signatory:____________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: ______________________________________________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ASSIGNMENT FORM</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: 9pt; text-align: justify;">(Please Print)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Please Print)</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Phone Number:</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Email Address:</td>
			<td style="vertical-align: top; width: 50%; text-align: justify; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt;">Dated: _______________ __, ______</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Signature:<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Address:<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>ex_422215.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html><head>
	<title>ex_422215.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 12:45:56 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.3</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE REPRICE OFFER LETTER DATED AS OF SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares: [_______]</td>
			<td style="width: 50%; text-align: right;">Original Issue Date: September 9, 2022</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time (x) on or after the later of (i) the six (6) month anniversary of September 9, 2022 and (ii) the Stockholder Approval Date (as defined in the Reprice Letter Agreement, dated September 9, 2022, between the Holder and the Company, as defined below (the &#8220;<u>Reprice Letter</u>&#8221;)) (the latter of such dates being herein after referred to as the &#8220;<u>Initial Exercise Date</u>&#8221;) and (y) on or prior to 5:00 p.m. (New York City time) on September 11, 2028 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in (x) that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated August 8, 2019, among the Company and the purchasers signatory thereto, and (y) the Reprice Letter.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$0.18</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the later of (x) the six month anniversary of the Closing Date and (y) the Stockholder Approval Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 99pt;text-indent:-27pt;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder's execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:-36pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt; text-align: justify; text-indent: 36pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Mechanics of Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: 27pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. Notwithstanding the foregoing, the provisions of this Section 2(e) shall not apply to any Holder (together with such Holder&#8217;s Attribution Parties and any other Persons acting as a group together) who beneficially owns in excess of the Maximum Percentage of the shares of Common Stock outstanding as of the Issue Date. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the date of the Purchase Agreement and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp; &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<u>Bloomberg</u>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt; text-align: justify; text-indent: 36pt;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as Exhibit B) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 54pt; text-align: justify;">The Company covenants that, following the Stockholder Approval Date, and during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Justin Hall</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title: Chief Executive Officer and General Counsel</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#9744; in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker Name:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;_____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker DTC DWAC #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;_____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker Contact:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 81pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Account #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_____________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 54pt; text-indent: 18pt;">(4) <u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Investing Entity: _______________________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Signature of Authorized Signatory of Investing Entity: _________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: ___________________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory: ____________________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date: ________________________________________________________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -9pt; text-indent: 9pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Please Print)</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Phone Number:</td>
			<td style="vertical-align: top; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">Email Address:</td>
			<td style="vertical-align: top; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt;">Dated: _______________ __, ______</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Signature:<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Address:<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>6
<FILENAME>ex_422216.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<html><head>
	<title>ex_422216.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 12:46:19 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.4</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE REPRICE OFFER LETTER DATED AS OF SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Warrant Shares: [_______]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
			<td style="width: 50%; text-align: right;">&nbsp;&nbsp;Original Issue Date: September 9, 2022</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time (x) on or after the later of (i) the six (6) month anniversary of September 9, 2022 and (ii) the Stockholder Approval Date (as defined in the Reprice Letter Agreement, dated September 9, 2022, between the Holder and the Company, as defined below (the &#8220;<u>Reprice Letter</u>&#8221;)) (the latter of such dates being herein after referred to as the &#8220;<u>Initial Exercise Date</u>&#8221;) and (y) on or prior to 5:00 p.m. (New York City time) on September 11, 2028 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in (x) that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated October 29, 2021, among the Company and the purchasers signatory thereto, and (y) the Reprice Letter.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$0.18</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the later of (x) the six month anniversary of the Closing Date and (y) the Stockholder Approval Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 99pt;text-indent:-27pt;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:-36pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt; text-align: justify; text-indent: 36pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Mechanics of Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-align: justify; text-indent: 18pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 18pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 18pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 18pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 18pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 18pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 18pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation (other than as a result of a Holder&#8217;s reliance on the number of issued and outstanding shares of Common Stock pursuant to this Section 2(e)). For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be [4.99/9.99]% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the date of the Purchase Agreement and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), as the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp; &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<u>Bloomberg</u>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt; text-align: justify; text-indent: 36pt;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 18pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 18pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as Exhibit B) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt;">The Company covenants that following the Stockholder Approval Date, and during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:36pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Justin Hall</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Title: Chief Executive Officer and General Counsel</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>EXHIBIT A</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 63pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 63pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt; text-align: justify;">&#9744; in lawful money of the United States; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt; text-align: justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 71pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt;">Broker Name:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;_____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt;">Broker DTC DWAC #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;_____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt;">Broker Contact:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 107pt;">Account #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_____________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 71pt;">(4) <u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Name of Investing Entity: _______________________________________________________________________</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Signature of Authorized Signatory of Investing Entity: _________________________________________________</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Name of Authorized Signatory: ___________________________________________________________________</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Title of Authorized Signatory: ____________________________________________________________________</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: ________________________________________________________________________________________</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Name:</p>
			</td>
			<td style="vertical-align: middle; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Address:</p>
			</td>
			<td style="vertical-align: middle; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Phone Number:</p>
			</td>
			<td style="vertical-align: middle; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Email Address:</p>
			</td>
			<td style="vertical-align: middle; width: 50%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Signature:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: auto; padding: 0pt 0pt 0pt 9pt; vertical-align: middle;">Holder&#8217;s Address:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>7
<FILENAME>ex_422217.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<html><head>
	<title>ex_422217.htm</title>

	<!-- Generated by ThunderDome Portal - 9/10/2022 7:36:57 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.5</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTION SET FORTH HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SERIES A-1 COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Warrant Shares: [_______]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
			<td style="width: 40%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Issue Date: [______], 2022</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on [_______]<sup>1</sup> (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup> To be the six year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated September 9, 2022, among the Company and the purchasers signatory thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$[____]</b>,<sup>2</sup> subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the six month anniversary of the Closing Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2 </sup>The Conversion Price shall be equivalent to $0.18, as adjusted for the reverse stock split.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 99pt;text-indent:-27pt;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:-36pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Mechanics of Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:72pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation (other than as a result of a Holder&#8217;s reliance on the number of issued and outstanding shares of Common Stock pursuant to this Section 2(e)). For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be [4.99/9.99]% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the date of the Purchase Agreement and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), as the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp; &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<u>Bloomberg</u>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp; <u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as Exhibit B) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:72pt;">The Company covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:36pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Justin Hall</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Title: Chief Executive Officer and General Counsel</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#9744; in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker DTC DWAC #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker Contact:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Account #:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">(4) <u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name of Investing Entity: _______________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Signature of Authorized Signatory of Investing Entity: ________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name of Authorized Signatory: __________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title of Authorized Signatory:____________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: _______________________________________________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Name:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Address:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Phone Number:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Email Address:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Signature:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Address:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>8
<FILENAME>ex_422218.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<html><head>
	<title>ex_422218.htm</title>

	<!-- Generated by ThunderDome Portal - 9/10/2022 8:18:30 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.6</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTION SET FORTH HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SERIES A-2 COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 70%;">Warrant Shares: [_______]&nbsp;&nbsp;</td>
			<td style="width: 30%; text-align: right;">Issue Date: [______], 2022</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS SERIES A-2 COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on [_______]<sup>1</sup> (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup> Insert the date that is the eighteen month anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated September 9, 2022, among the Company and the purchasers signatory thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$[____]</b>,<sup>2</sup> subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the six month anniversary of the Closing Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> The Conversion Price shall be equivalent to $0.18, as adjusted for the reverse stock split.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: -36pt; text-align: justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 36pt;">d)&nbsp;&nbsp;&nbsp;&nbsp; <u>Mechanics of Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: 27pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 72pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;"><u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties.&nbsp;&nbsp;Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation (other than as a result of a Holder&#8217;s reliance on the number of issued and outstanding shares of Common Stock pursuant to this Section 2(e)). For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;&nbsp;Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be [4.99/9.99]% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the date of the Purchase Agreement and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), as the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp; &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<u>Bloomberg</u>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 36pt;">f)&nbsp;&nbsp;&nbsp;&nbsp; <u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as Exhibit B) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: 45pt;">The Company covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Justin Hall</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Title: Chief Executive Officer and General Counsel</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#9744; in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker DTC DWAC #:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Broker Contact:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">Account #:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">(4) <u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name of Investing Entity: ___________________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Signature of Authorized Signatory of Investing Entity: ____________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name of Authorized Signatory: ______________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title of Authorized Signatory:________________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: ____________________________________________________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Name:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Address:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Phone Number:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Email Address:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Signature:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Holder&#8217;s Address:<u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u><u>&nbsp;</u></p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>9
<FILENAME>ex_422219.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_422219.htm</title>

	<!-- Generated by ThunderDome Portal - 9/13/2022 1:42:15 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="margin-bottom: 0px; margin-top: 0px; text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="logo01.jpg" src="logo01.jpg"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">September 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">[_________]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt; text-indent: 9pt;">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reprice Offer of Common Stock Purchase Warrants and Initial Warrant Exercise</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To Whom It May Concern:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">NovaBay Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;) previously issued and delivered to you (&#8220;<u>Holder</u>&#8221; or &#8220;<u>you</u>&#8221;) a warrant (the &#8220;<u>2020 Original Warrant</u>&#8221;) exercisable into shares of Company common stock, par value $0.01 per share (&#8220;<u>Common Stock</u>&#8221;), in connection with the Company&#8217;s warrant reprice transaction that closed on July 23, 2020 (the &#8220;<u>2020 Financing Transaction</u>&#8221;). The Company is pleased to offer you the opportunity to reduce the exercise price of your 2020 Original Warrant on the terms provided in this letter agreement, including as set forth on <u>Annex B</u> attached hereto (the &#8220;<u>Amended Warrant</u>&#8221;). The shares of Common Stock underlying the 2020 Original Warrant (&#8220;<u>Warrant Shares</u>&#8221;) have been registered pursuant to a registration statement on Form S-3 (File No. 333-248238) (the &#8220;<u>Registration Statement</u>&#8221;). The Registration Statement is currently effective and, upon amendment of the 2020 Original Warrant and exercise of the Amended Warrant pursuant to the terms hereof, will, to the Company&#8217;s knowledge, be effective for the issuance of the Warrant Shares.<b> </b>Capitalized terms not otherwise defined herein shall have the meanings set forth in the Securities Purchase Agreement, dated August 8, 2019 (the &#8220;<u>Purchase Agreement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -9pt; text-indent: 36pt;">In consideration for entering into the Voting Letter (as defined below), your 2020 Original Warrant will be amended to provide for the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Reducing the Exercise Price</i>&nbsp;&#8212;&nbsp;Section 2(b) of the Amended Warrant will have a reduced exercise price of<b>&nbsp;</b>$0.18<b>&nbsp;</b>(as reduced from the current exercise price of $1.65) (the&nbsp;&#8220;<u>Reduced Exercise Price</u>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Additional Warrant Exercise Limitation </i>&#8212;&nbsp;The first paragraph of the Amended Warrant will provide for a restriction upon your ability as holder of the Amended Warrant to exercise the remaining unexercised shares of Common Stock, being reduced by the amount of after your Initial Warrant Exercise (the &#8220;<u>Remaining Warrant Share Amount</u>&#8221;), until the <i><u>later to occur</u></i>&nbsp;of (i) six months or (ii) the date on which the Stockholder Approval and any Additional Stockholder Approvals (each as further discussed and defined below) have been obtained at a meeting of Company stockholders and such approvals become effective, including under the laws of the State of Delaware if applicable (the &#8220;<u>Stockholder Approval Date</u>&#8221;). For avoidance of doubt, if you did not make an Initial Warrant Exercise as provided below, then the Remaining Warrant Share Amount shall equal the number of shares of Common Stock currently underlying your 2020 Original Warrant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Only if the Stockholder Approval is received by the Company will your Amended Warrant once again continue to be exercisable for the Remaining Warrant Share Amount, which remaining number of unexercised shares of Common Stock is listed under the column heading &#8220;Remaining Amended Warrant Shares&#8221; on <u>Annex B</u> hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The actual text of each of these amendments listed above to your 2020 Original Warrant, as well as a few additional amendments and changes, that you will be agreeing to upon this letter agreement becoming effective are all expressly set forth and marked in the form of Amended Warrant attached hereto as <u>Annex E</u>. As such, upon accepting this offer and for the consideration as set forth in this letter agreement and upon this letter agreement becoming effective as provided in the paragraph below, you will have agreed to amend your 2020 Original Warrant pursuant to Section 5(l) to reflect each of the amendments and other changes reflected in the form of Amended Warrant set forth on <u>Annex E</u> hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In addition if you elected to make a cash exercise of all or a portion of your Amended Warrant on or before 5:00 p.m. (New York City time) on September 9, 2022 for the number of underlying shares of Common Stock as set forth under your signature and in the column heading &#8220;Initial Exercise Amount&#8221; set forth on Annex B hereto (the &#8220;<u>Initial Warrant Exercise</u>&#8221;) at the Reduced Exercise Price (as defined below), then as part of the consideration being provided, the Company shall also issue you or your designees within two (2) business days after the Closing Date (as defined below) a new Common Stock Purchase Warrant to purchase up to a number of shares of Common Stock equal to <b>100%</b> of the number of Warrant Shares issued in the Initial Warrant Exercise as set forth under the column heading &#8220;Initial Exercise Amount&#8221; on Annex B, which New Warrant shall be substantially in the form attached hereto as <u>Annex F</u> (the &#8220;<u>New Warrant</u>&#8221;). The New Warrant will be initially exercisable on the <i>later to occur</i> of (i) the six month anniversary of the date of issuance and (ii) the date on which both the Stockholder Approval has been obtained at a meeting of Company stockholders and such approval becomes effective under the laws of the State of Delaware and any Additional Stockholder Approvals (as further discussed and defined below) has been obtained. In addition, the New Warrant will have a term of exercise of six (6) years after Closing Date, and an exercise price equal to $0.18. If you do not make an Initial Warrant Exercise, then you will not receive a New Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">You may accept this offer and reflect your agreement with the terms of this letter agreement, including the amendment of your 2020 Original Warrant and acceptance of the New Warrant to the extent you make an Initial Warrant Exercise, by (i) signing below, (ii) delivering both your signed voting letter that relates to the Stockholder Approval and any Additional Stockholder Approvals (as defined below), a form of which is attached as <u>Annex C-1</u> (the &#8220;<u>Voting Letter</u>&#8221;), and your signed Leak-Out Agreement, a form of which is attached as <u>Annex G</u> (the &#8220;<u>Leak-Out Agreement</u>&#8221;). Such acceptance and this letter agreement and the Voting Letter will become effective <i>only</i> upon the acceptance by the Other Holders (defined below) listed on <u>Annex D</u> (collectively, the &#8220;<u>Participating Other Holders</u>&#8221;) of the same terms and conditions as the offer provided hereunder and having signed and delivered to the Company their respective Other Warrant Exercise Agreements (as defined below) and their respective voting letters. You will receive written notice from the Company in the event that it does not receive acceptances from all of the Participating Other Holders on or before 8:00 a.m. (New York City time) on September 9, 2022, and, in such event, this letter agreement, the Voting Letter and its terms, conditions and all obligations of the Company and the Holder will automatically terminate and be of no further force or effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Subject to this letter agreement becoming effective as provided above, your acceptance shall constitute your notice and authorization to consummate the Initial Warrant Exercise in the amount and for the aggregate exercise price as set forth on your signature page hereto and in the column heading &#8220;Initial Exercise Amount&#8221; set forth on <u>Annex B</u> hereto, if so elected, if any, on or before 8:00 a.m. (New York City time) on September 9, 2022. By signing below, you represent that the Beneficial Ownership Limitation (as defined in the Amended Warrant) will not be exceeded upon the issuance of all of the shares of Common Stock to the extent any are received from an Initial Warrant Exercise, if any. Additionally, the Company agrees to make the representations and warranties to the Holder, and each of the Company and the Holder, as the case may be, will acknowledge and agree to the covenants set forth on <u>Annex A</u> attached hereto. Further, in connection with the issuance of the New Warrant, to the extent that you made with an Initial Warrant Exercise and receiving New Warrants, you agree and shall make the representations and warranties as set forth in Section 3.2(a) through (g) of the Purchase Agreement to the Company, as the Company will be relying upon them in connection with the issuance of the New Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">If this offer is accepted by your execution and delivery of this letter agreement (together with the Voting Letter and the Leak-Out Agreement) and becomes effective, and subject to this letter agreement becoming effective with the Company having received acceptances by the Participating Other Holders as provided above, on or before 8:00 a.m. (New York City time) on September 9, 2022, then on or before 9:00 a.m. (New York City time) on September 13, 2022, the Company shall file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing all material terms of the transactions contemplated by this letter agreement, including this letter agreement, the Voting Letter and the Leak-Out Agreement as exhibits thereto (the &#8220;<u>8-K Filing</u>&#8221;). The Company shall also file a prospectus supplement to the Registration Statement with the Securities and Exchange Commission disclosing the Reduced Exercise Price of the Amended Warrants within two (2) trading days following the 8-K Filing. From and after the issuance of the 8-K Filing, the Company represents to the Holder that it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company or any of its officers, directors, employees or agents in connection with the transactions contemplated by this letter agreement. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement entered into in contemplation of the transactions contemplated by this letter agreement, whether written or oral, between the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and the Holder or any of its Affiliates on the other hand, shall terminate. From and after the issuance of the 8-K Filing, the Company represents to the Holder that none of the Company&#8217;s directors, officers, employees or agents will provide the Holder with any material, nonpublic information that is not disclosed in the 8-K Filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Subject to this letter agreement becoming effective as provided above, no later than September 9, 2022, the closing of the Initial Warrant Exercise to the extent elected by you shall occur at such location as the parties shall mutually agree. Unless otherwise directed by Ladenburg Thalmann &amp; Co. Inc. (the &#8220;<u>Placement Agent</u>&#8221;), settlement of any such Initial Warrant Exercise that is made by the Holder hereunder shall occur via &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;) (i.e., on the Closing Date, the Company shall issue the shares of Common Stock issued in any such Initial Warrant Exercise (the &#8220;<u>Exercised Warrant Shares</u>&#8221;), in the Holder&#8217;s name and address and be released by the Company&#8217;s transfer agent directly to the account(s) of the Placement Agent as identified by the Holder; upon receipt of such Exercised Warrant Shares, the Placement Agent shall promptly electronically deliver such Exercised Warrant Shares to the Holder; and payment of the aggregate exercise price therefor shall be made by the Placement Agent (or its clearing firm) on behalf of the Holder by wire transfer to the Company). On or prior to the Closing Date, the Holder making an Initial Warrant Exercise shall deliver or cause to be delivered to the Company such Holder&#8217;s aggregate exercise price for the Exercised Warrant Shares, which shall be made available for DVP settlement with the Company or its designee. The date of the closing of the Initial Warrant Exercise of the Amended Warrants shall be referred to as the &#8220;Closing Date&#8221;. After the Initial Warrant Exercise is completed, the Company will request the return of your 2020 Original Warrant and the Company will issue your Amended Warrant reflecting the Reduced Exercise Price, your Remaining Warrant Share Amount and the other amendments and changes to which you will have agreed; provided, however, if in connection with the Initial Warrant Exercise you fully exercised your Amended Warrant, then upon receiving the Warrant Shares, your Amended Warrant will be deemed cancelled and will not be reissued to you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any other Common Stock or Common Stock Equivalents; provided, however, that this prohibition shall not apply to the Company&#8217;s issuance of securities (x) in connection with the Company&#8217;s issuance and sale of Units (consisting of the Company&#8217;s Series C Non-Voting Convertible Preferred Stock, Series A-1 Warrants to purchase Common Stock and Series A-2 Warrants to Purchase Common Stock) in a private offering to accredited investors (the &#8220;<u>2022 Private Offering</u>&#8221;), (y) the amendment of certain outstanding common stock purchase warrants that were issued in a prior financing that closed on November 2, 2021 (the &#8220;<u>2021 Warrant Reprice Transaction</u>&#8221;) or (z) upon the exercise or exchange of or conversion of any securities exercisable or exchangeable for or convertible into shares of Common Stock, or other similar rights, issued and outstanding on the date of this letter agreement, provided that such outstanding securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than any amendment pursuant to any Other Warrant Exercise Agreement (as defined below) or anti-dilution adjustment of the conversion price of the Company&#8217;s&nbsp;Series B Non-Voting Convertible Preferred Stock or (ii) file any registration statement or any amendment or supplement to any existing registration statement (other than (1) the resale registration statement referred to herein or prospectus supplements to the Registration Statements to reflect the transactions contemplated hereby, (2) the resale registration statement contemplated by the 2022 Private Offering, (3) the resale registration statement, including any amendment or prospectus supplement, that relates to the underlying shares of Common Stock for the repriced warrants contemplated by the 2021 Warrant Reprice Transaction, or (4) to register additional shares of Common Stock as a result of anti-dilution adjustments with respect to the Company&#8217;s Series B Non-Voting Convertible Preferred Stock).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company shall hold a special meeting of stockholders (which may also be at the annual meeting of stockholders) (the &#8220;<u>Stockholder Meeting</u>&#8221;) at the earliest practical date after the date hereof and in any event on or before the 75<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> day following the Closing Date to obtain Stockholder Approval (defined below), with the recommendation of the Company&#8217;s board of directors that such proposal be approved (subject to their fiduciary duties at such time). The Company shall solicit proxies from its stockholders with respect to the Stockholder Approval in the same manner as all other management proposals contained in such proxy statement. The Company shall use its reasonable best efforts to obtain Stockholder Approval. If the Company does not obtain Stockholder Approval at the Stockholder Meeting, the Company shall call a stockholder meeting every four months thereafter to seek Stockholder Approval until the date Stockholder Approval is obtained. As used herein, &#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the laws of the State of Delaware from the stockholders of the Company with respect to the Company&#8217;s filing of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of Common Stock, which reverse stock split shall have a ratio of not less than 1-for-10 and not more than 1-for-35 (each 10 to 35 shares of Common Stock, as the case may be, shall be combined to become 1 share of Common Stock). In addition, at the Stockholder Meeting (or subsequently called meeting as provided above), the Company may also submit for stockholder approval additional proposals that may be required by the rules of the NYSE American (the &#8220;<u>Additional Stockholder Approvals</u>&#8221;).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Holder the executed Voting Letters, in the form attached hereto as <u>Annex C-2</u>, of all of the Company&#8217;s executive officers, directors, stockholders holding more than 10% of the issued and outstanding shares of Common Stock on the date hereof, Pioneer Pharma (Hong Kong) Company Ltd. and Jian Ping Fu, that provides for such persons to vote all Common Stock over which they have voting control as of the record date for the purpose of obtaining the Stockholder Approval and any Additional Stockholder Approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">As of the Closing Date, the Company shall have retained a financial public relations firm reasonably acceptable to the Placement Agent and the Company, which firm will be experienced in assisting issuers in public offerings of securities and in their relations with their security holders, and shall retain such firm or another firm reasonably acceptable to the Placement Agent for a period of not less than one year after the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Except as set forth herein, the terms of the Amended Warrant, including but not limited to the obligations to deliver the underlying shares of Common Stock in connection with the Initial Warrant Exercise to the extent so elected by the Holder, shall remain in effect as if the acceptance of this offer and entering into this letter agreement was a formal exercise notice under the Amended Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the obligations of any other holder of 2020 Original Warrants (each, an &#8220;<u>Other Holder</u>&#8221;), including the Other Holders who are Participating Other Holders that enter into similar letter agreements (together with similar voting letters) as the Holder (the &#8220;<u>Other Warrant Exercise Agreement</u>&#8221;), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof until 180 days after the date hereof, that none of the terms offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver thereof) relating to any of the 2020 Original Warrants, is or will be more favorable to such Other Holder than those of the Holder and this letter agreement, unless such terms are concurrently offered to the Holder. If, and whenever on or after the date hereof until thirty (30) days after the date hereof, the Company enters into an Other Warrant Exercise Agreement relating to 2020 Original Warrants, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence thereof (&#8220;<u>Notice of Transaction</u>&#8221;) and (ii) the terms and conditions of this letter agreement shall be, without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and the obligation of the conditions (as the case may be) set forth in such Other Warrant Exercise Agreement (including, if applicable, the issuance of additional underlying shares of Common Stock), provided that upon written notice to the Company within five (5) days after receiving a Notice of Transaction, the Holder may provide written notice to the Company electing not to accept all of the benefits of any such amended and modified term and the related conditions, in which event the terms and conditions contained in this letter agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of this paragraph shall apply similarly and equally to each such Other Warrant Exercise Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of the Exercised Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Upon the countersignature and delivery of this letter agreement by the Holder (together with your signed Voting Letter and Leak-Out Agreement) and subject to this letter agreement becoming effective with the Company having received acceptances by the Participating Other Holders as provided above, the parties will have mutually agreed to amend (in accordance with Section 5(l) of the 2020 Original Warrant) those terms and conditions in your 2020 Original Warrant to provide for the Amended Warrant that will set forth the amendments and changes reflected in <u>Annex E</u> to this letter agreement, if applicable due to an Initial Warrant Exercise by the Holder, and for the Company to issue you the New Warrant after the Closing Date. Unless otherwise agreed to in this letter agreement, the Amended Warrant will not otherwise be amended or modified.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">This letter agreement shall be governed by the laws of the State of New York without regard to the principles of conflicts of law thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">***************</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">To accept this offer and to enter into this letter agreement, you must counter execute this letter agreement and sign the Voting Letter and the Leak-Out Agreement and return the fully executed letter agreement and signed Voting Letter and the Leak-Out Agreement to the Company at e-mail: jhall@novabay.com, attention: Justin Hall, on or before 8:00 am (New York City time) by September 9, 2022. As noted above, your acceptance and this letter agreement, including the amendment to your 2020 Original Warrant, will be effective only upon the similar acceptance of the Participating Other Holders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Please do not hesitate to call me if you have any questions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sincerely yours,</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;"><b>NOVABAY PHARMACEUTICALS, INC.</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">By:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">Name: Justin M. Hall</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">Title: Chief Executive Officer and General Counsel</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 216pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accepted and Agreed to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Holder: ________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Signature of Authorized Signatory of Holder</i>: _________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: _______________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory: ________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Warrant Shares (<i>prior to any applicable Initial Warrant Exercise</i>): _____________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Number of Warrant Shares, if any, being exercised under the Amended Warrant contemporaneously with signing this letter agreement (<i>Initial Exercise Amount</i>): _____________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;"><i>Note: If you are not making an Initial Warrant Exercise, then you may insert the dollar amount of zero (0) or leave blank.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Aggregate Exercise Price for the Initial Exercise Amount: $__________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Number of Warrant Shares After the Initial Warrant Exercise (Remaining Amended Warrant Shares):&nbsp;______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;"><i>Note: If you are not making an Initial Warrant Exercise, then this number will equal the number of Warrant Shares under your 2020 Original Warrant prior to this transaction.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex A </u></b><u>&#8211;</u><b><u> Representations, Warranties and Covenants</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -9pt; text-indent: 36pt;"><u>Representations, Warranties and Covenants</u>. The Company hereby makes the following representations and warranties to the Holder, and each of the Company and the Holders receiving New Warrants, as the case may be, acknowledged and agree to covenants set forth below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement</u>. The Warrant Shares are registered for issuance on a Registration Statement on Form S-3 (File No. 333-248238) (the &#8220;<u>Registration Statement</u>&#8221;) and the Company knows of no reason as of the date hereof why such registration statement shall not remain available for the issuance and resale of such Warrant Shares for the foreseeable future. The Company shall use commercially reasonable efforts to keep the Registration Statement effective and available for use by the Holder until all remaining Warrant Shares underlying the Amended Warrant are sold by the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization; Enforcement</u>. The Company will have the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby will be duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected, other than for which a waiver has been obtained by the Company; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>NYSE American Corporate Governance</u>. The transactions contemplated under this letter agreement comply with all applicable rules of the NYSE American LLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance of the New Warrant</u>. The issuance of the New Warrants is duly authorized and, upon the execution of this letter agreement by the undersigned and it becomes effective, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company, and the shares issuable upon exercise of the New Warrant (the &#8220;<u>New Warrant Shares</u>&#8221;), when issued in accordance with the terms of the New Warrant, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. After the Stockholder Approval Date, the Company shall reserve from its duly authorized capital stock a number of shares of Common Stock for issuance of the New Warrant Shares in full in accordance with its terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 36pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Legends and Transfer Restrictions.</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 54pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;The New Warrant and New Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of New Warrant or New Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the undersigned or in connection with a pledge, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred New Warrant and New Warrant Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this letter agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 54pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned agrees to the imprinting, so long as is required by this Section (i), of a legend on any of the New Warrant and New Warrant Shares in the following form:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 63pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH IN THE APPLICABLE WARRANT REPRICE LETTER, DATED SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">The Company acknowledges and agrees that the undersigned may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the New Warrant to a financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this letter agreement and, if required under the terms of such arrangement, the undersigned may transfer pledged or secured New Warrant to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate undersigned&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of New Warrant may reasonably request in connection with a pledge or transfer of the New Warrant or New Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;Certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth in Section (f)(ii) hereof), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144, (iii) if such New Warrant Shares are eligible for sale under Rule 144, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to its transfer agent (if required by the transfer agent) and the undersigned (if requested by the undersigned) in connection with the removal of the legend hereunder. If all or any portion of a New Warrant is exercised at a time when there is an effective registration statement to cover the resale of the New Warrant Shares, or if such New Warrant Shares may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such New Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this Section (f), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive legend (such date, the &#8220;<u>Legend Removal Date</u>&#8221;)<u>,</u>&nbsp;deliver or cause to be delivered to the undersigned a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section (f). Certificates for New Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the undersigned by crediting the account of the undersigned&#8217;s prime broker with the Depository Trust Company System as directed by the undersigned. &#8220;Standard Settlement Period&#8221;&nbsp;means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 54pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;In addition to such undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section (f)(iii), $2.50 per Trading Day (increasing to $15 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the undersigned by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such undersigned that is free from all restrictive and other legends and (b) if after the Legend Removal Date such undersigned purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such undersigned of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such undersigned anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such undersigned&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<u>Buy-In Price</u>&#8221;) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to such undersigned by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such undersigned to the Company of the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Public Information Failure</u>. At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the New Warrant Shares may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if there is no effective registration statement covering the resale of all of the New Warrant Shares and the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<u>Public Information Failure</u>&#8221;) then, in addition to the undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the New Warrant Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of the undersigned&#8217;s New Warrant on the day of a Public Information Failure and on every thirtieth (30th) day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required for the undersigned to transfer the New Warrant Shares pursuant to Rule 144. The payments to which the undersigned shall be entitled pursuant to this Section (g) are referred to herein as &#8220;Public Information Failure Payments.&#8221; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit the undersigned&#8217;s right to pursue actual damages for the Public Information Failure, and the undersigned shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(h) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Listing of Common Stock</u>. The Company shall, subject to applicable requirements of the NYSE American, apply to list or quote all of the New Warrant Shares on the NYSE American and promptly secure the listing of all of the New Warrant Shares on such NYSE American.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">(i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement</u>. As soon as practicable (and in any event within 30 calendar days of the Stockholder Approval Date), the Company shall file a registration statement on Form S-1 or Form S-3 (or other appropriate form) providing for the resale by the Holders of the New Warrant Shares issued and issuable upon exercise of the New Warrants. The Company shall use commercially reasonable efforts to cause such registration to become effective on or prior to 60 calendar days of the Stockholder Approval Date and to keep such registration statement effective at all times until no Holder owns any New Warrants or New Warrant Shares issuable upon exercise thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex B </u></b><u>&#8211;</u><b><u> Amended Warrant Amounts</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0) black; vertical-align: top; width: 31.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>TOTAL AMENDED </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>WARRANTS</u></b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>INITIAL EXERCISE </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>AMOUNT </u></b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>REMAINING AMENDED </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>WARRANT SHARES</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.6%; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.6%; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.6%; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="text-align: center;">&nbsp;</div>

<div style="text-align: center;"><img alt="logo01.jpg" src="logo01.jpg"></div>

<div style="text-align: center;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex C-1 </u></b><u>&#8211;</u><b><u> Voting Letter (Participating Holders)</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Voting Letter (Participating Holders) is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.5.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="text-align: center;">&nbsp;</div>

<div style="text-align: center;"><img alt="logo01.jpg" src="logo01.jpg"></div>

<div style="text-align: center;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex C-2 </u></b><u>&#8211;</u><b><u> Voting Letter (Other)</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Voting Letter (Other) is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.6.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex D </u></b><u>&#8211;</u><b><u> Participating Other Holders</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex E </u></b><u>&#8211;</u><b><u> Form of Amended Warrant</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Form of Amended Warrant is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 4.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex F </u></b><u>&#8211;</u><b><u> Form of New Warrant</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Form of New Warrant is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 4.3.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex G </u></b><u>&#8211;</u><b><u> Form of Leak-Out Agreement</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Form of Leak-Out Agreement is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.7.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>10
<FILENAME>ex_422220.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html><head>
	<title>ex_422220.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 11:26:27 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.2</b></font></p>

<p style="margin-bottom: 0px; margin-top: 0px; text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="logo01.jpg" src="logo01.jpg"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">September 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">[__________]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 27pt;">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reprice Offer of Common Stock Purchase Warrants and Initial Warrant Exercise</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To Whom It May Concern:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">NovaBay Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;) previously issued and delivered to you (&#8220;<u>Holder</u>&#8221; or &#8220;<u>you</u>&#8221;) a warrant (the &#8220;<u>2021 Original Warrant</u>&#8221;) exercisable into shares of Company common stock, par value $0.01 per share (&#8220;<u>Common Stock</u>&#8221;), in connection with your investment in the Company&#8217;s financing transaction that closed on November 2, 2021 (the &#8220;<u>2021 Financing Transaction</u>&#8221;). The Company is pleased to offer you the opportunity to reduce the exercise price of your 2021 Original Warrant on the terms provided in this letter agreement, including as set forth on <u>Annex B</u> attached hereto (the &#8220;<u>Amended Warrant</u>&#8221;). The shares of Common Stock underlying the 2021 Original Warrant (&#8220;<u>Warrant Shares</u>&#8221;) have been registered pursuant to a registration statement on Form S-1 (File No. 333-262550) (the &#8220;<u>Registration Statement</u>&#8221;). The Registration Statement is currently effective and, upon amendment of the 2021 Original Warrant and exercise of the Amended Warrant pursuant to the terms hereof, will, to the Company&#8217;s knowledge, be effective for the issuance of the Warrant Shares.<b> </b>Capitalized terms not otherwise defined herein shall have the meanings set forth in the Securities Purchase Agreement, dated October 29, 2021, that was entered into in connection with the Company&#8217;s 2021 Financing Transaction (the &#8220;<u>Purchase Agreement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In consideration for exercising a portion of your Amended Warrant for the number of underlying shares of Common Stock as set forth under the column heading &#8220;Initial Exercise Amount&#8221; set forth on <u>Annex B</u> hereto (the &#8220;<u>Initial Warrant Exercise</u>&#8221;) at the Reduced Exercise Price (as defined below), your 2021 Original Warrant will be amended to provide for the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Reducing the Exercise Price</i>&nbsp;&#8212;&nbsp;Section 2(b) of the Amended Warrant will have a reduced exercise price of<b>&nbsp;</b>$0.18<b>&nbsp;</b>(as reduced from the current exercise price of $0.53) (the&nbsp;&#8220;<u>Reduced Exercise Price</u>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Extending the Termination Date</i>&nbsp;&#8212;&nbsp;The first paragraph of the Amended Warrant will provide for the &#8220;Termination Date&#8221;&nbsp;of the Amended Warrant to be extended to September 11, 2028.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Additional Warrant Exercise Limitation </i>&#8212;&nbsp;The first paragraph of the Amended Warrant will provide for a restriction upon your ability as holder of the Amended Warrant to exercise the remaining unexercised shares of Common Stock after your Initial Warrant Exercise (the &#8220;<u>Remaining Warrant Share Amount</u>&#8221;), until the <i><u>later to occur</u></i>&nbsp;of (i) six months or (ii) the date on which the Stockholder Approval and the Additional Stockholder Approvals (each as further discussed and defined below) have been obtained at a meeting of Company stockholders and such approvals become effective, including under the laws of the State of Delaware as applicable (the &#8220;<u>Stockholder Approval Date</u>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Following the Initial Warrant Exercise and only if the Stockholder Approval is received by the Company will your Amended Warrant once again continue to be exercisable for the Remaining Warrant Share Amount, which remaining number of unexercised shares of Common Stock is listed under the column heading &#8220;Remaining Amended Warrant Shares&#8221; on <u>Annex B</u> hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The actual text of each of these amendments listed above to your 2021 Original Warrant, as well as a few additional amendments and changes, that you will be agreeing to upon this letter agreement becoming effective are all expressly set forth and marked in the form of Amended Warrant attached hereto as <u>Annex E</u>. As such, upon accepting this offer and for the consideration as set forth in this letter agreement and upon this letter agreement becoming effective as provided in the paragraph below, you will have agreed to amend your 2021 Original Warrant pursuant to Section 5(l) to reflect each of the amendments and other changes reflected in the form of Amended Warrant set forth on <u>Annex E</u> hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In addition as part of the consideration being provided, the Company shall also issue you or your designees within two (2) business days after the Closing Date (as defined below) a new Common Stock Purchase Warrant to purchase up to a number of shares of Common Stock equal to <b>100%</b> of the number of Warrant Shares issued pursuant to each Warrant Exercise, including the Initial Warrant Exercise, that occurs from and after the date hereof and prior to 5:00 p.m. on September 9, 2022, which New Warrant shall be substantially in the form attached hereto as <u>Annex F</u> (the &#8220;<u>New Warrant</u>&#8221;). The New Warrant will be initially exercisable on the <i>later to occur</i> of (i) the six month anniversary of the date of issuance and (ii) the date on which both the Stockholder Approval has been obtained at a meeting of Company stockholders and such approval becomes effective under the laws of the State of Delaware and any Additional Stockholder Approvals (as further discussed and defined below) has been obtained. In addition, the New Warrant will have a term of exercise of six (6) years after Closing Date, and an exercise price equal to $0.18.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">You may accept this offer and reflect your agreement with the terms of this letter agreement, including the amendment of your 2021 Original Warrant and acceptance of the New Warrant, by (i) signing below, (ii) delivering both your signed voting letter that relates to the Stockholder Approval and any Additional Stockholder Approvals (as defined below), a form of which is attached as <u>Annex C-1</u> (the &#8220;<u>Voting Letter</u>&#8221;), and your signed Leak-Out Agreement, a form of which is attached as <u>Annex G</u> (the &#8220;<u>Leak-Out Agreement</u>&#8221;). Such acceptance and this letter agreement and the Voting Letter will become effective <i>only</i> upon the acceptance by the Other Holders (defined below) listed on <u>Annex D</u> (collectively, the &#8220;<u>Participating Other Holders</u>&#8221;) of the same terms and conditions as the offer provided hereunder and having signed and delivered to the Company their respective Other Warrant Exercise Agreements (as defined below) and their respective voting letters. You will receive written notice from the Company in the event that it does not receive acceptances from all of the Participating Other Holders on or before 8:00 a.m. (New York City time) on September 9, 2022, and, in such event, this letter agreement, the Voting Letter and its terms, conditions and all obligations of the Company and the Holder will automatically terminate and be of no further force or effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Subject to this letter agreement becoming effective as provided above, your acceptance shall constitute your notice and authorization to consummate the Initial Warrant Exercise in the amount and for the aggregate exercise price as set forth on your signature page hereto on or before 8:00 a.m. (New York City time) on September 9, 2022. By signing below, you represent that the Beneficial Ownership Limitation (as defined in the Amended Warrant) will not be exceeded upon the issuance of all of the shares of Common Stock received from the Initial Warrant Exercise. Additionally, the Company agrees to make the representations and warranties to the Holder, and each of the Company and the Holder, as the case may be, will acknowledge and agree to the covenants set forth on <u>Annex A</u> attached hereto. Further, in connection with the issuance of the New Warrant, the Holder agrees and shall make the representations and warranties as set forth in Section 3.2(a) through (g) of the Purchase Agreement to the Company, as the Company will be relying upon them in connection with the issuance of the New Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">If this offer is accepted by your execution and delivery of this letter agreement (together with the Voting Letter and the Leak-Out Agreement) and becomes effective, and subject to this letter agreement becoming effective with the Company having received acceptances by the Participating Other Holders as provided above, on or before 8:00 a.m. (New York City time) on September 9, 2022, then on or before 9:00 a.m. (New York City time) on September 13, 2022, the Company shall file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing all material terms of the transactions contemplated by this letter agreement, including this letter agreement, the Voting Letter and the Leak-Out Agreement as exhibits thereto (the &#8220;<u>8-K Filing</u>&#8221;). The Company shall also file a prospectus supplement to the Registration Statement with the Securities and Exchange Commission disclosing the Reduced Exercise Price of the Amended Warrants within two (2) trading days following the 8-K Filing. From and after the issuance of the 8-K Filing, the Company represents to the Holder that it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company or any of its officers, directors, employees or agents in connection with the transactions contemplated by this letter agreement. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement entered into in contemplation of the transactions contemplated by this letter agreement, whether written or oral, between the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and the Holder or any of its Affiliates on the other hand, shall terminate. From and after the issuance of the 8-K Filing, the Company represents to the Holder that none of the Company&#8217;s directors, officers, employees or agents will provide the Holder with any material, nonpublic information that is not disclosed in the 8-K Filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Subject to this letter agreement becoming effective as provided above, no later than September 9, 2022, the closing of the Initial Warrant Exercise shall occur at such location as the parties shall mutually agree. Unless otherwise directed by Ladenburg Thalmann &amp; Co. Inc. (the &#8220;<u>Placement Agent</u>&#8221;), settlement of the Initial Warrant Exercise hereunder shall occur via &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;) (i.e., on the Closing Date, the Company shall issue the shares of Common Stock issued in the Initial Warrant Exercise (the &#8220;<u>Exercised Warrant Shares</u>&#8221;) in the Holder&#8217;s name and address and be released by the Company&#8217;s transfer agent directly to the account(s) of the Placement Agent as identified by the Holder; upon receipt of such Exercised Warrant Shares, the Placement Agent shall promptly electronically deliver such Exercised Warrant Shares to the Holder; and payment of the aggregate exercise price therefor shall be made by the Placement Agent (or its clearing firm) on behalf of the Holder by wire transfer to the Company). On or prior to the Closing Date, the Holder shall deliver or cause to be delivered to the Company such Holder&#8217;s aggregate exercise price for the Exercised Warrant Shares, which shall be made available for DVP settlement with the Company or its designee. The date of the closing of the Initial Warrant Exercise of the Amended Warrants shall be referred to as the &#8220;<u>Closing Date</u>&#8221;. After the Initial Warrant Exercise is completed, the Company will request the return of your 2021 Original Warrant and the Company will issue your Amended Warrant reflecting the Reduced Exercise Price, your Remaining Warrant Share Amount and the other amendments and changes to which you will have agreed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any other Common Stock or Common Stock Equivalents; provided, however, that this prohibition shall not apply to the Company&#8217;s issuance of securities (x) in connection with the Company&#8217;s issuance and sale of Units (consisting of the Company&#8217;s Series C Non-Voting Convertible Preferred Stock, Series A-1 Warrants to purchase Common Stock and Series A-2 Warrants to Purchase Common Stock) in a private offering to accredited investors (the &#8220;<u>2022 Private Offering</u>&#8221;), (y) the amendment of certain outstanding common stock purchase warrants that were issued in a prior warrant reprice transaction that closed on July 23, 2020 (the &#8220;<u>2020 Warrant Reprice Transaction</u>&#8221;) or (z) upon the exercise or exchange of or conversion of any securities exercisable or exchangeable for or convertible into shares of Common Stock, or other similar rights, issued and outstanding on the date of this letter agreement, provided that such outstanding securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than any amendment pursuant to any Other Warrant Exercise Agreement (as defined below) or anti-dilution adjustment of the conversion price of the Company&#8217;s&nbsp;Series B Non-Voting Convertible Preferred Stock or (ii) file any registration statement or any amendment or supplement to any existing registration statement (other than (1) the resale registration statement referred to herein or prospectus supplements to the Registration Statements to reflect the transactions contemplated hereby, (2) the resale registration statement contemplated by the 2022 Private Offering, (3) the resale registration statement, including any amendment or prospectus supplement, that relates to the underlying shares of Common Stock for the repriced warrants contemplated by the 2020 Warrant Reprice Transaction, or (4) to register additional shares of Common Stock as a result of anti-dilution adjustments with respect to the Company&#8217;s Series B Non-Voting Convertible Preferred Stock).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company shall hold a special meeting of stockholders (which may also be at the annual meeting of stockholders) (the &#8220;<u>Stockholder Meeting</u>&#8221;) at the earliest practical date after the date hereof and in any event on or before the 75<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> day following the Closing Date to obtain Stockholder Approval (defined below), with the recommendation of the Company&#8217;s board of directors that such proposal be approved (subject to their fiduciary duties at such time). The Company shall solicit proxies from its stockholders with respect to the Stockholder Approval in the same manner as all other management proposals contained in such proxy statement. The Company shall use its reasonable best efforts to obtain Stockholder Approval. If the Company does not obtain Stockholder Approval at the Stockholder Meeting, the Company shall call a stockholder meeting every four months thereafter to seek Stockholder Approval until the date Stockholder Approval is obtained. As used herein, &#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the laws of the State of Delaware from the stockholders of the Company with respect to the Company&#8217;s filing of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of Common Stock, which reverse stock split shall have a ratio of not less than 1-for-10 and not more than 1-for-35 (each 10 to 35 shares of Common Stock, as the case may be, shall be combined to become 1 share of Common Stock). In addition, at the Stockholder Meeting (or subsequently called meeting as provided above), the Company may also submit for stockholder approval additional proposals that may be required by the rules of the NYSE American (the &#8220;<u>Additional Stockholder Approvals</u>&#8221;).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Holder the executed Voting Letters, in the form attached hereto as <u>Annex C-2</u>, of all of the Company&#8217;s executive officers, directors, stockholders holding more than 10% of the issued and outstanding shares of Common Stock on the date hereof, Pioneer Pharma (Hong Kong) Company Ltd. and Jian Ping Fu, that provides for such persons to vote all Common Stock over which they have voting control as of the record date for the purpose of obtaining the Stockholder Approval and any Additional Stockholder Approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">As of the Closing Date, the Company shall have retained a financial public relations firm reasonably acceptable to the Placement Agent and the Company, which firm will be experienced in assisting issuers in public offerings of securities and in their relations with their security holders, and shall retain such firm or another firm reasonably acceptable to the Placement Agent for a period of not less than one year after the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Except as set forth herein, the terms of the Amended Warrant, including but not limited to the obligations to deliver the underlying shares of Common Stock in connection with the Initial Warrant Exercise, shall remain in effect as if the acceptance of this offer and entering into this letter agreement was a formal exercise notice under the Amended Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the obligations of any other holder of 2021 Original Warrants (each, an &#8220;<u>Other Holder</u>&#8221;), including the Other Holders who are Participating Other Holders that enter into similar letter agreements (together with similar voting letters) as the Holder (the &#8220;<u>Other Warrant Exercise Agreement</u>&#8221;), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof until 180 days after the date hereof, that none of the terms offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver thereof) relating to any of the 2021 Original Warrants, is or will be more favorable to such Other Holder than those of the Holder and this letter agreement, unless such terms are concurrently offered to the Holder. If, and whenever on or after the date hereof until thirty (30) days after the date hereof, the Company enters into an Other Warrant Exercise Agreement relating to 2021 Original Warrants, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence thereof (&#8220;<u>Notice of Transaction</u>&#8221;) and (ii) the terms and conditions of this letter agreement shall be, without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and the obligation of the conditions (as the case may be) set forth in such Other Warrant Exercise Agreement (including, if applicable, the issuance of additional underlying shares of Common Stock), provided that upon written notice to the Company within five (5) days after receiving a Notice of Transaction, the Holder may provide written notice to the Company electing not to accept all of the benefits of any such amended and modified term and the related conditions, in which event the terms and conditions contained in this letter agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of this paragraph shall apply similarly and equally to each such Other Warrant Exercise Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of the Exercised Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Upon the countersignature and delivery of this letter agreement by the Holder (together with your signed Voting Letter and the Leak-Out Agreement) and subject to this letter agreement becoming effective with the Company having received acceptances by the Participating Other Holders as provided above, the parties will have mutually agreed to amend (in accordance with Section 5(l) of the 2021 Original Warrant) those terms and conditions in your 2021 Original Warrant to provide for the Amended Warrant that will set forth the amendments and changes reflected in <u>Annex E</u> to this letter agreement and for the Company to issue you the New Warrant after the Closing Date. Unless otherwise agreed to in this letter agreement, the Amended Warrant will not otherwise be amended or modified.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">This letter agreement shall be governed by the laws of the State of New York without regard to the principles of conflicts of law thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">***************</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">To accept this offer and to enter into this letter agreement, you must counter execute this letter agreement and sign the Voting Letter and the Leak-Out Agreement and return the fully executed letter agreement and signed Voting Letter and the Leak-Out Agreement to the Company at e-mail: jhall@novabay.com, attention: Justin Hall, on or before 8:00 am (New York City time) by September 9, 2022. As noted above, your acceptance and this letter agreement, including the amendment to your 2021 Original Warrant, will be effective only upon the similar acceptance of the Participating Other Holders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Please do not hesitate to call me if you have any questions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sincerely yours,</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;"><b>NOVABAY PHARMACEUTICALS, INC.</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">By:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">Name:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">Justin M. Hall</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">Title:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">Chief Executive Officer and General Counsel</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 216pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accepted and Agreed to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Holder: ________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Signature of Authorized Signatory of Holder</i>: _________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: _______________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory: ________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Warrant Shares (<i>prior to the Initial Warrant Exercise</i>): _____________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Number of Warrant Shares being exercised under the Amended Warrant contemporaneously with signing this letter agreement (<i>Initial Exercise Amount</i>): _____________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Aggregate Exercise Price for the Initial Exercise Amount: $__________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Number of Warrant Shares After the Initial Warrant Exercise (Remaining Amended Warrant Shares):&nbsp;______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex A </u></b><u>&#8211;</u><b><u> Representations, Warranties and Covenants</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><u>Representations, Warranties and Covenants</u>. The Company hereby makes the following representations and warranties to the Holder, and each of the Company and the Holder, as the case may be, acknowledged and agree to covenants set forth below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement</u>. The Warrant Shares are registered for issuance on a Registration Statement on Form S-1 (File No. 333-262550) (the &#8220;<u>Registration Statement</u>&#8221;) and the Company knows of no reason as of the date hereof why such registration statement shall not remain available for the issuance and resale of such Warrant Shares for the foreseeable future. The Company shall use commercially reasonable efforts to keep the Registration Statement effective and available for use by the Holder until all remaining Warrant Shares underlying the Amended Warrant are sold by the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization; Enforcement</u>. The Company will have the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby will be duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected, other than for which a waiver has been obtained by the Company; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>NYSE American Corporate Governance</u>. The transactions contemplated under this letter agreement comply with all applicable rules of the NYSE American LLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance of the New Warrant</u>. The issuance of the New Warrants is duly authorized and, upon the execution of this letter agreement by the undersigned and it becomes effective, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company, and the shares issuable upon exercise of the New Warrant (the &#8220;<u>New Warrant Shares</u>&#8221;), when issued in accordance with the terms of the New Warrant, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. After the Stockholder Approval Date, the Company shall reserve from its duly authorized capital stock a number of shares of Common Stock for issuance of the New Warrant Shares in full in accordance with its terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Legends and Transfer Restrictions.</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 54pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;The New Warrant and New Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of New Warrant or New Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the undersigned or in connection with a pledge, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred New Warrant and New Warrant Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this letter agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 54pt;text-indent:54pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned agrees to the imprinting, so long as is required by this Section (i), of a legend on any of the New Warrant and New Warrant Shares in the following form:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH IN THE APPLICABLE WARRANT REPRICE LETTER, DATED SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 27pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that the undersigned may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the New Warrant to a financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this letter agreement and, if required under the terms of such arrangement, the undersigned may transfer pledged or secured New Warrant to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate undersigned&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of New Warrant may reasonably request in connection with a pledge or transfer of the New Warrant or New Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:19pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;Certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth in Section (f)(ii) hereof), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144, (iii) if such New Warrant Shares are eligible for sale under Rule 144, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to its transfer agent (if required by the transfer agent) and the undersigned (if requested by the undersigned) in connection with the removal of the legend hereunder. If all or any portion of a New Warrant is exercised at a time when there is an effective registration statement to cover the resale of the New Warrant Shares, or if such New Warrant Shares may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such New Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this Section (f), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive legend (such date, the &#8220;<u>Legend Removal Date</u>&#8221;)<u>,</u>&nbsp;deliver or cause to be delivered to the undersigned a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section (f). Certificates for New Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the undersigned by crediting the account of the undersigned&#8217;s prime broker with the Depository Trust Company System as directed by the undersigned. &#8220;Standard Settlement Period&#8221;&nbsp;means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 54pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;In addition to such undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section (f)(iii), $2.50 per Trading Day (increasing to $15 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the undersigned by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such undersigned that is free from all restrictive and other legends and (b) if after the Legend Removal Date such undersigned purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such undersigned of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such undersigned anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such undersigned&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<u>Buy-In Price</u>&#8221;) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to such undersigned by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such undersigned to the Company of the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Public Information Failure</u>. At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the New Warrant Shares may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if there is no effective registration statement covering the resale of all of the New Warrant Shares and the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<u>Public Information Failure</u>&#8221;) then, in addition to the undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the New Warrant Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of the undersigned&#8217;s New Warrant on the day of a Public Information Failure and on every thirtieth (30th) day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required for the undersigned to transfer the New Warrant Shares pursuant to Rule 144. The payments to which the undersigned shall be entitled pursuant to this Section (g) are referred to herein as &#8220;Public Information Failure Payments.&#8221; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit the undersigned&#8217;s right to pursue actual damages for the Public Information Failure, and the undersigned shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(h) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Listing of Common Stock</u>. The Company shall, subject to applicable requirements of the NYSE American, apply to list or quote all of the New Warrant Shares on the NYSE American and promptly secure the listing of all of the New Warrant Shares on such NYSE American.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement</u>. As soon as practicable (and in any event within 30 calendar days of the Stockholder Approval Date), the Company shall file a registration statement on Form S-1 or Form S-3 (or other appropriate form) providing for the resale by the Holders of the New Warrant Shares issued and issuable upon exercise of the New Warrants. The Company shall use commercially reasonable efforts to cause such registration to become effective on or prior to 60 calendar days of the Stockholder Approval Date and to keep such registration statement effective at all times until no Holder owns any New Warrants or New Warrant Shares issuable upon exercise thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex B </u></b><u>&#8211;</u><b><u> Amended Warrant Amounts</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 31.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>TOTAL AMENDED</u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>WARRANTS</u></b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>INITIAL EXERCISE </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>AMOUNT (25%)</u></b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>REMAINING AMENDED </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>WARRANT SHARES (75%)</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.6%; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.6%; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.6%; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35.4%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34.3%; border-right: 1px solid black;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="text-align: center;">&nbsp;</div>

<div style="text-align: center;"><img alt="logo01.jpg" src="logo01.jpg"></div>

<div style="text-align: center;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex C-1 </u></b><u>&#8211;</u><b><u> Voting Letter (Participating Holders)</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Voting Letter (Participating Holders) is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.5.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="text-align: center;">&nbsp;</div>

<div style="text-align: center;"><img alt="logo01.jpg" src="logo01.jpg"></div>

<div style="text-align: center;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex C-2 </u></b><u>&#8211;</u><b><u> Voting Letter (Other)</u></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Voting Letter (Other) is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.6.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex D </u></b><u>&#8211;</u><b><u> Participating Other Holders</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex E </u></b><u>&#8211;</u><b><u> Form of Amended Warrant</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Form of Amended Warrant is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 4.2.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex F </u></b><u>&#8211;</u><b><u> Form of New Warrant</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Form of New Warrant is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 4.4.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex G </u></b><u>&#8211;</u><b><u> Form of Leak-Out Agreement</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Form of Leak-Out Agreement is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.7.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>11
<FILENAME>ex_422221.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<html><head>
	<title>ex_422221.htm</title>

	<!-- Generated by ThunderDome Portal - 9/12/2022 11:28:30 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.3</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: center;"><b>SECURITIES PURCHASE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Securities Purchase Agreement (this &#8220;<u>Agreement</u>&#8221;) is dated as of September 9, 2022, between NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221; and collectively, the &#8220;<u>Purchasers</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE I.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DEFINITIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Certificate of Designation (as defined herein), and (b) the following terms have the meanings set forth in this Section 1.1:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Acquiring Person</u>&#8221; shall have the meaning ascribed to such term in Section 4.7.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Action</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(j).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Amendment</u>&#8221; means the amendment to the Company&#8217;s certificate of incorporation to effect a reverse stock split of the outstanding shares of Common Stock, which reverse stock split shall have a ratio of not less than 1-for-10 and not more than 1-for-35 (each 10-35 shares of outstanding Common Stock shall be combined to become 1 share of outstanding Common Stock, without change to the number of authorized shares of Common Stock).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Certificate of Designation</u>&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock to be filed prior to the Closing by the Company with the Secretary of State of Delaware, in the form of <u>Exhibit A</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount and (ii) the Company&#8217;s obligations to deliver the Securities, in each case, have been satisfied or waived.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Company Counsel</u>&#8221; means Squire Patton Boggs (US) LLP, with offices located at 2550 M Street, NW, Washington, D.C. 20037.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Conversion Price</u>&#8221; shall mean the conversion price of $0.18 for the Preferred Stock, which will be adjusted to reflect reverse stock split contemplated by the Amendment and shall be provided for in the in the Certificate of Designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Conversion Shares</u>&#8221; shall have the meaning ascribed to such term in the Certificate of Designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Disclosure Schedules</u>&#8221; means the Disclosure Schedules of the Company delivered concurrently herewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Disclosure Time</u>&#8221; means, (a) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (b) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Effective Date</u>&#8221; means the earliest of the date that (a) the initial Registration Statement has been declared effective by the Commission, (b) all of the Underlying Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary of the Closing Date provided that a holder of Underlying Shares is not an Affiliate of the Company, or (d) all of the Underlying Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act without volume or manner-of-sale restrictions and Company Counsel has delivered to such holders a standing written unqualified opinion that resales may then be made by such holders of the Underlying Shares pursuant to such exemption which opinion shall be in form and substance reasonably acceptable to such holders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>EGS</u>&#8221; means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Escrow Agent</u>&#8221; means Continental Stock Transfer &amp; Trust Company with offices at 1 State Street, New York, New York 10004.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Escrow Agreement</u>&#8221; means the escrow agreement entered into on or about the date hereof, by and among the Company, the Escrow Agent and the Placement Agent pursuant to which the Purchasers shall deposit the Subscription Amounts with the Escrow Agent to be applied to the transactions contemplated hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Evaluation Date</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(s).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Exempt Issuance</u>&#8221; means the issuance of (a) shares of Common Stock, options, restricted stock units or other equity awards to employees, officers or directors of the Company pursuant to any stock or option plan or any other equity award plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement or in connection with the Warrant Reprice Transactions, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations or pursuant to anti-dilution adjustments) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>FCPA</u>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>FDA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(ll).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>FDCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(ll).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>GAAP</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Indebtedness</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(bb).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Legend Removal Date</u>&#8221; shall have the meaning ascribed to such term in Section 4.1(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Liens</u>&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Material Adverse Effect</u>&#8221; shall have the meaning assigned to such term in Section 3.1(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(n).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Maximum Rate</u>&#8221; shall have the meaning ascribed to such term in Section 5.17.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Pharmaceutical Product</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(ll).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Placement Agent</u>&#8221; means Ladenburg Thalmann &amp; Co. Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Preferred Stock</u>&#8221; means up to 3,250 shares of the Company&#8217;s Series C Non-Voting Convertible Preferred Stock issued hereunder having the rights, preferences and privileges set forth in the Certificate of Designation, in the form of <u>Exhibit A</u> hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Proceeding</u>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Public Information Failure</u>&#8221; shall have the meaning ascribed to such term in Section 4.3(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Public Information Failure Payments</u>&#8221; shall have the meaning ascribed to such term in Section 4.3(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Purchaser Party</u>&#8221; shall have the meaning ascribed to such term in Section 4.10.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Registration Rights Agreement</u>&#8221; means the Registration Rights Agreement, dated on or about the date hereof, among the Company and the Purchasers, in the form of <u>Exhibit B</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Registration Statement</u>&#8221; or &#8220;<u>Registration Statements</u>&#8221; means the registration statement(s) meeting the requirements set forth in the Registration Rights Agreement and covering the resale of the Underlying Shares by each Purchaser as provided for in the Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Required Minimum</u>&#8221; means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant to the Transaction Documents, including any Underlying Shares issuable upon exercise in full of all Warrants or conversion in full of all shares of Preferred Stock, ignoring any conversion or exercise limits set forth therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Reverse Stock Split Approval</u>&#8221; means approval of the Amendment by the stockholders of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Reverse Stock Split Date</u>&#8221; means, subject to Reverse Stock Split Approval, the date on which the Amendment is filed with and accepted by the State of Delaware.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Securities</u>&#8221; means the Preferred Stock, the Warrants and the Underlying Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Series A-1 Warrants</u>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be immediately exercisable and have a term of exercise equal to six (6) years from the initial exercise date set forth therein, in the form of <u>Exhibit C-1</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Series A-2 Warrants</u>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be immediately exercisable and have a term of exercise equal to eighteen (18) months from the initial exercise date set forth therein, in the form of <u>Exhibit C-2</u> attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Short Sales</u>&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Stated Value</u>&#8221; means $1,000 per share of Preferred Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the applicable rules and regulations of the NYSE American (or any successor entity) from the stockholders of the Company with respect to the transactions contemplated by the Transaction Documents, including the issuance of all of the Underlying Shares in excess of 19.99% of the issued and outstanding Common Stock on the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Subscription Amount</u>&#8221; shall mean, as to each Purchaser, the aggregate amount to be paid for the Preferred Stock and the Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company as set forth on <u>Schedule 3.1(a)</u> and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Day</u>&#8221; means a day on which the principal Trading Market is open for trading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Transaction Documents</u>&#8221; means this Agreement, the Certificate of Designation, the Warrants, the Registration Rights Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Transfer Agent</u>&#8221; means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing address of 462 South 4<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> Street, Suite 1600, Louisville KY 40202, and any successor transfer agent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Underlying Shares</u>&#8221; means the Conversion Shares and the Warrant Shares, which number of shares shall be subject to adjustment to account for the Company&#8217;s reverse stock split contemplated by the Amendment and as otherwise set forth therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Variable Rate Transaction</u>&#8221; shall have the meaning ascribed to such term in Section 4.12(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Warrants</u>&#8221; means, collectively, the Series A-1 Warrants and the Series A-2 Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Warrant Reprice Transactions</u>&#8221; mean, collectively, the two separate warrant reprice transactions contemplated by letter agreements between the Company and (i) certain holders of Common Stock purchase warrants issued by the Company in connection with the Company&#8217;s warrant reprice transaction that closed on July 23, 2020, for the first transaction, and (ii) certain holders of Common Stock purchase warrants issued by the Company in connection with the Company&#8217;s private placement financing transactions that closed on November 2, 2021, for the second transaction, which transactions provide for those holders participating, among other terms, changes to the terms of the Common Stock purchase warrants that will reduce the exercise price, and, for those participating holders that exercise a portion of their outstanding Common Stock purchase warrants (such exercise, the &#8220;<u>Initial Exercise</u>&#8221;), such participating holders will also receive a new warrant to purchase a number of shares of Common Stock equal to the number of shares of Common Stock received by such investor pursuant to its applicable Initial Exercise (including the registration of the resale of the Common Stock underlying such new warrants).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Warrants, which number of shares shall be subject to adjustment to account for the Company&#8217;s reverse stock split contemplated by the Amendment and as otherwise set forth therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ARTICLE II.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURCHASE AND SALE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing</u>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $3,250,000 of shares of Preferred Stock with an aggregate Stated Value for each Purchaser equal to such Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and Warrants as determined pursuant to Section 2.2(a). The aggregate number of shares of Preferred Stock sold hereunder shall be up to 3,250. Each Purchaser shall deliver to the Escrow Agent, via wire transfer or a certified check, immediately available funds equal to such Purchaser&#8217;s Subscription Amount and the Company shall deliver to each Purchaser its respective shares of Preferred Stock and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2(b) deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree and the Placement Agent shall deliver to the Escrow Agent the Form of Escrow Release Notice (as defined in the Escrow Agreement), duly executed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">2.2&nbsp; &nbsp; <u>Deliveries</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;a legal opinion of Company Counsel, substantially in the form of <u>Exhibit D</u> attached hereto;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;a certificate evidencing a number of shares of Preferred Stock equal to such Purchaser&#8217;s Subscription Amount divided by the Stated Value, registered in the name of such Purchaser and evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of Delaware;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;a Series A-1 Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&#8217;s Subscription Amount divided by the initial Conversion Price, with an exercise price equal to $0.18, subject to adjustment to account for the Company&#8217;s reverse stock split contemplated by the Amendment and as otherwise set forth therein;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;a Series A-2 Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&#8217;s Subscription Amount divided by the initial Conversion Price, with an exercise price equal to $0.18, subject to adjustment to account for the Company&#8217;s reverse stock split contemplated by the Amendment and as otherwise set forth therein;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have provided each Purchaser with the Escrow Agent&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;evidence of filing and acceptance of the Amendment from the Secretary of State of Delaware; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;the Registration Rights Agreement duly executed by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company or the Escrow Agent, as applicable, the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;to the Escrow Agent, such Purchaser&#8217;s Subscription Amount by wire transfer to the account specified in the Escrow Agreement; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Registration Rights Agreement duly executed by such Purchaser.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">2.3&nbsp; &nbsp;&nbsp;<u>Closing Conditions</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have received Stockholder Approval and Reverse Stock Split Approval;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the filing and acceptance of the Amendment with the Secretary of State of Delaware;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have received Stockholder Approval and Reverse Stock Split Approval;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;the filing and acceptance of the Amendment with the Secretary of State of Delaware;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE III.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>REPRESENTATIONS AND WARRANTIES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.1 &nbsp; &nbsp; <u>Representations and Warranties of the Company</u>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsidiaries</u>. The Company has no subsidiaries other than DERMAdoctor, LLC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;); provided that a change in the market price or trading volume of the Common Stock alone shall not be deemed, in and of itself, to constitute a Material Adverse Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.6 of this Agreement, (ii) the filing(s) with the Commission pursuant to the Registration Rights Agreement, (iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Underlying Shares for trading thereon in the time and manner required thereby, (iv) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws, (v) Stockholder Approval and (vi) Reverse Stock Split Approval (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance of the Securities</u>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer, conversion and/or exercise provided for in the Transaction Documents. The Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Capitalization</u>. The capitalization of the Company as of the date hereof is as set forth on <u>Schedule 3.1(g)</u>, which <u>Schedule 3.1(g)</u> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act, pursuant to the Company&#8217;s At The Market Offering Agreement, dated May 14, 2021, between the Company and the Placement Agent, and in connection with the Warrant Reprice Transactions. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities as contemplated hereby and in connection with the Warrant Reprice Transactions, or as otherwise disclosed in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. Except as disclosed in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Stockholder Approval and the Reverse Stock Split Approval, no further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except for the rights provided in the Transaction Documents and the voting letters being entered between the Company and certain security holders in connection with the Warrant Reprice Transactions, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>SEC Reports; Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<u>GAAP</u>&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Changes; Undisclosed Events, Liabilities or Developments</u>. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on <u>Schedule 3.1(i)</u>, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans or other equity plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <u>Schedule 3.1(i)</u>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation</u>. Except as set forth on <u>Schedule 3.1(j)</u>, there is no material action, suit, inquiry, notice of violation, Proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;). None of the Actions set forth on <u>Schedule 3.1(j)</u>, (i) would adversely affect or challenge the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance</u>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Laws</u>.The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of Proceedings relating to the revocation or modification of any Material Permit.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;<u>Title to Assets</u>. The Company and the Subsidiaries do not own any real property. The Company and the Subsidiaries have good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all material respects.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property</u>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have would have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual Property Rights</u>&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(r)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transactions with Affiliates and Employees</u>. Except as set forth on <u>Schedule 3.1(r)</u>, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements or other equity awards under any stock option plan or other equity plan of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(s)&nbsp;&nbsp;&nbsp;&nbsp;<u>Sarbanes-Oxley; Internal Accounting Controls</u>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(t)&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Fees</u>. Except for the fees paid to the Placement Agent, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(u)&nbsp;&nbsp;&nbsp;&nbsp;<u>Private Placement</u>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>Investment Company.</u> The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(w)&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Rights</u>. Other than each of the Purchasers and in connection with the Warrant Reprice Transactions, and as disclosed in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(x)&nbsp;&nbsp;&nbsp;&nbsp;<u>Listing and Maintenance Requirements</u>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as described in the SEC Reports, (i) the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market and (ii) the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(y)&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Takeover Protections</u>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(z)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disclosure</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor, to the Company&#8217;s knowledge, any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities under the Securities Act, or (ii) any applicable stockholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.<u> </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<u>Solvency</u>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <u>Schedule 3.1(bb)</u> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &#8220;<u>Indebtedness</u>&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Status</u>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<u>No General Solicitation</u>. Neither the Company nor, to the Company&#8217;s knowledge, any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain other &#8220;accredited investors&#8221; within the meaning of Rule 501 under the Securities Act and introduced to the Company by the Placement Agent.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<u>Foreign Corrupt Practices.</u> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<u>Accountants</u>. The Company&#8217;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending December 31, 2022.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<u>Seniority</u>. As of the Closing Date, no Indebtedness or other claim against the Company is senior to the Preferred Stock in right of payment, whether with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior only as to the property covered thereby) or otherwise provided by law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Disagreements with Accountants and Lawyers.</u> There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company&#8217;s ability to perform any of its obligations under any of the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgment Regarding Purchasers</u><u>&#8217;</u><u> Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities. The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgment Regarding Purchaser</u><u>&#8217;</u><u>s Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.15 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or indirectly, may presently have a &#8220;short&#8221; position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Underlying Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&#8217; equity interests in the Company at and after the time that the hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulation M Compliance</u>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&#8217;s placement agent in connection with the placement of the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(ll)&nbsp; &nbsp;&nbsp; <u>FDA</u>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<u>FDCA</u>&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<u>Pharmaceutical Product</u>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. Except as set forth on <u>Schedule 3.1(ll)</u>, there is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA.&nbsp; The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(mm)&nbsp;&nbsp; <u>Form S-1 Eligibility</u>.The Company is eligible to register the resale of the Underlying Shares for resale by the Purchaser on Form S-1 promulgated under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Option Plans</u>. Each stock option granted by the Company under the Company&#8217;s stock option plan or other equity plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan or other equity plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan or other equity plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.<u> </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cybersecurity</u>.&nbsp; (i)(x) There has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to their IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<u>OFAC</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(qq)&nbsp;&nbsp;&nbsp;&nbsp;<u>U.S. Real Property Holding Corporation</u>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#8217;s request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(rr)&nbsp;&nbsp;&nbsp;&nbsp;<u>Bank Holding Company Act</u>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;<u>BHCA</u>&#8221;) or to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<u>Federal Reserve</u>&#8221;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(ss)&nbsp;&nbsp;&nbsp;&nbsp;<u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in material compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(tt)&nbsp; &nbsp;&nbsp; <u>No Disqualification Events</u>. &nbsp;With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an "<u>Issuer Covered Person</u>" and, together, "<u>Issuer Covered Persons</u>") is subject to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a "<u>Disqualification Event</u>"), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(uu)&nbsp;&nbsp; <u>Other Covered Persons</u>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(vv)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Disqualification Events</u>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(b)&nbsp; &nbsp;&nbsp; <u>Own Account</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. Such Purchaser understands that the Securities are &#8220;restricted securities&#8221; and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement(s) or otherwise in compliance with applicable federal and state securities laws).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants or converts any shares of Preferred Stock, it will be either: (i) an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A(a) under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(e)&nbsp;&nbsp; &nbsp; <u>General Solicitation</u>. Such Purchaser is not, to such Purchaser&#8217;s knowledge, purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(f) &nbsp;&nbsp; &nbsp; <u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">(g)&nbsp; &nbsp;&nbsp; <u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE IV.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>OTHER AGREEMENTS OF THE PARTIES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration Rights Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following form:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">[NEITHER] THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTION SET FORTH HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 9, 2022, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Certificates evidencing the Underlying Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement (including the Registration Statement(s)) covering the resale of such security is effective under the Securities Act, (ii) following any sale of such Underlying Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants), (iii) if such Underlying Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants) or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any shares of Preferred Stock are converted or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Underlying Shares, or if such Underlying Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144, or if the Underlying Shares may be sold under Rule 144 (assuming cashless exercise of the Warrants) without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Underlying Shares and without volume or manner-of-sale restrictions or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Underlying Shares shall be issued free of all legends. The Company agrees that following the Effective Date or at such time as such legend is no longer required under this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Underlying Shares, as applicable, issued with a restrictive legend (such date, the &#8220;<u>Legend Removal Date</u>&#8221;), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates for Underlying Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&#8217;s prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Underlying Shares, as applicable, issued with a restrictive legend.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;In addition to such Purchaser&#8217;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of Underlying Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such Purchaser anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such Purchaser&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<u>Buy-In Price</u>&#8221;) over the product of (x) such number of Underlying Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (y) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Underlying Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company&#8217;s reliance upon this understanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgment of Dilution</u>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Furnishing of Information; Public Information</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the Securities may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<u>Public Information Failure</u>&#8221;) then, in addition to such Purchaser&#8217;s other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to two percent (2.0%) of the aggregate Subscription Amount of such Purchaser&#8217;s Securities on the day of a Public Information Failure and on every thirtieth (30<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required&nbsp; for the Purchasers to transfer the Underlying Shares pursuant to Rule 144.&nbsp; The payments to which a Purchaser shall be entitled pursuant to this Section 4.3(b) are referred to herein as &#8220;<u>Public Information Failure Payments</u>.&#8221;&nbsp; Public Information Failure<b> </b>Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure<b> </b>Payments are incurred and (ii) the third (3<sup style="vertical-align:top;line-height:120%;font-size:pt">rd</sup>) Business Day after the event or failure giving rise to the Public Information Failure<b> </b>Payments is cured.&nbsp; In the event the Company fails to make Public Information Failure<b> </b>Payments in a timely manner, such Public Information Failure<b> </b>Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&#8217;s right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conversion and Exercise Procedures</u>. Each of the form of Notice of Exercise included in the Warrants and the form of Notice of Conversion included in the Certificate of Designation sets forth the totality of the procedures required of the Purchasers in order to exercise the Warrants or convert the Preferred Stock. Without limiting the preceding sentences, no ink-original Notice of Exercise or Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise or Notice of Conversion form be required in order to exercise the Warrants or convert the Preferred Stock. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants or convert their Preferred Stock in accordance with their respective terms. The Company shall honor exercises of the Warrants and conversions of the Preferred Stock and shall deliver the applicable Underlying Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with (i) any registration statement contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;<u>Acquiring Person</u>&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.6, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, director, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general corporate purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.10, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<u>Purchaser Party</u>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&#8217;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.10 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="33" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reservation and Listing of Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;From and after the Reverse Stock Split Date, the Company shall maintain a reserve of the Required Minimum from its duly authorized shares of Common Stock pursuant to the Transaction Documents in such amount as may then be necessary to fulfill its obligations in full under the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Following the date each of the Stockholder Approval and the Reverse Stock Split Approval is received and effective, if, on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than 130% of (i)&nbsp;the Required Minimum on such date, minus (ii) the number of shares of Common Stock previously issued pursuant to the Transaction Documents, then the Board of Directors shall use commercially reasonable efforts to amend the Company&#8217;s certificate or articles of incorporation to increase the number of authorized but unissued shares of Common Stock to at least 130% of the Required Minimum at such time (minus the number of shares of Common Stock previously issued pursuant to the Transaction Documents), as soon as possible and in any event not later than the 75<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> day after such date, provided that the Company will not be required at any time to take such action to amend the Company&#8217;s certificate or articles of incorporation if such action would be authorizing a number of shares of Common Stock greater than the maximum remaining number of shares of Common Stock that could possibly be issued after such time pursuant to the Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and file with such Trading Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required Minimum on the date of such application, (ii) take all steps necessary to cause such shares of Common Stock to be approved for listing or quotation on such Trading Market as soon as possible thereafter, (iii) provide to the Purchasers evidence of such listing or quotation and (iv) maintain the listing or quotation of such Common Stock on any date at least equal to the Required Minimum on such date on such Trading Market or another Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. In addition, the Company shall hold a special meeting of shareholders (which may also be at the annual meeting of shareholders) at the earliest practical date after the date hereof, but no later than seventy-five (75) days after the date of this Agreement (assuming no review of the Proxy Statement by the Commission), or one-hundred and five (105) days after the date of this Agreement (assuming a review of the Proxy Statement by the Commission) for the purpose of obtaining the Stockholder Approval and the Reverse Stock Split Approval (collectively, the &#8220;<u>Approvals</u>&#8221;), with the recommendation of the Company&#8217;s Board of Directors that such proposals be approved, and the Company shall solicit proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. The Company shall use its reasonable best efforts to obtain such Approvals. If the Company does not obtain the Approvals at the first meeting, the Company shall call a meeting every four (4) months thereafter to seek the Approvals until the earlier of the date the Approvals are obtained or the Preferred Stock is no longer outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="34" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Equity Sales</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof until ninety (90) days after the later of (i) the date each of the Stockholder Approval and the Reverse Stock Split Approval is received and effective and (ii) the Effective Date, and the Closing occurs, neither the Company nor any Subsidiary shall (x) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents, (y) incur, enter into any agreement to incur or announce the incurrence or proposed incurrence of any Indebtedness, or (z) file any registration statement or any amendment or supplement thereto, in each case other than as contemplated pursuant to the Registration Rights Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof until the one (1) year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;<u>Variable Rate Transaction</u>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price; <u>provided</u>, <u>however</u>, that after the period described in Section 4.12(a) above, the effecting or entering into an agreement to effect any issuances of shares of common stock in an &#8220;at the market&#8221; offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="35" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of (i) the issuance of any securities in connection with any Warrant Reprice Transaction or (ii) an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.13&nbsp;&nbsp;&nbsp;&nbsp;<u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.14&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales, of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the consummation of the Closing of the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.6.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.6, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.6, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.6 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.6.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="36" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.15&nbsp; &nbsp; &nbsp; &nbsp;<u>Form D; Blue Sky Filings</u>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or &#8220;Blue Sky&#8221; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE V.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>MISCELLANEOUS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>.&nbsp;This Agreement may be terminated by the Company or any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) Trading Day following the date Stockholder Approval and Reverse Stock Split Approval are received and effective; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties); provided, further, that the right to terminate this Agreement pursuant to this Section 5.1 shall not available to a party if such party&#8217;s breach of any representation, warranty, covenant or other agreement contained in this Agreement is the primary cause of the failure of the Closing to be consummated in accordance with the foregoing.<u> </u><b> </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any conversion or exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the e-mail address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile or email attachment at the facsimile number or e-mail address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="37" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Preferred Stock based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. &nbsp;Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned or transferred (in whole or in part) by any Party (whether by operation of law or otherwise) without the prior written consent of the other party.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Third-Party Beneficiaries</u>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the Company in Section 3.1 hereof and with respect to the representations and warranties of the Purchasers in Section 3.2 hereof. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.10 and this Section 5.8.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.10, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="38" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; <u>provided</u>, <u>however</u>, that, in the case of a rescission of a conversion of the Preferred Stock or exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded conversion or exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#8217;s right to acquire such shares pursuant to such Purchaser&#8217;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="39" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Usury</u>. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any time hereafter in force, in connection with any Action or Proceeding that may be brought by any Purchaser in order to enforce any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the &#8220;<u>Maximum Rate</u>&#8221;), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Transaction Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective date thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness evidenced by the Transaction Documents, such excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of handling such excess to be at such Purchaser&#8217;s election.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="40" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Nature of Purchasers</u><u>&#8217;</u><u> Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Liquidated Damages</u>. The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc.</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="41" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>WAIVER OF JURY TRIAL</u></b><b>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i>(Signature Pages Follow)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="42" data-prefix="" data-suffix="" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-align: center;">42</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td rowspan="1" style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Address for Notice:</u></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</td>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Email</u>:</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 3%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name:&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 4%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Fax</u>:</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 3%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Title:</p>
			</td>
			<td style="vertical-align: top; width: 4%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 3%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">With a copy to (which shall not constitute notice):</td>
			<td rowspan="1" style="vertical-align: top; width: 4%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 58%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">SIGNATURE PAGE FOR PURCHASER(S) FOLLOWS]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="43" data-prefix="" data-suffix="" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-align: center;">43</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">[PURCHASER SIGNATURE PAGES TO NBY SECURITIES PURCHASE AGREEMENT]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name of Purchaser: ____________________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Signature of Authorized Signatory of Purchaser</i>: __________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name of Authorized Signatory: ____________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Title of Authorized Signatory: _____________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Email Address of Authorized Signatory: ___________________________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Address for Notice to Purchaser:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Address for Delivery of Securities to Purchaser (if not same as address for notice):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Subscription Amount: $</td>
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 65%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Shares of Preferred Stock:</td>
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 64%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 17%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Series A-1 Warrant Shares:</td>
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 61%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 17%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Series A-2 Warrant Shares:</td>
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 61%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">EIN Number:</td>
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">[SIGNATURE PAGES CONTINUE]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="44" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Exhibit A</u><br>
Form of Certificate of Designations</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><br>
The Form of Certificate of Designations is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 3.1.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="45" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Exhibit B</u><br>
Form of Registration Rights Agreement</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><br>
The Form of Registration Rights Agreement is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 10.4.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="46" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Exhibit C-1</u><br>
Form of Series A-1 Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><br>
The Form of Series A-1 Warrants is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 4.5.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="47" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Exhibit C-2</u><br>
Form of Series A-2 Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><br>
The Form of Series A-2 Warrants is attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 13, 2022 as Exhibit 4.6.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="48" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Exhibit D</u><br>
Form of Legal Opinion</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="49" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">49</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>12
<FILENAME>ex_422222.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<html><head>
	<title>ex_422222.htm</title>

	<!-- Generated by ThunderDome Portal - 9/11/2022 4:46:42 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.4</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION RIGHTS AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This Registration Rights Agreement (this &#8220;<u>Agreement</u>&#8221;) is made and entered into as of [_______] [_], 2022, between NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each of the several purchasers signatory hereto (each such purchaser, a &#8220;<u>Purchaser</u>&#8221; and, collectively, the &#8220;<u>Purchasers</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the &#8220;<u>Purchase Agreement</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company and each Purchaser hereby agrees as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">1. &nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp; <u>Definitions</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b>Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement or the Certificate of Designation.</b> As used in this Agreement, the following terms shall have the following meanings:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">&#8220;<u>Advice</u>&#8221; shall have the meaning set forth in Section 6(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Effectiveness Date</u>&#8221; means, (a) with respect to the Initial Registration Statement required to be filed hereunder, the 60<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> calendar day following the Stockholder Approval and Reverse Stock Split Approval (or, in the event of a &#8220;full review&#8221; by the Commission, the 90<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> calendar day following Stockholder Approval and Reverse Stock Split Approval) and (b) with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the 60<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> calendar day following the date on which an additional Registration Statement is required to be filed hereunder (or, in the event of a &#8220;full review&#8221; by the Commission, the 90<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> calendar day following the date such additional Registration Statement is required to be filed hereunder); <u>provided</u>, <u>however</u>, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Effectiveness Period</u>&#8221; shall have the meaning set forth in Section 2(a).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Event</u>&#8221; shall have the meaning set forth in Section 2(d).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Event Date</u>&#8221; shall have the meaning set forth in Section 2(d).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Filing Date</u>&#8221; means (a) with respect to the Initial Registration Statement required hereunder, the 30<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> calendar day following Stockholder Approval and Reverse Stock Split Approval or (b) with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Holder</u>&#8221; or &#8220;<u>Holders</u>&#8221; means the holder or holders, as the case may be, from time to time of Registrable Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Indemnified Party</u>&#8221; shall have the meaning set forth in Section 5(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Indemnifying Party</u>&#8221; shall have the meaning set forth in Section 5(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Initial Registration Statement</u>&#8221; means the initial Registration Statement filed to register the shares of Common Stock underlying the Preferred Stock and the Warrant Shares underlying the Warrants as provided in and pursuant to this Agreement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Losses</u>&#8221; shall have the meaning set forth in Section 5(a).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Plan of Distribution</u>&#8221; shall have the meaning set forth in Section 2(a).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Prospectus</u>&#8221; means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Registrable Securities</u>&#8221; means, as of any date of determination, (a) all Shares of the shares of Common Stock then issued and issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all Warrant Shares then issued and issuable upon exercise of the Warrants (assuming on such date the Warrants are exercised in full without regard to any exercise limitations therein), (c) any additional shares of Common Stock issued and issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; <u>provided,</u> <u>however</u>, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company), as reasonably determined by the Company, upon the advice of counsel to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Registration Statement</u>&#8221; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Rule 415</u>&#8221; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Selling Stockholder Questionnaire</u>&#8221; shall have the meaning set forth in Section 3(a).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>SEC Guidance</u>&#8221; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">2. &nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp; <u>Shelf Registration</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities underlying the Preferred Stock and/or the Warrants. Each Registration Statement filed hereunder shall be on Form S-1, or such other form as determined by the Company, and shall contain (unless otherwise directed by at least 85% in interest of the Holders or otherwise modified by the Company to comply with applicable law, rule or regulation or to make any disclosure contained therein not misleading) substantially the &#8220;<u>Plan of Distribution</u>&#8221; attached hereto as <u>Annex A</u> and substantially the &#8220;<u>Selling Stockholder</u>&#8221; section attached hereto as <u>Annex B</u>; <u>provided</u>, <u>however</u>, that no Holder shall be required to be named as an &#8220;underwriter&#8221; without such Holder&#8217;s express prior written consent. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the &#8220;<u>Effectiveness Period</u>&#8221;). The Company shall telephonically request from the Commission for the effectiveness of a Registration Statement to be as of 5:00 p.m. (New York City time) on a Trading Day, provided that the actual effectiveness shall be subject to the Commission&#8217;s approval of such effectiveness. The Company shall promptly notify the Holders via e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities on the Initial Registration Statement cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on such registration statement, then the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form S-1 or, in the Company&#8217;s discretion, such other form available to register for resale the Registrable Securities as a secondary offering; with respect to filing on Form S-1 or other appropriate form as determined by the Company, and subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; <u>provided</u>, <u>however</u>, that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all of the Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Second, the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Warrant Shares held by such Holders); and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Third, the Company shall reduce Registrable Securities represented by Conversion Shares (applied, in the case that some Conversion Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Conversion Shares held by such Holders).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days&#8217; prior written notice along with the calculations as to such Holder&#8217;s allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-1 or such other appropriate form as determined by the Company to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;If: (i) the Initial Registration Statement is not filed on or prior to the Filing Date (if the Company files the Initial Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five (5) Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement within twenty (20) calendar days after the receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective, or (iv) the Initial Registration Statement registering the applicable Registrable Securities for resale is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement , or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an &#8220;<u>Event</u>&#8221;, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such twenty (20) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as an &#8220;<u>Event Date</u>&#8221;), then, in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 3.0% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate of a Holder as any Underwriter without the prior written consent of such Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">3. &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Registration Procedures</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">In connection with the Company&#8217;s registration obligations hereunder, the Company shall:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is notified of such objection in writing setting forth in detail the basis of such objection no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as <u>Annex B</u> (a &#8220;<u>Selling Stockholder Questionnaire</u>&#8221;) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) Trading Day following the date on which such Holder receives draft materials in accordance with this Section. Each Holder shall provide any additional information as may be reasonably requested by the Company and is necessary for purposes of complying with requirements under applicable securities laws and regulations or rules of any applicable stock exchange where the Common Stock is then listed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission the Initial Registration Statement or such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities to the extent provided in Section 2, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a &#8220;review&#8221; of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; <u>provided</u>, <u>however</u>, that in no event shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of this Agreement, the Company hereby consents to the use of such final Prospectus and each amendment or supplement thereto that are part of an effective Registration Statement by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp; Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account the Company&#8217;s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period not to exceed sixty (60) calendar days (which need not be consecutive days) in any 12-month period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall use its best efforts to maintain eligibility for use of Form S-1 (or any successor form thereto) for the registration of the resale of Registrable Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Company&#8217;s request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company; provided, however, if such delay prevents the filing of a Registration Statement or an amendment or supplement thereto, then liquidated damages shall be tolled until such Holder provides the information or withdraws its Registrable Securities from inclusion in the Registration Statement as provided in Section 2(e).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Expenses</u>. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company&#8217;s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">5. &nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp; <u>Indemnification</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by the Company</u>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#8217; fees) and expenses (collectively, &#8220;<u>Losses</u>&#8221;), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder&#8217;s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A and Annex B hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by Holders</u>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to such Holder&#8217;s information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A and Annex B hereto for this purpose), such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Conduct of Indemnification Proceedings</u>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an &#8220;<u>Indemnified Party</u>&#8221;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#8220;<u>Indemnifying Party</u>&#8221;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Contribution</u>. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&#8217; or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">6. &nbsp;&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp; <u>Miscellaneous</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Piggyback on Registrations; Prohibition on Filing Other Registration Statements</u>. Neither the Company (without the prior written consent of a majority of the Holders) nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements or any registration statements contemplated by the Warrant Reprice Transactions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Discontinued Disposition</u>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the &#8220;<u>Advice</u>&#8221;) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments and Waivers</u>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; <u>provided</u>, <u>however</u>, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Inconsistent Agreements</u>. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Except as set forth on <u>Schedule 6(g)</u>, neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in full.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution and Counterparts</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cumulative Remedies</u>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 54pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Nature of Holders</u><u>&#8217;</u><u> Obligations and Rights</u>. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Pages Follow)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="38%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td align="left" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[SIGNATURE PAGE OF HOLDERS FOLLOWS]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[SIGNATURE PAGE OF HOLDERS TO NBY RRA]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name of Holder: __________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Signature of Authorized Signatory of Holder</i>: __________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name of Authorized Signatory: _________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title of Authorized Signatory: __________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[SIGNATURE PAGES CONTINUE]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>Annex A</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PLAN OF DISTRIBUTION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Each Selling Stockholder (the &#8220;<u>Selling Stockholders</u>&#8221;) of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ordinary brokerage transactions and transactions in which the broker&#8209;dealer solicits purchasers;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">block trades in which the broker&#8209;dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">purchases by a broker&#8209;dealer as principal and resale by the broker&#8209;dealer for its account;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an exchange distribution in accordance with the rules of the applicable exchange;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">privately negotiated transactions;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">settlement of short sales;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">in transactions through broker&#8209;dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a combination of any such methods of sale; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any other method permitted pursuant to applicable law.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), if available, rather than under this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Broker&#8209;dealers engaged by the Selling Stockholders may arrange for other brokers&#8209;dealers to participate in sales. Broker&#8209;dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker&#8209;dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="2" data-prefix="" data-suffix="" style="width: 100%; text-align: center;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: right;"><b><u>Annex B</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SELLING SHAREHOLDERS<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see &#8220;Private Placement of Shares of Preferred Stock and Warrants&#8221; above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below lists the selling shareholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling shareholders. The second column lists the number of shares of common stock beneficially owned by each selling shareholder, based on its ownership of the shares of common stock and warrants, as of ________, 2022, assuming exercise of the warrants held by the selling shareholders on that date, without regard to any limitations on exercises.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The third column lists the shares of common stock being offered by this prospectus by the selling shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i) the number of shares of common stock issued to the selling shareholders in the &#8220;Private Placement of Shares of Preferred Stock and Warrants&#8221; described above and (ii) the maximum number of shares of common stock issuable upon exercise of the related warrants, determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the warrants.<b> </b>The fourth column assumes the sale of all of the shares offered by the selling shareholders pursuant to this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the terms of the preferred stock and warrants, a selling shareholder may not convert or exercise, as applicable, shares of preferred stock and/or warrants to the extent such exercise would cause such selling shareholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation. The selling shareholders may sell all, some or none of their shares in this offering. See "Plan of Distribution."</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup>&nbsp;If the Registration Statement filed covers both the Warrant Shares and Conversion Shares, then this description and related disclosure will be updated accordingly.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="3" data-prefix="" data-suffix="" style="width: 100%; text-align: center;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><u>Name of Selling Shareholder</u></b></p>
			</td>
			<td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Number of shares of<br>
			Common Stock Owned<br>
			Prior to Offering</u></b></p>
			</td>
			<td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Maximum Number of<br>
			shares of Common Stock<br>
			to be Sold Pursuant to this<br>
			Prospectus</u></b></p>
			</td>
			<td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Number of shares of<br>
			Common Stock Owned<br>
			After Offering</u></b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:36pt;"><b>Annex C</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Selling Stockholder Notice and Questionnaire</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The undersigned beneficial owner of common stock (the &#8220;<u>Registrable Securities</u>&#8221;) of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) a registration statement (the &#8220;<u>Registration Statement</u>&#8221;) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the &#8220;<u>Registration Rights Agreement</u>&#8221;) to which this document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The undersigned beneficial owner (the &#8220;<u>Selling Stockholder</u>&#8221;) of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="5" data-prefix="" data-suffix="" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>QUESTIONNAIRE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b></td>
			<td colspan="2" rowspan="1" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Name.</b></td>
		</tr>
		<tr>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 92%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">(a)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">Full Legal Name of Selling Stockholder</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">(b)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">(c)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-72pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 100%;"><b>2. Address for Notices to Selling Stockholder:</b></td>
		</tr>
		<tr>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Telephone:</td>
			<td style="width: 92%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Email:</td>
			<td style="width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Contact Person:</td>
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>3. Broker-Dealer Status:</b></td>
		</tr>
		<tr>
			<td colspan="3" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">(a)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">Are you a broker-dealer?</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: center;">Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</td>
		</tr>
		<tr>
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: center;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">(b)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">If &#8220;yes&#8221; to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: center;">Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</td>
		</tr>
		<tr>
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">Note:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">If &#8220;no&#8221; to Section 3(b), the Commission&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-72pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(c)</td>
			<td style="width: 92%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Are you an affiliate of a broker-dealer?</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: center;">Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; vertical-align: top;">(d)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: center;">Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">Note:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">If &#8220;no&#8221; to Section 3(d), the Commission&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;"><b>4. Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.</b></td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: justify;"><i>Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.</i></td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">(a)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; text-align: justify;">Type and Amount of other securities beneficially owned by the Selling Stockholder:</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="7" data-prefix="" data-suffix="" style="width: 100%; text-align: center;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5. Relationships with the Company:</b></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; text-align: justify;"><i>Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.</i></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">State any exceptions here:</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date:</td>
			<td style="width: 40%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beneficial Owner:</td>
			<td style="width: 40%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</td>
			<td colspan="2" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title:</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center;">4</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>13
<FILENAME>ex_422223.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<html><head>
	<title>ex_422223.htm</title>

	<!-- Generated by ThunderDome Portal - 9/11/2022 4:47:04 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.5</b></font></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Form of Participant Voting Commitment</u></b></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">DATE: September 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holders who entered into Reprice Letter Agreements with NovaBay Pharmaceuticals, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To Whom It May Concern:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Reference is made to that certain Letter Agreement, dated as of September 9, 2022 (the &#8220;<u>Letter Agreement</u>&#8221;), between the undersigned and NovaBay Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;), which provides for the execution and delivery of this voting letter (&#8220;<u>Voting Letter</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">By signing this Voting Letter, the undersigned confirms and agrees that it shall vote all shares of the Company&#8217;s common stock, par value $0.01 per share (&#8220;<u>Common Stock</u>&#8221;), over which the undersigned has voting control in favor of any and all proposals and/or resolutions presented by the Company at any meeting of its stockholders to approve (i) a reverse stock split of the Common Stock (referred to as the &#8220;Stockholder Approval&#8221; in the Letter Agreement) and (ii) additional proposals that may be required by the rules of the NYSE American (referred to as the &#8220;Additional Stockholder Approvals&#8221; in the Letter Agreement). The undersigned understands that the Company intends to hold a special meeting of stockholders as soon as practicable and that the Board of Directors of the Company has established a record date of September 13, 2022 for this special meeting (the &#8220;<u>Record Date</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This commitment and agreement is being given by the undersigned in consideration of, and pursuant to its Letter Agreement, and is not revocable by the undersigned.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Voting Letter is intended for the exclusive benefit of the Company and its respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person, including without limitation any Other Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</td>
			<td colspan="2" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">Name of Stockholder:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">Number of shares of Common Stock (and other voting shares) over which I have voting control as of the date hereof (which number may increase or decrease after the date hereof and prior to the record date of any such stockholder meeting): _________________</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>14
<FILENAME>ex_422224.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<html><head>
	<title>ex_422224.htm</title>

	<!-- Generated by ThunderDome Portal - 9/11/2022 4:47:22 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; margin-top: 0px; text-align: right;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.6</b></font></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>Form of Additional Voting Commitment</u></b></p>

<p style="margin-bottom: 0px; margin-top: 0px; text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin-bottom: 0px; margin-top: 0px; text-align: justify;">DATE: September 9, 2022</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TO:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Holders who entered into Reprice Letter Agreements with NovaBay Pharmaceuticals, Inc.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To Whom It May Concern:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">NovaBay Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;) has entered into letter agreements, dated September 9, 2022 (the &#8220;<u>Reprice Letter Agreements</u>&#8221;), with certain warrant holders in connection with two separate warrant reprice transactions, which provide for, among other terms, amendments to outstanding Common Stock purchase warrants that are exercisable into shares of Company common stock, par value $0.01 per share (&#8220;<u>Common Stock</u>&#8221;). These Common Stock purchase warrants were originally issued by the Company in the following transactions:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>July 2020 Warrant Reprice</u>. The Company issued Common Stock purchase warrants to a limited number of accredited investors (the &#8220;<u>July 2020 Investors</u>&#8221;) in connection with the Company&#8217;s warrant reprice transaction that closed on July 23, 2020 (the &#8220;<u>July 2020 Original Warrants</u>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>November 2021 Private Placement</u>. The Company also issued Common Stock purchase warrants to a limited number of accredited investors (the &#8220;<u>November 2021 Investors</u>&#8221;) in connection with the Company&#8217;s private placement financing transaction that closed on November 2, 2021 (the &#8220;<u>November 2021 Original Warrants</u>&#8221;&nbsp;and, together with the July 2020 Original Warrants, collectively, the &#8220;<u>Original Warrants</u>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The amendments to the Original Warrants as contemplated by the Reprice Letter Agreements entered into with certain November 2021 Investors (the &#8220;<u>2021 Participants</u>&#8221;) and with certain July 2020 Investors (the &#8220;<u>2020 Participants</u>&#8221; and together with the 2021 Participants, collectively, the &#8220;<u>Participants</u>&#8221;) as well as the transactions and agreements provided in the Reprice Letter Agreements are collectively referred to as the &#8220;<u>Warrant Reprice Transactions</u>&#8221;. A summary of certain terms of the Warrant Reprice Transactions is included as <u>Attachment A</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Warrant Reprice Transactions and pursuant to the terms of the Reprice Letter Agreements, the Company is required, among its other obligations, to call a special meeting of the Company&#8217;s stockholders (&#8220;<u>Special Meeting</u>&#8221;) at the earliest practical date, and in any event on or before the 75<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> day following the closing date of the Warrant Reprice Transactions, to seek stockholder approval of (i) an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of Common Stock, which reverse stock split shall have a ratio of not less than 1-for-10 and not more than 1-for-35 (each 10 to 35 shares, as the case may be, of Common Stock shall be combined to become 1 share of Common Stock) (the &#8220;<u>Stockholder Approval</u>&#8221;) and (ii) additional proposals that may be required by the rules of the NYSE American (the &#8220;<u>Additional Stockholder Approvals</u>&#8221;). In addition, pursuant to the Reprice Letter Agreements, the Company is required to secure voting commitments from all of its executive officers, directors and significant stockholders (including stockholders holding more than 10% of issued and outstanding shares of Common Stock, Pioneer Pharma (Hong Kong) Company Ltd. and Jian Ping Fu) to vote their shares of Common Stock in favor of the Stockholder Approval and any Additional Stockholder Approvals. The 2021 Participants and 2020 Participants will also execute such voting commitments. If the Company does not obtain Stockholder Approval (and, if applicable, any Additional Stockholder Approvals) at the Special Meeting, it must call additional meetings every four months thereafter until such Stockholder Approval is approved. Concurrently with the Warrant Reprice Transactions, the Company is also entering into definitive agreements providing for the issuance and sale of Units (consisting of the Company&#8217;s Series C Non-Voting Convertible Preferred Stock, Series A-1 Warrants to purchase Common Stock and Series A-2 Warrants to Purchase Common Stock) in a private offering to accredited investors (the &#8220;<u>2022 Private Offering</u>&#8221;). The Stockholder Approval is a condition to the closing of the 2022 Private Offering.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the Warrant Reprice Transactions, the undersigned confirms and agrees that the undersigned will vote all shares of Common Stock, or other Company voting stock, over which the undersigned has voting control, in favor of the Stockholder Approval and any Additional Stockholder Approvals at the Special Meeting (or any subsequently called meeting of Company&#8217;s stockholders called for this purpose), as provided in the Reprice Letter Agreements. The Board of Directors of the Company has established the record date for this Special Meeting to be September 13, 2022.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This commitment and agreement is being given by the undersigned in furtherance of the Warrant Reprice Transactions and to support the Company&#8217;s compliance with its covenants under the Reprice Letter Agreements, and is not revocable by the undersigned. Until such time as the Stockholder Proposal (and, if applicable, any Additional Stockholder Approvals) is approved by Company stockholders, the amended 2020 Original Warrants and the amended 2021 Original Warrants that have not been exercised will not be further exercisable until after such approvals are obtained.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This letter is intended for the benefit of the Participants and the Company (to satisfy its obligation under the Reprice Letter Agreements with the Participants) and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</td>
			<td colspan="2" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">Name of Stockholder:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%; text-align: justify;">Number of shares of Common Stock (and other voting shares) over which I have voting control as of the date hereof (which number may increase or decrease after the date hereof and prior to the record date of any such stockholder meeting): _________________</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="width: 100%; text-align: justify;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><u>ATTACHMENT A</u></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The following is a brief overview of certain material financial terms of the Warrant Reprice Transactions. You are encouraged to contact the Company for any additional information that you may require relating to the Warrant Reprice Transactions or otherwise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Amendments to the Original Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Pursuant to the terms of the Reprice Letter Agreements entered into with certain November 2021 Investors (the &#8220;<i>2021 Participants</i>&#8221;) and certain July 2020 Investors (the &#8220;<i>2020 Participants</i>&#8221; and together with the 2021 Participants, collectively, the &#8220;<i>Participants</i>&#8221;), the July 2020 Original Warrants and the November 2021 Original Warrants of each Participant are being amended to provide for the following terms summarized below.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 31pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Reducing the Exercise Price</u>: The exercise price for the July 2020 Original Warrants and the November 2021 Original Warrants will each be reduced to $0.18 (the &#8220;<i>Reduced Exercise Price</i>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 31pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Limitation on Future Exercise</u>: The amended July 2020 Original Warrants include a new restriction (the &#8220;<i>Exercise Restriction</i>&#8221;) on the holder&#8217;s ability to exercise their unexercised shares of Common Stock, until the later to occur of (i) six months or (ii) the date on which the Stockholder Approval (as defined and discussed below) has been obtained at a meeting of Company stockholders and such approval becomes effective under the laws of the State of Delaware (the &#8220;<i>Stockholder Approval Date</i>&#8221;). The amended 2021 Original Warrants and the amended 2021 Original Warrant will permit the Initial Warrant Exercise by the 2021 Participants and by any 2020 Participants, respectively, as discussed below, however, after such Initial Warrant Exercise, such warrants will be subject to the same Exercise Restriction.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 31pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Extending the Termination Date</u>: The Termination Date of the November 2021 Original Warrants being extended by approximately seven months to September 11, 2028. No such extension was made to the July 2020 Original Warrants.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Warrant Exercise and New Warrant for Certain Participants</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition to amendment to the 2021 Original Warrant and 2020 Original Warrant, the Letter Agreements with the 2021 Participants also provided for the 2021 Participants to exercise 25% of the shares of Common Stock underlying their 2021 Original Warrants (the &#8220;<i>2021 Initial Warrant Exercise</i>&#8221;) and the Letter Agreements with the 2020 Participants also provided each 2020 Participant with the option to exercise all or a portion of its amended 2020 Original Warrants (the &#8220;<i>2020 Initial Warrant Exercise</i>&#8221;, and together with the 2021 Initial Warrant Exercise, the &#8220;<i>Initial Warrant Exercise</i>&#8221;). Related to this Initial Warrant Exercise, the 2021 Participants and such 2020 Participants that elected to make a cash exercise of its amended 2020 Original Warrants received a new Common Stock Purchase Warrant to purchase up to a number of shares of Common Stock equal to <b>100%</b> of the number of shares of Common Stock that were received as part of the Initial Warrant Exercise (such warrants, the &#8220;<i>New Warrants</i>&#8221;). Such New Warrants are in substantially the same form and terms (as updated by the reprice transaction) as the November 2021 Original Warrants and July 2020 Original Warrants and have an exercise price equal to the Reduced Exercise Price and have a term of six years form the date of issuance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>15
<FILENAME>ex_422225.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<html><head>
	<title>ex_422225.htm</title>

	<!-- Generated by ThunderDome Portal - 9/10/2022 9:46:54 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.7</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LEAK-OUT AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 252pt;text-indent:36pt;">September 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">This agreement (the &#8220;<b>Leak-Out Agreement</b>&#8221;) is being delivered to you in connection with an understanding by and between NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;), and the person or persons named on the signature pages hereto (collectively, the &#8220;<b>Holder</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Reference is hereby made to the letter agreements, dated September 9, 2022 (the &#8220;<b>Letter Agreements</b>&#8221;), by and between the Company and the Holder and certain of the Other Holders (defined below) that provide for, among other terms, (a) certain amendments to the common stock, par value $0.01 per share (&#8220;<b>Common Stock</b>&#8221;) warrants issued to the Holder and such Other Holders (as defined below) (the &#8220;<b>Original Warrants</b>&#8221;) that reduces the exercise price (&#8220;<b>Reduced Exercise Price</b>&#8221;), extends the termination date, and restricts the further exercise of the remaining unexercised shares of Common Stock after the Initial Warrant Exercise until the later of (i) six months and (ii) the Company receiving certain stockholder approvals described in the Letter Agreements (the &#8220;<b>Amended Warrants</b>&#8221;), (b) the exercise by the Holder and such Other Holders of a portion of their Amended Warrant at the Reduced Exercise Price (the &#8220;<b>Initial Warrant Exercise</b>&#8221;), and (c) the issuance to the Holder of a new Common Stock Purchase Warrant to purchase up to a number of shares of Common Stock equal to 100% of the number of shares of Common Stock received by such Holder in the Initial Warrant Exercise or other warrant exercise that occurs from and after the date of such Holder&#8217;s Letter Agreement and prior to 5:00 p.m. on September 9, 2022 (such warrants, the &#8220;<b>New Warrants</b>&#8221;). Capitalized terms not defined herein shall have the meaning as set forth in the Letter Agreement, unless otherwise set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Holder agrees solely with the Company that from the date that the Letter Agreement is entered into by and between the Company and the Holder and ending at the end of the Trading Day (as defined in the Securities Purchase Agreement, dated October 29, 2021, that was entered into in connection with the Company&#8217;s 2021 financing transaction (the &#8220;<b>Purchase Agreement</b>&#8221;)) on September 13, 2022 (such period, the &#8220;<b>Restricted Period</b>&#8221;), neither the Holder, nor any affiliate of such Holder which (x) had or has knowledge of the transactions contemplated by the Letter Agreement, (y) has or shares discretion relating to such Holder&#8217;s investments or trading or information concerning such Holder&#8217;s investments, including in respect of the Amended Warrants and the New Warrants, or (z) is subject to such Holder&#8217;s review or input concerning such affiliate&#8217;s investments or trading (together, the &#8220;<b>Holder</b>&#8217;<b>s Trading Affiliates</b>&#8221;), collectively, shall sell, dispose or otherwise transfer, directly or indirectly (including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or short positions), on any Trading Day (as defined in the Purchase Agreement) during the Restricted Period (any such date, a &#8220;<b>Date of Determination</b>&#8221;), shares of Common Stock, or shares of Common Stock underlying any Common Stock Equivalents (as defined in the Purchase Agreement), including, but not limited to, the shares of Common Stock issuable upon conversion of the Company&#8217;s&nbsp;Series B Non-Voting Convertible Preferred Stock and upon exercise of the Amended Warrants and the New Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Leak-Out Agreement must be in writing and shall be given in accordance with the terms of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">This Leak-Out Agreement, together with the Letter Agreement and Voting Letter, constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes all prior negotiations, letters and understandings relating to the subject matter hereof and are fully binding on the parties hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Leak-Out Agreement shall be effective upon the execution and delivery by the Holder of this Agreement, together with its Letter Agreement and the Voting Letter. This Leak-Out Agreement may be executed simultaneously in any number of counterparts. Each counterpart shall be deemed to be an original, and all such counterparts shall constitute one and the same instrument. This Leak-Out Agreement may be executed and accepted by electronic communication or PDF signature and any such signature shall be of the same force and effect as an original signature.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The terms of this Leak-Out Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective successors and assigns.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">This Leak-Out Agreement may not be amended or modified except in writing signed by each of the parties hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">All questions concerning the construction, validity, enforcement and interpretation of this Leak-Out Agreement shall be governed by Sections 5.9 and Section 5.20 of the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Each party hereto acknowledges that, in view of the uniqueness of the transactions contemplated by this Leak-Out Agreement, the other party or parties hereto may not have an adequate remedy at law for money damages in the event that this Leak-Out Agreement has not been performed in accordance with its terms, and therefore agrees that such other party or parties shall be entitled to seek specific enforcement of the terms hereof in addition to any other remedy it may seek, at law or in equity.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The obligations of the Holder under this Leak-Out Agreement are several and not joint with the obligations of any other holder of an Original Warrant that entered into a Letter Agreement or any other holder as listed in the Letter Agreements (each, an &#8220;<b>Other Holder</b>&#8221;) pursuant to any other agreement, and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder under any such other agreement. Nothing contained in this Leak-Out Agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Leak-Out Agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this Leak-Out Agreement or any other agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Leak-Out Agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered to any Other Holder with respect to any restrictions on the sale of shares underlying the Amended Warrants, the New Warrants, and the Company&#8217;s&nbsp;Series B Non-Voting Convertible Preferred Stock substantially in the form of this Leak-Out Agreement (or any amendment, modification, waiver or release thereof) (each a &#8220;<b>Settlement Document</b>&#8221;), is or will be more favorable to such Other Holder than those of the Holder and this Leak-Out Agreement. If, and whenever on or after the date hereof, the Company enters into a Settlement Document with terms that are materially different from this Leak-Out Agreement, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence thereof (&#8220;<b>Notice of Transaction</b>&#8221;) and (ii) the terms and conditions of this Leak-Out Agreement shall be, without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and the obligation of the conditions (as the case may be) set forth in such Settlement Document, provided that upon written notice to the Company within five (5) days after receiving a Notice of Transaction, the Holder may provide written notice to the Company electing not to accept all of the benefit of any such amended or modified term and the related conditions, in which event the terms and conditions contained in this Leak-Out Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of this paragraph shall apply similarly and equally to each Settlement Document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">[The remainder of the page is intentionally left blank]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The parties hereto have executed this Leak-Out Agreement as of the date first set forth above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="38%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sincerely,</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="38%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">&nbsp;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="38%"><b>NOVABAY PHARMACEUTICALS, INC.</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td align="left" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:216pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:216pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;margin:0pt;">Agreed to and Accepted:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#8220;HOLDER</b>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Name:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Title:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>16
<FILENAME>ex_422226.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_422226.htm</title>

	<!-- Generated by ThunderDome Portal - 9/10/2022 9:48:14 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="logo01.jpg" src="logo01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>EMERYVILLE, Calif. (September 9, 2022) </b>&#8211; NovaBay&#174; Pharmaceuticals, Inc. (NYSE American: NBY) (&#8220;NovaBay&#8221; or the &#8220;Company&#8221;) announces it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a private placement of 3,250 shares of a newly created Series C Non-Voting Convertible Preferred Stock (the &#8220;Series C Preferred Stock&#8221;) at a price of $1,000 per share, Series A-1 warrants (the &#8220;Series A-1 Warrants&#8221;) exercisable to purchase up to an aggregate of 18,055,557 shares of Company common stock at an exercise price of $0.18 per share and Series A-2 warrants (the &#8220;Series A-2 Warrants&#8221; and, collectively with the Series A-1 Warrants, the &#8220;Warrants&#8221;) exercisable to purchase up to an aggregate of 18,055,557 shares of Company common stock at an exercise price of $0.18 per share. The Company expects to receive gross proceeds from the private placement of approximately $3.25 million. The private placement is expected to close in the fourth quarter of 2022 on or about the date of effectiveness of Stockholder Approval and the Reverse Stock Split (each as defined below) (the &#8220;Stockholder Approval Date&#8221;) and subject to satisfaction of customary closing conditions in the Securities Purchase Agreement. The exercise price for the Warrants and the number of shares of Company common stock underlying the Warrants will be adjusted to reflect the Reverse Stock Split.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay intends to use the net proceeds received from the offering for working capital and general corporate purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Ladenburg Thalmann &amp; Co. Inc. is acting as the exclusive placement agent for the private placement and as warrant solicitation agent for the warrant reprice transactions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Series C Preferred Stock will initially be convertible into an aggregate of approximately 18,055,557 shares of Company common stock at a conversion price of $0.18 per share, subject to adjustment following the Reverse Stock Split. In addition, the conversion of the Series C Preferred Stock will be subject to certain ownership limitations, as provided in the Securities Purchase Agreement and in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock, which will be filed and become effective in connection with the closing of the private placement. The Series C Preferred Stock will only be entitled to dividends in the event dividends are paid on the Company common stock and will not have any preferences over the Company common stock, including liquidation rights. As a result of the number of shares of Company common stock that may be issued upon the future conversion of the Series C Preferred Stock and exercise of the Warrants and as a condition to closing as set forth in the Securities Purchase Agreement, the Company will be required to obtain stockholder approval in accordance with the NYSE American LLC Company Guide Rule 713(a) and Rule 713(b) (&#8220;Stockholder Approval&#8221;). In addition, as a further condition to closing the private placement, the Company will take appropriate corporate action, including at a meeting of stockholders, to effect a reverse split of its common stock, as required by its governing documents and applicable law, in order to have a sufficient number of shares of Company common stock to issue upon the full conversion of the Series C Preferred Stock and the full exercise of the Warrants (&#8220;Reverse Stock Split&#8221;). After the closing of the private placement, the Series C Preferred Stock issued will be immediately convertible, the Series A-1 Warrants will be immediately exercisable and will expire six years following the closing date and the Series A-2 Warrants issued will be immediately exercisable and will expire eighteen months following the closing date. <b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the Securities Purchase Agreement, the Purchasers and the Company will enter into a Registration Rights Agreement, which will provide for the Company to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of the Company&#8217;s common stock underlying the Series C Preferred Stock and the Warrants no later than 30 days after the Stockholder Approval Date and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days after the Stockholder Approval Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Warrant Reprice Transactions</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company also entered into warrant reprice transactions with certain of its existing warrant holders (such holders, the &#8220;Participants&#8221;) to amend previously issued Company common stock purchase warrants to reduce their exercise price, provide an opportunity to make an initial cash exercise and for such exercising holders to receive new Company common stock purchase warrant, as well as certain other terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Participants in the warrant reprice transactions include warrant holders from the Company&#8217;s prior warrant reprice transaction that closed on July 23, 2020 where the Company issued common stock purchase warrants (&#8220;2020 Original Warrants&#8221;) to a limited number of accredited investors (the &#8220;2020 Investors&#8221;) and from its prior private placement transaction that closed on November 2, 2021 where the Company issued common stock purchase warrants (the &#8220;2021 Original Warrants&#8221;) to a limited number of accredited investors (the &#8220;2021 Investors&#8221;). The 2020 Original Warrants have an aggregate of 6,898,566 underlying shares of Company common stock that are currently exercisable at $1.65 per share. The 2021 Original Warrants have an aggregate of 37,500,000 underlying shares of Company common stock that are currently exercisable at $0.53 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By letter agreement, dated September 9, 2022, the Company provided the 2020 Investors holding 2020 Original Warrants and the 2021 Investors holding 2021 Original Warrants with an opportunity to amend their respective warrants to reduce their exercise price to $0.18 (&#8220;Reduced Exercise Price&#8221;) and, in the case of the 2021 Original Warrants, extend the term of those warrants (the &#8220;Amended Warrants&#8221;). The Amended Warrants will not be exercisable until the later of six months and the Stockholder Approval Date, except for an Initial Exercise (as defined below) by a Participant. The terms of the letter agreements also provided the Participants with the opportunity to make a cash exercise of their respective warrants at the Reduced Exercise Price (the &#8220;Initial Exercise&#8221;), and to receive a new common stock purchase warrant (&#8220;New Warrant&#8221;) to purchase a number of shares of Company common stock equal the shares of Company common stock received by such Participant in its own Initial Exercise. The New Warrants will be initially exercisable on the later to occur of the six-month anniversary of the date of issuance and the Stockholder Approval Date. In addition, the New Warrants will have a term of exercise of six (6) years and an exercise price equal to $0.18. The Company will receive approximately $2 million in aggregate proceeds from the Initial Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The offer and sale of the Preferred Stock and the Warrants in the private placement and the New Warrants in the warrant reprice transactions are each being made in a transaction not involving a public offering, and these securities have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or applicable state securities laws. Accordingly, these securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About NovaBay Pharmaceuticals, Inc. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay Pharmaceuticals, Inc. creates science-based, problem-solving, accessible solutions for improved well-being through its two brands, Avenova&#174;&nbsp;and DERMAdoctor&#174;. Avenova products are scientifically created and clinically proven to help patients and consumers with common eye irritations. DERMAdoctor products are premium dermatologist-developed skincare solutions sold through traditional domestic retailers, digital beauty channels and international distributors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release contains forward&#8209;looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay, the private placement of Series C Preferred Stock and the Warrants (&#8220;Private Placement&#8221;), and the warrant reprice transactions. This release contains forward-looking statements that are based upon management&#8217;s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings and marketing efforts, the financial and business impact and effect of the completed warrant reprice transactions, the expected completion of and impact of the Private Placement, our partnerships, and any future revenue that may result from selling our products, as well as generally NovaBay&#8217;s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Other risks relating to NovaBay&#8217;s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay&#8217;s latest Form 10-Q, Form 10-K and/or 8-K filings with the SEC, especially under the heading &#8220;Risk Factors.&#8221; The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Socialize and Stay Informed on NovaBay</u></b><u>&#8217;</u><b><u>s Progress </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Like us on <u>Facebook</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Follow us on <u>Twitter</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Connect with NovaBay on <u>LinkedIn</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Visit NovaBay&#8217;s <u>Website</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Avenova Purchasing Information </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For NovaBay Avenova purchasing information:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Please call 800-890-0329 or email sales@avenova.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Avenova.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>DERMAdoctor Purchasing Information </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For DERMAdoctor purchasing information:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Please call 877-337-6237 or email service@dermadoctor.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>DERMAdoctor.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>NovaBay Contact </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Justin Hall</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer and General Counsel</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">510-899-8800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>jhall@novabay.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Investor Contact </u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">LHA Investor Relations</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jody Cain</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">310-691-7100<br>
<u>jcain@lhai.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"># # #</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>nby-20220909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2022 2:15:05 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:nby="http://www.nby.com/20220909" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nby.com/20220909">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20220909_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20220909_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20220909_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.nby.com/20220909/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="nby_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>nby-20220909_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2022 2:15:05 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.nby.com/20220909/role/statement-document-and-entity-information" xlink:href="nby-20220909.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.nby.com/20220909/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>nby-20220909_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2022 2:15:05 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>nby-20220909_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2022 2:15:05 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.nby.com/20220909/role/statement-document-and-entity-information" xlink:href="nby-20220909.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.nby.com/20220909/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>logo01.jpg
<TEXT>
begin 644 logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MX'W6786.&PT*$5:R7W]?Q/Q4_P""G_\ P5X'C<ZQ9Z1XB\4F&35K_2-"\/\
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M ,&LGPW\57CS^#/B/XO\-KR4M=5MH=8A0^@;]U(!]6)]Z]7"TL#45JU64/\
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<JM:I5FZE5MM]6=-&C3I05.E%)+H@HHHK,T/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140694583283600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">NovaBay Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Sep.  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-33678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">68-0454536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">2000 Powell Street, Suite 1150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">899-8800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001389545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>nby20220909_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nby-20220909.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0001389545</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">NovaBay Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">001-33678</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">68-0454536</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">2000 Powell Street, Suite 1150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">899-8800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20228K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K">NBY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" "Q12U5EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "Q12U5F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M +%%+571/XK)4 0  *L0   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "Q12U5GZ ;\+$"  #B#   #0
M            @ &4#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +%%+567
MBKL<P    !,"   +              "  7 /  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( +%%+54ZJJ+G0 $  #P"   /              "  5D0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "Q12U5)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "Q12U599!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nby20220909_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nby.com/20220909/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nby20220909_8k.htm">nby20220909_8k.htm</File>
    <File>ex_422212.htm</File>
    <File>ex_422213.htm</File>
    <File>ex_422214.htm</File>
    <File>ex_422215.htm</File>
    <File>ex_422216.htm</File>
    <File>ex_422217.htm</File>
    <File>ex_422218.htm</File>
    <File>ex_422219.htm</File>
    <File>ex_422220.htm</File>
    <File>ex_422221.htm</File>
    <File>ex_422222.htm</File>
    <File>ex_422223.htm</File>
    <File>ex_422224.htm</File>
    <File>ex_422225.htm</File>
    <File>ex_422226.htm</File>
    <File>nby-20220909.xsd</File>
    <File>nby-20220909_def.xml</File>
    <File>nby-20220909_lab.xml</File>
    <File>nby-20220909_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>29
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nby20220909_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "nby-20220909_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nby20220909_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nby-20220909_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nby-20220909_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nby-20220909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nby",
   "nsuri": "http://www.nby.com/20220909",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nby20220909_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.nby.com/20220909/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nby20220909_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nby.com/20220909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>30
<FILENAME>0001437749-22-022258-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-022258-xbrl.zip
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M9 7^8U2,%V 83>M9]O+_ U!+ P04    " "Q12U5=CBKCUI&  #TG@$ #0
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M31 EHCW0:W(#6V_NX>5.DP@X.(_/FR&]"W Q(,C F("C SP[/L)@!L L( R
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MA">V$_4E"9Q3MV*'&'??P8:QBM94Z><K^SQ[1F/4]Y 1LQ21=!"!6)]X*&(
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M'5:1YW(OZ=HFZ#=-QTZ(,IF<]GMRH?$0,"+=(%B% C6I 9C0C^ IQ6KL%5\
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M0 HV-E(J!<7#R6R/J4Y*,5)5)=51.JHF4CHS##L15SUNM3-:DH+0<\8$4$]
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M>&%EEBF%P%(VIN( 0/E]'>FJI7&33T/]].1UADQSZJ]"KC@=Y?KXGIS$<DO
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M[!VR/%!*<K:3\P6HHA&5E&SXBOTB\YH**&-KWF(#%#4!X=A/_PW?MS8R*;U
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M?[MZGYYLU[^\[Z64P17^TU=_^M.SNH1?\"<K$%<YS%G,'O!$/SSXAK1+?,!
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M\__] N+-/RO03D339"1' 7F A5A@ 2M(S-K_[L,N;786;-7M2D2?%UR2Y@.
MX#[L59]HVS8_R*G>ATU2-,9'W>6]V"9V;_IP-_$^[O!W$,VQ+*Q@$U?QQ\X8
M[)0%6L(G#C:! 4'X1/\"1;K7@Y/+Z,7I^>O/>'Y[>]W@PO3ORT**8/D]:&R-
M74GL9*<.N3^I7,)\-LL6MM9HFE,Q-]0+=J*C@FM=5^Y;KNN=V^GM?.8D\WN
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M_K-6_]X']=MIMQ7\@@V5X1"OZVGV_/\#4$L#!!0    ( +%%+56BJJ+0A$8
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MG9=#I"_B"R#'%SB +VF2V$[Z&\O/Y50-49LUZA8Z64%D1UM2P^' N5XGB$>
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M0!-?U77NX[(Q$=G/6XTVL@G@)1G)J84:@@X%%.#2TLSE,YA1-7DE\XT!."_
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M\K(B.R@078O>GJ^BMO R-TLFZ_'&2 X>>0VZO$E 0,]TV17G4U(@&<&]<%X
MR17-WA!2U]T+#W(&TIBI(D*#!U?$P$LP5C\%DLQ\\B+/,0X'V9O0B!,;,T>S
M3>+?\P+Q-<'Q8 )E28C#^NA$7*<OGB0["@%9C+L1Q3#?H2U;19Z"KZ@/L&#Q
M5O,]-B;H:9P82J:]X?>.GWP-)N*'=V@B?K@V$7_C)N*/EHG0?O-'%(=&,<#S
M+KCW6CI:2T=KZ6@M'=T?Z>B+<99@60WLYL$+C7!1$*CR1L&19V*E63G7X1N
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M..DB+3EJ-S,Z(Y3OYUM1+YN+*:SIB$3^7092\GG0@$#=TB"!VR1H>^D'MHB
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M;8+;_']G^Z<%Z_KSDQ\?/7I&C7'B:T!IROPVE0W>9I0F<X8EGT#*RXLU+%>
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M.#;H(4@2P2-I745)5<%JJW"6ET4&5\&;)*TB6#BJV3#:?%;D$;X"-WL*H^2
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MA]R]V1QLH_*K;UYIE+YB!!JC.EU*X7EI.MDPNP1*"MM3@$TJ)!X>:Q:^XCQ
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MIG9VG "'QKA1O6O QQ:D7I9GVHH?2]?R\0^\F9AG+!%^4<=&)NVRR"+LUUS
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MQ!,1Z]%6] MGQ(&",,\KE76( J ]D5"[\<#<P@/SXUUZ8'[<>&"^. \,K;E
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M"QR:Y8O;&@U]::)FL%Q%O*B=W8?(,9$K4T0/?P@7HZ40T&EF>_H*[R"!V?I
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M9VYU'6+<?@=KEBI:4ZF?+^WS[!;MHK*'C)BEB+B%"'3UB8<B!E"&24P"JF<
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M.L%4A[%;W35VU!;&6;]\E*$=OMJ-%F54O477;D 9SN8F3"0/%I8;H67J)-,
MCEP((2C[Y^1"6#@/ 89,@TL]?">LA1*"NLP=QX)ZC][,TB3'2.*YFS0YP?H-
MTW2.,Z,U<;&Q]4H$"0VCF]C!OE8;R0875_2';EF_.]I .7NI&=8=3-<PX7/M
MT&'E62;WDJYMC$[39.3$)Y/):;<C%QH/ </1#8*5*%"3&H#Y_ B>0JS&7NT%
M "804"G.$=M4&AE_?[7L)=2KR2G!JVFN5D!Z.4 '-H*$K/64$!KB+?6#WV-V
MQ5_EP"W4B&B"K5$2/!Q:0H5GJA&1AW9;V-(#=J+^K4 L$=17L5\[HV(V@H:_
M-!&C(IV[5X+62K/F*)R:#EO1"[3MO(]A#).@K5=L2Y9X:X2%D2&D^:["COZR
MP\8S9#0Y5=G0?# T.& >056IR;12(\_ST@(>1M;,,<H2<>295T5$6N$VKK K
MF7<<Y$/43+"J.2&."GXAKZM3PK 43^Q=2+8F>I50Q&[)IF>?;!3HW,RDB A&
M)J">8KR71*6PML>\SO$CJJ'"X)6=".0!%:28L:,Q.;-VM<IBK9(3[25E.V%>
MEE2WR"U3Q)L@-YM1OPPI-Q(E,7OEBBUX:1(5""Z)5S<6[D$:WTBN/4*6XBJ$
M#72-[\^Z^+# [4@-,74"U\P.JR$:T*B+$_ENL]'W-.#O%+="CD^X.N,V0YAG
M0QM; 4YNGK[G+<C:D*KCD"N'-;C"$"FBE*YCJIVL;6BWL*$]OD<;VN.U#>TK
ML:'=94V66RJ,"_7%XSQZ4;"L#YQ4)!2@4.?#(IFR[@>/C.TCI7D$*X%/;1U*
M),KUYPQO$A'"5+-ORR D=X:HF'HX-Y2NIF*PK.)$1?BE2PS_K2L=;58]DF!2
MEDZ-"(C\5+(1G2I"/K>CT;F6FUEZ<PTS?E(_(T*^$]P09K4"Q\(;%SF2.IRU
M5(,AP*SM(QK=%]K-#@!6EWC5+^+WXH/M2Q2C6#J<$*/&[$4IK&KX_Y!&#*0@
M[9XFK(\XBI:M'%7\WJCS*$Z0+92*^-$J&N0G-^BIP8O9U542Y6:8?9GHS$5!
MF5V;X]ZV6YM,6K5'!<G5XF\+^HD=+W32Y0C$C&&U>O#.LPC.2D=%X,%T\8.K
M_$9=<SN&;J2S4XF87!MW:X.+EU55NXU8EFFC)YHWUO4M]C=H@3 &?3&&UQ4R
M-$@A:)W;W*-R>T0P7BPI0;L?5,;UX=5<O+#)@DJ"'6>_V_X?^! 7SQ:E.N=B
MJW 500/*89<JGY5N_ E0W=DD(MEEF(AY#N3NR0 $1H7RLD9T#[\=M)89FR(O
MB:*F:6@ I.AB(YE2%#R<S.:(2J/D0U664A"EI5 BY2_#L&-QS^-66R,D*>H\
M8TP E004@:3$@QFF*J92&VZ?"A'D20^3.'43?MYI63+QD2+/0 ]8YM5!+2.V
M%4ES89,5!81K-65-Y@V97TSGI3@<P'H_S]^5]?!?<CZ@O87K;R#3+YW"<0-\
MB\-)N2(H,?*Y!'@*L071!RE/:;QW?'4;!9ON6LNZ0RWKAWO4LGY8:UE?G);U
MH4WT&!YT +?(&US6)4]:C.D5UMO=7:.W?QBGLJ,JGSZ3E?PDP\/C=Y71Z-U\
MU2&(_8D:XZVRKD6+N:\BIUY;M.?L!MKY\9G\90N(1J]L?'U;@@>2>(D?PP_;
MR3,)#O42YW7IRK%NSWUG0!NU-RY(SY,7,GG.\"17HEB29=U:832: #_DUO"W
MC5SR%2K6>T'5&U5^J4@",@[4P([: Z*:HBVZ[)H2TBPSG:JB1',^*K(<OAA'
M2+9036T>-!*!L3GWQ<XD(>8R@1O4V*NJ(AEP<;53+F#C-6CKFJ)%F4*QE<K1
MYS>DBJ/'K31A,/OFB>CD!KAZ>95,'93RRNE1;X".)W*\X"K3'&]N\G8+=9F[
MIOJP:'6+K39<;:/LCT)*P_9-O T:I]5J\ZU8SZDY&)X]W9+!R+!*=+4=[CJ"
M#>1X50#RU5?%P[<4G4+G?6C-Y@!9,L@CBS6!6RW7<CF8+7JV =O$PMNUD Z%
MY8D=M^#,60U5#L[XF<I?G;U+3L5%WS/B>)];W YF# ^8?>.,!/7$BWJW+T=<
MJ<BLW:4J69SFEZ@0UOI,DLH8NPVF/AZNWM7JO\<,5)^P);IJ8^@,Z^IZ[\Y-
M].HM80B[72 MC^^Z4=J!!0ZQ-J88"%H*7NT\W!@9!QTL\2K.+A46NS**>3%+
M!4,*4VRS]"IM5HZ'*:GDSCCUMT*XU7SZDK#MV5U#/Z^N":VW)1>4_.[HJ_V0
MK=EXEC)/4=%!J@"[,QERQ'+1K$$P" (%@*S78$N@P%4 VZXSPE:,2[+Z^>K"
M"%+2P*-,9!I38NQQJ\\9/S61F VRO FP,).P=BD;L-KG<@B!!LSF-I[&0M=&
MFH+U6%/O,C9E+75\0_!\HE%2#@O5%-.@#Y0Z*Y6:9#6FPH11!I+_6N?;3FKZ
MMP!\WQ@3]MM=<A[=16:Z+'<# 6# :U2&YL)"*'*+I+<A[#P>SHW-UX.J%X_'
M7F<7YK%QH+ HAI$K,[+&BJ6/"1W'P3E'; H2W",)_-2@8O.V-RB0OP$(F=7<
M,^"&I0=%&B\44=L&RKF2 .G8F$DVYH8\;JRX#590,KH(\%96$LLUX;&3!]0B
M0OE6IH!.=CC<9@FO3#(#Q'H/G.5+Z%HU"LW_!3*+VJ96V E%*(QM_0O)'J_%
M1;CU/3A;*1FRO)&ANXWK> @',D=W8(+WNKHQ,]UU=EAT.30,ABZ4&7H&V#C$
M4?,9G!.9R'UG"N63'X3O!=$T]5>J>A0LYE^10Y4DGY5$9P>@GBCU1GM<]3H:
M$A::$AJ#AD-NXIV^?GE!XAYI)AF-WR2,K!1TYA<D\39PQ(97VZCK5DC41-]:
M=&S"@699&)?>)IYW;5108 *H2<"-NENBX[DH=#AVJZF02^TVN[UQRB.Q,<2)
MJEU,K!P=FN%N(/>/1UM/GGS_!/[YYU_UWIN.5%^K)I3TXMD6P-]S=GZ,YNJ&
MNDG<&3N\@NL8%KB94# QY;4J#J64WU>A]PT=L'S*ZB=ZKS)DDE&C&G)PZGAA
M/(HOX206FPZN5-KFOUP")UV:)4?M9D9GA/+]?"OJ97,QA34=D<B_RT!*GA\:
M$*A;&J1MF[1L+\W!E@[0>65-:[G-_-(]T59 L:T0?]@!ZCSR$YQU*.:B?H 7
MS9 U/=@<=1>^KPHM5"08>COA5K+D'A<?EXVIT24&X*4$, 3I/SI"JWE;A6_O
M-"D*MR@(M_P%;8C:J*5R]H5UA/SIV &E042!!KAVK%.BC5.$JV@(P&NU#/1B
MK;#*)+?:F&#U9I9E.;1I-A60@+*MT&1(?:<*JGQ2Z'!1@#6(&RDWE MMM59U
MY8-Q*\'4==GPC!@[R59#-<_*,G>1L)XQY]CWX2>Z*;Z#G[C2M5=Q=:_BC_?H
M5?QQ[57\XKR*]U)3M*F,J-.<_>''-6<_4 45H^B9(,7RVRXF=Y?=V%FL.4PH
M$6'$5HQST/J;TVN#-NI!]W2WOHJNTPC:7:%8<\2A@<TA)PGL4(ZLQFVTIE2!
MAZ-3N(N>RD:>)Y$8&#XSPB)J6L- ?N7\30W>K22'9GA?1BP<@4?R'7+SFY/9
MY&A".@<DR=IDQ WBY5(']SI/1EJF'.6S0=5U'*W:?24J:)OHK\(0QL5B:$?*
M<96S 8.N7$6/ H&"_"08VEG41.RNE.$:YI,!=N'UT@,QZTY:\J(FJ>3<2D2C
MSBWF+B>8<E^?G/LA77<8&"6WX25"R^4$Q+JY0!GP 3R,IPE&ZO$R0]66-'//
M&%K5PY-M8*P7R!Q[ =PV<!MVI(JXRIUZ7BM9"3;8E4AZ-@K<LV)N#D2G7[8I
M.I+0R_'?U_H">LN"6Y63V?#6"UNL7=DYK;FS-N2*[E@;R@NR)PO-,I7N<<2]
M0+5VV5H[K'E@]J:"*L*R\(B5'"?>G2*?6RV,V!#&+)'*KEGUI@X70R39:NO0
M-9^*H7VW=.RX*PYMOZ=):@72A""P!9!OLBDW7%#5S>TGS_Q[M6:BJ[1V/I\-
M2C0Q H)P:8KH!(X"HVG+UF("%L6:JTP09I'#@J^ZPW==3G!)JGE7D\:<ZB>G
M)3W<YAJG\^9UNNDB)5NR;T3=[WKV/QV_SQI@19')V)LJUCJY%!ADC:W4?G["
MID4$KO(,=D9JL!4^&O+AW5H:0>Y+/)0P<)-UPUJZ$QNDU=5@KFY /8*OZUDX
M0YLQ++..@EQ>3!XFD]!*))4'L121O"^J:L\; D%#(B-PR<5(8Y:K=[N4E4T-
MKNVV*;)B!7-.IXG/6 %0YW#'&B>P"BE(:YG)BK]D8[&UMQ61+F#;?#0YU]7(
MY.B"<;MV<M>6W(R5;= W61..U;QAO4L7&VVLE,?1& G7X&:V";VZGAY3]EB;
MXOSI)9!(G&Z)=U_8EJK=6TM=NN%ULV)KF&_FKZQI5;9P(VUV@^J--$2G:)BV
MN\=<A^+RF3HVUV?QBHR40?<5X3M0<\)-C0,"!:>T(M)B0DL\67*IH8(A!R9Y
M+GP<'+WRL4?R^5NH?2G,>+B(&9\"8SI#QG3H:H+,AP^YFZSM'A]6G_25T5HQ
M'T:3$2H?A12_EB9X-24U$.E8^P1FJ)!$> Q8N(?S !F0E]*LKJ=Y5;,B<Y4;
M3UE>)9PN7"\7<BVUHAS&IW2M*(#?3IG?V!7%!B0PR!3=JN-QMZ:W=9U"QJ#@
MX"%<DK6@2X%5G)_F?.RL1/*1G*)!';^FCGO^OB3A"E-6?/9+K;M>322%-D!&
MXLS:"C4O(XWNLC03P.2I%D[@5B9QAI.8$NQZL98Y+,]OECEJ</_L$H4]2?%X
MUE'C3N2(_UE!@O!F_4+DA_"2A-*#K*Q-B%A@4&N2(1;,UK$>7!M'5W]IN?S
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M7_YZT7SBT89SEC-\_S_<Y>'A#X\Y'8[RN;4]"#O4Y$7'.74W1=F5^JUT\M'
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MPAM8T;!B(SU[6N$:SC+= S:T)BT J7L7E^*^Q],7+; ;5@MIVXB) 0Y P<*
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MS7'O<QONZ\C%^AG=<:>)XK-\K3LN")^N=-Z;M4KJ;-K $.H3ITM,2<-J:4!
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MWLX3_W'Z</?)9@]!Y3$M3,ZC\.W^R]?PT=]_BU[VWYQO-Z8^@S]?[__O $
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MV4'K8.NJHW#9C3LT\E8>R=+-/"(EPM'4PU\C:X3S(BNMB^F3#&AB2]:ZNP=
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M\M@HK+M+CL'(!-TWV E5:=$U7VPJR^?(;;/JZ_+]WXZ._#L'1-RL,HJSY"C
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MKC!$"B<EVYA:-VO[V"WL8P_OT#[V<&T?6]O'EBF,"_7%XR)Z7K*L#S>I2"C
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M2-[M3XL]H&)4480;4723DKO,[=8?S:TU.H5A-Q(R!,;/HYW$;ZEJ14GB.D:
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M=:ASY3ZM]-(C1;@.B74R0EQ'\@6*XU6AEY)H#:E1<M98H*E58XYW'=:=[<P
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M(*[T'*VO+6[!>>/^=O3&]3GI&I8ZO H#P.P*=7F9D('EMA8DQ@Z1)5S#K),
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M 0 -    97A?-#(R,C$X+FAT;>U]^5/;6-;HSS-_A5YF^? K00-)NCM+I\J
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ML(H\EWM)US9"9VL:6X'09*;:[<F%QD/ 0'F-8!4*X:0Z8-4,!$\IEF:GP@D
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M:-R"6"(]3D:8HX%K9B?7"(UNU)R-_+UY_!T-^#O%NY"S%*[.N,MXYMC=QD:
MDYNG[GD'LK8D$5GDRF(-MC!$BBPE$NF:0FN[VPWL;H_OT.[V>&UW^T+L;O=$
M>5RH.QX5P<N2Y7[@JB*M +4Z&Y7IE/5 >&1L'JGT(]A78FHJOR*!;CZG^92(
M$[JU1U>>([E#1-U4P]GA> UU@^46*ZK"K2JD>7%3 >FR$)(TD[&DJL5!Y*V2
M,VE5ZG(Y'XW.U1/UTMNK!O*3ZAD1^*W@"#]#%[@7WK[ DMKAK*50$P'F\T>8
MW1=T7VAIVP=87>"U/X\^B ]W()&08O6P0I1:4R:EE+&6!48THB<1*?<V87W
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MD:94(;D :Q W,FZ-Z=MJC>K*!V-7Z&GJLOX9,7:2K8;JT55582-A,ZO1\@S
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M9I08)7INFKBAC;V9?.T+N+[E;)9;"CE(!1'<Y]5L,3H]8*&-KJL'*I</9%<
MAQO8X%;ZMZYLV% ;50LA27M1D$LI%9ONG>O34J%7[?!4:16FZGM*%2(=+9-%
M E> :+.$-=)["(Q-Q;?@UFG3B,P:?%-Z=M:7LD4LC8-B"4A;]Q8GM*P6#;70
M:+8:AC"55'VT]&#,/R7TB0N-N;/Q [JLD9ZF"\(;6!ZQ9B,]>UKA&LYRU?37
MMR8M *E]%Y?BOL/3%RTP]$N/=&U$1P1[H&!A0(=AL=R+K\/5KBW+60(<MI@
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M6P0 */\W_()]]P#\E_4D>_'_ 5!+ P04    " "Q12U5HJ!GT=HW  #W/ $
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M4K)1&C@Q#%A20>6%P=:.Y=9NE*P?\@Q+,B_L>B^<-+U FT8;( "\D#@829<
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MD<A7NR1R-WEHM:T7)QHM>^Q/6+O$NIE8!8UD#P;<VV! K_)<%>:-.Q>&5PF
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MU SN_H89'NSUL_0QG%R*MY52-:X0@F62*]$.X-<\Q3H;Y]7[CQ)G0OU+)^S
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M6THPTI;"_JA<6$=G"YVF.I<PEQ9?= 3:"E\2RB-$1S8O)D<E,JG6 LGLNI
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M8!^7"B\?!;#LH[.7P]/!\X-#!#0"#)X9' Y[^&_X8W__^/3%P=&KPW>]X,T
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M9/"&$FP_UWG<[^]][>=Q.GPS@#,Y>O5%;TAP]GIP.FR])RMZ=M_$,1$ATN?
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M)>FX\8H. YZJWY2##_JK(0WG(>!E<!6J41@F +Q9E!=$$0O0,Y?X BPYD!]
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MTW]Q,3@'WA=?!ZO\B8@5Y$])Z"WF"=B9O*L]##""%8O!U+_OTG_P7C!^-\N
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MF3NNX9;2257UPX0QK))NB/Y\S1Z/P7LJ??9*5[290QY!-S.Y%$QWO7*C9<%
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MLP.W;M>FU9X=RKE1T^AEG[?R\JZQA(NU!J.:88Y*LB$IT?14TM8E%D5GQB4
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M-#W\W8%-G!'!OA &AZ=K4=3=U_G@H@\P$QP3F)5WB' O<\\AH#\.1GQ*^.7
M((-Y53!)")8!?'(R8#I@C%4'<(J 5L\'\/3Y2T'J-P -^=WANP?GI[\,SG>>
M#X!IG!N"5\>G?3.:Q<^CD^'%T<4;FHK._0B9M.:!, F,>'1!JV*2T'=) W )
M<WG!YV]@FX]V>ZU^>RU+<)9"/^)R 37? /SMP_>N[8VN[=[NO6_[K^';_APN
MU'+7M[I&;TU*^?H_W6RRC??EN;H]&KA\13Q&=%'%Q[_9%/9M<T#'!*\<G82R
M3?>"0[:@G23249:^"[.=21C$?$G(C-5[>[MGA/05YA0]RU,.)SMW0[A& $UO
M+SN-))!O[BV+<N>F/;":*>1,;LTKF"#--"\$,V423O7M#^1&0%X8M!L-4+F:
M)G5LH+(=67/Q0EU.';5B-Q:2G<^8H1Q\Q W/G%[%Y;,R=OA"$J=3N3"U9&CK
MEKKT%"<5Z,>D5757#6E&?=CHTM"#7YL *.S6Z;IM+GRO3XJC&UQ<GP=_H3T?
M.M6!U]3Q%D3.&_HES5ROA<"K,3'N!>?A=7!ZR=JHOJVARS-W59_I@'8#QBSZ
MB1PX.W>.4Y=\WR-$GF_=C-1);-3)QR:Q5R>EF"L_-*3#\F&LRDXS]CH9APWN
M0PBER6OEG5X-!=6ZX3Y_8TB6:#\_V'U0ZA%9[A!9DN\D]&Y@>=O>CO6="'L_
M>2NL-JVXPER<<1 +RR[2Q1-Y\T?;+.835'J08R9J$]#^1GTMMEG:NO5\;+G6
MY*=F6![:C"Z@'YO&TQ LL4GY<B\/9[:PDZCE]YZ5;[UKF(R#:=JF7 ZY(ZU#
MN6G7EUB2$#0YDK'()-.#E[+]K9!RHH&-0D(R.JUSBAR3[G@U6W=EJW5H2VIF
M\VN8DP\,9Q;IQ'^:AU=FAZ&4HBL[D, N\CRW6@JY86[^A3O]Z^[MOD!T3N5W
M^$L$,DBQ!=[-;6N&@+4FP/?',I@$&D5FPBE,IXX0F<//\&:[KGABC+DZ%#O3
M<L3<%A"4) [^@#$V_^Z0EBMX2TYW?L26G;CB5K\'K->^Z#S0;KIA! #H"DD!
MOI,=?\2!3[G[;P'8K!.PO"-'Y#-ER0$J3Z2<4>"61* H/AMC)E)2E950O9XH
M"7O68* D %-AB(]W[HL^QMEZ@KN+>_@Y:=RU42ID, IEZW@^!S1+M[0Z2K?E
M#!RNP%,,\BJ@R)E.:7DE-='UI2-[B_C2"M)Z,*_%7-H(S"'(XHB5 +J:\#I5
MK;TV!EHG?'7&RB2!\PV!-O#M/8.A0;D^E8/O\!+6, Q!MXT9K<Z ?Z83NBU/
MJ]54I>>R0BK3TJG,F"RNSI;9^#+(PZPN>@<?34BX/Y.4^L!+%#8%BM6")JHS
M=&_9D\,RYHG$F*\,4;;H#"8FB<"F3W"46IT++6.>@9L_ 4]TZ#.)/:T#4B+M
MDLMF1J%3;R%;]:(JS;MB&<2(IPT<0CB^VY33&\Q6G(*%.D1$>D4:Q&)/XC?P
M(=!5+G2O;HAI"KE))>9,7$F>DH676*I<.!Z#6J!KEFSXGJIG]/.>N"XC<E=Y
M^L*T/ECLV!]R:IK!VOHC0YXT\1RO)6S@]75' 0^RS6CZW/.E6C718V,< '$
M%;.9:UG_\W"1YA%%5B\RO+Y G\)P!5)D3A8H50#52I2NB6DT4IO@'Z/=/ R2
M7#,U?B&W+RSH!2RD0=3*)<VG@=X[NN:IG*./^PQH._SPZR![%Q:UUQ%ZZ3+>
M)8DR]D0B\FXMV-;$O9&8NV6M>=NN</>N2G)5]NY=E5^YJ_+&J4E7C3D$1_9&
M=',A:AT;9<%E:YEUH5I=3A]=CUCAWG3WZSC(+SNZ5I <7 'F68(:-:&TWTDP
M#[0[E"J9R!T3)D&,)2DH>*@VX!^]#N!>V1VC.RN- LJ<DDMF?NN?N5JD87PN
MKZ-M.THL550O1R*?9"^^PM-VM(8IU8!XQD2-#E.Z&<^WB3'SXA][W4>[* Y<
MCD_*-#J9)#WF'[U'E4?,;<&^]D@9F:(X,5BI3&(4SI:)7/2;+<.V!:L[IKW-
MK4;#DJ)U&ML5"YCW:Z!BKJ9V = 2N]G%FBD@%6DPZ.$5B]%QV+6:M+5V@X[0
MM.@U(JQDQ.1I52?4J]4W<+J3?H#RQ] 8$3#6P[HRVT(T\YRO*,3L-;"(YBSP
MG93Z4AU60[YL8?9*'GZ==&8L7;)"ZS:=-EG'OK52/RU9KX'QOFR1UTLW(!/:
M?O"D3IZ<GU8N-QF%$^>2;8ZV>!YE>]5ZE;SYFGE,=E,!M<6R"^:$]S%=@CAM
M9K%%BGG.^G!1H1N'KBG-.BS0,?6H8&O8O5\5UK:33G<6L%'  WUUK+Y:MFUZ
M833 !G!>SSWYF-.6TMT/EJL=$#K46<SK*&(<'XLLG2S'I-1C^)O@94^VAN&;
M@)DYJ<!)<G/PNT; K>,7\V5<1&"D\E.M [;#P6!&)_]8[K@D#.:S:I RN"*7
MLTZ6QIW)JC_W'&$';$D#+YOE5<Y3LLVG.F*BW35U K+:Y8<]:Z%T"O#7P!+$
M*W,.5F2Y.&X/+M4C]G[K*9EWILIFMBZ]_FPY@C-21PE5C!,;>P&"<)E)?52?
M.0TYH=:BC&%4>?1>M;YO*\ ^RO9.\,2H749-'Q[GO$WN,(66D9@:XKLUGD7-
M%%GG,9[!NIMC1V%=*KMV2K;&[5:O7>IJ8N\?=>I?,VYJP""K=\^S@L&.UR3=
M['AMB#&L!T.Y!1)JM:P HT)#$&!10=V0D/>0;&5^0]=YH_'/6! Y6.""T7?<
M HQ,X3S6*X?(U*AH.9 2H0P(-1]GT<@)G>.+$0(7%TCW$W+YE'U'9^U28Z1.
M96/.IIQ=<!&R3OCV_$?NM'L@ 0*'_Z]'>R,-6)A&OG72Y./YJ,;)AQ@F(W/,
M4IVM>69 W0#(/)@LC5)%5\1+OQ"$*)JX34Y^JT_("AV]XCI%=C"FX,E>=_=;
M<R5UT-3*<XVCS M#:PD@KI_F0V."I<X,&6638\X"8$%K?Q<[#N (+1#H.QE!
M$6F"&9BH.TAS=#NT^,4CC++#2WF;"9@U8[8VRE[SH%TRX-:L$B44Q?&UUEUB
M>)QV4*7%>G>_9FYE0:P-Q :&4<>KV <L C7WJ_;=X8WC% V6(F8KP(SF.VQG
M;6D5)X4=\ #",J+L!J'$-; ZD\5T=3K.%L_:]5%-85H?XT#M*0#=2?"*=9 X
M1(^H""T1=$X_B&TFQ]V"PKK,S GKH EB%'S<S\!8/%B"PH:XYINWW%,$3G0J
MP\Y8_\^DK18^L\TB-(I1Z94=N-;0)1__5H,F$DV,,4"0))A!LS58])D$F4WB
M$DTY$]VNUWWT+;D3&/Q(J@ZE"ANDW_*VD"$=L%1/=M4)\%Z$EB 83TGRN9'1
MD.>4RK$0@]&)7R!#TQQ6$U?S#JV$JE*([<Y6GH4;[$EW)2,J*!2-4,&;R[GB
MC+HQK>R-NAVCAEB]HT/=9,827*QK^(1K_(X&++5]NL_&W>SBWKMW<?\U7-P?
MO=UV794RZ!$?EFV+X>$H)P=?R=M1[>U([*-32J)<E_/@=9?HT-.DS<4P(W(2
M-#?##2:$R$F_485D1LP7!1:!4OXABTZ[E8VC<GJ$.^RM6^6?!56B/X$JZ[KQ
M]M$GS.FABPR]HXP7+>I(P2X>%O<H*N"+_5VKV: Z:Q)EFGHCM.MLE>G:Q#BW
MK2_@F_Q[G_SE8A$YB;,HE]I2 2V%F:ZUZ[6.K>LE48KNTL:W;7F1_XEFN^SY
MKW8,)H<"]75S[ZZG[&1]J\;W-ST$W9R5&ORN:U+L=/AE9TE!R,T*$A@,TMHW
MO4ZXSYO7'*4^>Z(!F 6[:[X(I>%&-P#T]O^Z4O^KN@+@8/T5 .5FU7QGR&TT
M_/_0U/8;@-+)@G<))%@6Z1.//NB;YNQWN>95(Q4BKGQ%#SSF2U_-EX*YHQB0
M6?[T[H-5I5QTA<GHYO+(7O?[;S]IJCQCPL7I1?]8%Y#ZQ_^)9Y9"UZ$W:4/6
M_G87[*X'Z*.N<U6O\$,[$)V/^1E>K/[XZ0\#*Z2Q7-44T7[6 ^F_IE+;UMZC
M;]N?ZU >=O?O^J&<#U[WX6!.7IHRZ]L@$S5\U3\?#%7KAS6GL^;NWH]Q6,22
M]&FPCM%T5@U'N:YHZ'/1^*=>PS8H?8-+E^\/[O[@[@_N4QW<?7;S=J[?A_>N
MW[6N7WR_&?JE,38__C2:SP!^Q<\/XG26[O:ZOR]FL,-L['WQ[$.GOP5[]'"G
MM]XB_34E-^HQ%_^WSC#*1>E_^*TXP-IWY4(Z50;6AY0"/WB&[K>M]DVEBD41
MC"\KR67_RM6A9*V<AYAY:3R0/^[\0K[*B2VP<9.IDXD:O!]?8L,$IY /WQ[B
M)>:4V=?;YRY#Z&$=O+^,1E$!V^L^^B(<7Y^69:[A&O=L\YYM;LTV]V[$-D_1
M,[T5F_SHG0UN(P>TGH<R$.X8S_Q^+<_\^%ATST._$A[ZA60=;.*$S]?S05]O
M(@Z@M:=;4!KO1K"N)+[^<@3S507L!NOQFZ13.BT'[NZ,0?1I!'O#KN^2:'_8
MW?LBK*%[SO*E<I87VW&6TGU"7P%7*76+NCL<Y>$]1[GG*'>8H[S<CJ,<A\&[
MG=-EH?JZE>M7PEBJ&[]+_*6WV_WAEAC,<7]XL6,INM:=\%'=!)H2X1^C=+("
MQ+LLYO&S_P]02P,$%     @ L44M59ARN';>K0  :A $  T   !E>%\T,C(R
M,C$N:'1M['W[<QM'DN;/MW]%GVYVEXQHTB0E^26/(R *LGDC45R2&J]C8^*B
M 13(MAK=<#](8?[ZRU=59?4#)"59YHC8B!V+0*.ZGEF97V9^^<-EO<A^_.'2
M)+,?_^U__5"G=69^-.__WY,#^+_]7?CVAZ_XPW_[7_#]_][9B7XRN2F3VLRB
MR2HZOVSRF2E?% L3G11EG6313O3=5_L'7QWL'1Q$^_O?'WS[_>.]Z.1UM+/S
MXP\+4R?1]#(I*U/_]5%3SW>^?22?YLG"_/71O"@72;TS,[69UFF1/XJF15Z;
M')ZN36:6ET5N_IH7CW[\MQ^^XD[_,"EFJZBJ5QG]/*]WJO2?YOMH?V]9/XOH
M@WFR2+/5]]%__-X4];/S=&&JZ-A<1Z?%(LGYPV?1,IG-TOSB^V@OS:.]W?TT
M?Q9-F[(JRN^CI*F+9_C.I7W1(BDOTGQG4M1UL8#?+-\_BVKSOMY)LO0B_SXJ
MTXM+>+T\5A=+>@;&BAT*>FL[]Y^M?OUG'-$G<529,IW+4/S8H*W)C^/WE^DD
MK>&#W<<_?#7Y\8>O\"GXS_+'?[M#;S,S_Z,[^Q_YI%H^&^C?[5>I?X&ODC)-
M\OK[*,?MD]FAX#!J&6D*VQ2?^,Y](F.?PL>F?$;3>38^?'MZ='XT/HM.WIX>
M_CPZ&T>CGT['X]?CXW.>W^&.=^;DF>\L]37HJO14.HI?^SD:?D?K%;=Y@QKK
M;TU5I_.5?JF>F\=?4R_.+],J.C.P]],ZA;>=-"6<V,I$HXO2F 4\&6W5^,Q_
M_)]O#P[VGOW0_.B^^>&KYD?Z>/_9=@2/S$A.)%54S*')96T6$U-&W\412H<X
MFICZVI@\.BZNDN?)*CH!R;!(IJ:ITVF2P6XZRJ>[<91$+TR67">E 6E0+@N0
M/B :L!=&=>*P6"R3?*6[ #_-9Y%)II?14D911BD.-IVGT#%H!-NH8'*2NH'F
ME\D%C/C2E*8NHBW\81RE^31K4#1$:5U%53.=F@JD0D5M)Q7^N,(^^I[8&2M5
M7^CI:9%E*->N3+:*H[#[[D>5'L'N0]AQO_P\/AV/SD!X-)/?8'XBF'R<'#B7
MBTHF+I^EN.BP *:&0U_6E[ P$>U#OR_Q45CHJH'>8"-G?(E$3[:2[:V#;=R%
MV*[:W"-XVQ;LSYF9ISE>:28KKF7?G#:9B9[N?1TMRV+19!>TEVO<''3G\0+*
MKH,&JK2$!N&M:54UAEJH3);A)[0#W0*K7:D^J\P57*M9MJ)O\Z*.?BO2O,:-
MHMJVVSB:0Y]T![ !-RH9I^T;C&]1P.Z>-]@\M#8MTPF,I3.!#V*W';_Y!6XK
MW'(OWYR.0<8<1X=OCL^.7HQ/1^=';X[M["V:N@%U9EI<F1S>5Y$FDM NZ4P<
M+RELRZC #1)=%,6,/KI*LB:99"BX\@HDCX@N;+\T4Y,N>=,F,_-[DTQ7^.[K
MRQ1V!@H[W&J@8R73=WEQG9G9A9F%FZZ[CZ($NX0K/@=94UQ7W_]K+ZG<SL$[
MX:(>G9X?';X:1T>[-]W*?\CK7XQ?'AT?X68Y>RA:P?[N/G?DKO\+5]L+%*XL
MOO%NVX5K/4)MFX^"EO56#)NL,M>X_;M'[7N0U]O1-%FF8&S &&?RT_HRJ>G4
MH.BD4WB=@IRT+6)CT-9E<F7X=)LDASN]BB[@-J9>P,U^*6VE?$(/38F*PA0$
M/Q[,%X85!=(]U)W!3<NEL379IM_R\4.M@9OLOKA[D=GK"N;Z7_S8=O=49/^?
M]E//!E/:Y/3W)BUQZDY &RIRK455EW!%=B83Y)U<:7H=<5Z=!K#[S1=WN=UI
M2G$6/L5$/M[=W_KMRU-+[S*7\WF:I2 3]'3B_*&JNI(]2^((-#?0VZ:@PT6@
M&4![]J_ZLBR:BTNP/PQ^0\I9BC?-PLQ2Z#4:TJAME$56T4\K^V?&L M_1FHH
M?+-8P OE@>@Z!8F22#=BU 248$/YV%2LP8A>7=5E Q]P6Z3R/ME[*G]VE>4'
MO?!P_<Q:5JXL/$Y48K^V5YIH:?CD_C?/8 G#ZP3L2F7,HI4PGZ/QDX!F"*8
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MW:7)X,*"Q=A99LFT\WU>Y#NP%HCC03?-8ID5*V.?XFV$/<)5X2FO4M@_"2Q
M"==:Q;V%BR^=,J94\%6'_6Q8%N%/EY>K"G'(:%(F.2Q55O <5=AM?)[/"4IO
M^<5% 3.;XQT OY+9@66L"O@M*5?T,X,88%GDZ32:P]: #Z']:H[=7%6U@6MZ
MRV..N$+7*4I@>:@B&.O6V^:"O#4$*^'(EF#K8).@!. Z3>%(P/SCE.2L)\#F
M_)S'?)9>X0:LJK\^.OGI^=\>V5=>I[/Z$C'^O7]WC@GT4@BD+Y^0EX4^0N=,
MT-;+\U/76 _<'ZD7M'Y[.=\IB^ONAU,$\TY^.G[[VH\!GD!/E/[/O_UP6=H7
MGXQ^&N\\/QV/_K8S>GD^/OT^2K+K9%4] UF+.Q$=%KD).O,,S$D>U0%Z::9%
MA@ZH_[-'_P>_2Z;O+D!YS&<[X5>="?CY1?\$L*_G X=__N;P59J_6SL!;A[H
M]^R] [6V1A@,]E("IOTC= PD.\ERF:WJXJ^/EO:#IBYVEA=PL?_U$<B'LI;/
M9RGH+\F*/C^0SW"?L<^PM2/5][@K__J('%#\(;0@4Y+()\L2K/CW?WTD?]);
M@_=4S5P_@%-),_G71[R56G,QY-6ZJ\>LSX>E5O">WY;#R$F_ZK$&:8$_3V"-
M3&GR*4[7*9X.]@J\ JE>BT@F!Q-:3M%A= S7P]^+FO7(_ K;1@B6F\$;BM52
MOL3 F(-/EF6*EX H[G /X(\GJP!M)<M*3*+2P$8A27M6NTZSCRJV\!'ZLO$+
MF _KIQWA\.'ZJ$%_%N2H+AZR6B53W;\KIK(.HH4ZWP>Y5I+,]/AS^KP_![O[
MFRF^ ,6U#[+ ^3LODQD_H1135/ID?L]1]4AX,E\4TP85'$$T)^B^->]A <C1
M"PLS,UD*1X[U0+*+0<K#R<83N 3ABJM4\\9GQ!1?I/Q[2_2+S,2,WDH93?7.
M4;&FHV(",R-G'_UB";_LK)D@@K6DOHX6<%&R@V4KE9;:1GFK'>E]:UO1D2:;
M=PJ=B-70*_AIQ;YDT-,2^.WL0>\U4$O3JAJ4\V_SM";Y"WLQ"#+ -1J_%_O>
MM_+0Y]+B%P/RD9]@A"<TU6,\:^1]--%?]G;W]J,EVA>7=#_1J7.V$:EX^'/E
M0$YS. LL!\@J4%\MX*3A\4WFH/S@!0KG%5M([2G@17SPQ\"A7V,PBV$A4&;V
M P?#CGNQ2U&HI0(,RZI<%TTVB]  KC-&\"^+3"#;TF S1920'\6@M8J-U3 ?
M+5S-F9D>8LN<3A4SJF$F=8Q"652GBG])EE<,]B0_"7I/B;>NPSA2PI49#47'
M7%H%W9@JM8SV&OP0;A$P:"NZ*.A/WDCT-ZA2L6N<_'HR]&I@[.1<OX*]K@?\
MP+<D;:E#N!(KDW5WXAEOEA-03F&^GA<7%U6T]?9L.WKUZH2W!^Q.4-%A  2$
MX'5?1P=/G^Y%KV%Z2V-@/QS_$D>_)-4E;*D:]\6+W</=Z&!O[_&#]KZQ$8+W
M&=@@,(-=/QPN@8AT]^@2'T6) /)[_UM";4@5"JT8"_=?IPRQ)S/L*D-T\"1"
M3;VN #+,%V!5UUY3<PX.UK M:F\A1.J"V#8W>L@WZTV+>$;NB(]QO&ZF>6B:
M7Z2516S/T)QN,C/@V>A[LGW7>KL%C@9<R*7!X#M2=5#X;2::I@][T9GCF$)R
MTGD['!/^P(W*@;8)^3VL,H#NA"0T/,N(5<KOOM_;BY+=Q6ZTY5!L@K51<]@F
MT30Q<W1*+M)9CGI(_X/X3EA7]8X8V]Y?T[9$YNENI0ORR=<&]H**Z4'T'T\C
M:QQQU.3D0?7Z"2M 4PE_1FT,+<@R2U%/015(9.X)^C=HMD87+I 0@XC63:>-
MFUX_ =C2#9/9-T=Y$>&M(&ZLV\W8'S(7&S_$37X(!VI/3.D1ZS:D[0#L-=WH
MH,\!>-V6/8]^/-CX/M;Z/C9.@.;',<6SP*6Z!GID,5"Y^!82)'1)X)7"FF9*
M7MY3<Y&"&&&G  %()"DN0:(0$C=#& *O;^->Z_%[@9-BDJP*V7R+84[9"F4?
M:VH:V@.C,L"3*3AJ_\D3"MF"JP%4X^%GK#W-D=YD6U%_K1IOU0YV0J"3'#[(
M8!E YW>.!E%#X V3+)W"4YP>AS/@O.TJ< O?BT+?OONJR, $Y^[FN2EWBOD.
MX>;:^0US,MUN76T8E[:"I8'6<E2**O%U:.<(KJDW#3CZUAKB\&AW9NVMGT<N
M@JX#6D%7MV8WK-#0U"<$1"\8^J7TB%)O&9ZG("-D?R@CY$X32%/>,J]I6WJ-
MTNKT/#WPB\@%.EW#:VN#W?N]@3/'(-H2-KW$$.*KDDR&#5W-<>R+9$:[.VAT
M<,+T)-$O_#2Q[6C?YRR^-&?G%9F!S00[.\5!)U61)Q.,)9A.S9(\NNVQ/60]
M>?S365?*C;/,Y,5\'OU4%E4%/8K^(UDLGZ$A4L#TK457]A\_>1J-KDS>N*,"
M-CILO 2.K57'_+_@SMC?>[JS]WCOX$$O YC2Q37KD-WU ..\3G,.T6& ]MR&
MW_#"G)?P\M#I:Y<&ET0<O@[QZEN%O;TGFP6(^K)"]=7/3R7.OB%5E&*3$1#.
MR2*<V#LTL# FG/J4+ JYL-P%@G_H]:?G>FR+0"BR% S]C"(,9V8)UUT]Y%NL
M_%T=O%7BX]#SR>*?4ER\&[4*\3>74_B@=PWERK&3N:4O?DRR0O6@8W^=3Q74
MFOYCJ%0?_3#>-_O?/7Y"&004VH[)A_8TE82@X5^@8S598EWW?7FR#WOZ4=.*
MCBJ4-=,!&RB5;W'*T>H9BNMG9QO<_%;[M.XX4!XQ-=TYW] TJ$%$7B?EC/ 6
M&R$+O^6KC&-@A^*\6VKURGJ82^E"!&(K#P-L]2OYZUF#>N(,?B&> SJAT#((
M5,,B'/38WSA"5MY/<;W25Y@@A#5<W[I1[-2#3AOJ9PEYR%&_-ISGH%KW8X?)
M!$4VK2Y[^LD?F/**KO\23T'I!;J[=="J5%[<9BFPF+@T W\F93J4VM$CP</J
M(%(&N;H6\*1]Y997O>D&GZE_D7*U]F\O^TX\TSH10P-\10>29(<0O"(7B>NN
MPU_$(WQJV(^E8HBJN&4WMD,,2-!SP#G8.R)\(K ZIV9=9S#U/I^BE6):^2'M
M%W"HW\RHA]U247=COUSBABM[77/MAK=4 D#/Q"@'7,5-8CZ,C6 L6^>N3G=F
M:=;0S]FM1X%7V])]D#M&Q#'=>]WN")@\#3:GK'/P*@P4J%+7#;*9P7:>ABH+
MJ#.P;.PN[)Z[&;1 "AQY'X=$RTU+CT'J=B<ZAA$M[]RC5H[J3%R8<@N$,/P]
MA5VX0D0[@ )*#B$5\YK]WCC[,(NBZB$^P8&'>#*#'U<.>@H7N+:>(I!\I052
M8+ 4^$F;!@RW8A8FI>X?H,#G!&)>K1:BDHN1[^X(5H6*/",0!!?/9AQN^0!6
MEL8*&+ /;8NNFV)(6UV9;,XQ)IR.R/PF/M8$>X0I SAR&-#41Z7@Y]>Y)%_E
MR()B:#Z2:&+S9*H5?(_S!MO(207W;9NAPOF;9?PM$>O2Q3'?P>2PW#6E/+2S
MR%,XHGQ,\ V470%735.K)!:.><$$.+6YL2UO!=B7IGQ:*-=.A9B6*>@"*?F#
M2AN82I<%O+),4D+')#]=CBI"4QBO N;D9<$R9H&0FIL.?!-UG6AF<O6ZC1/D
M;DZ0QY_1"?)XXP39.$%NL !>'IZ,^M7^EP5(_8L<I$U9-M#628FR:"H0-)E?
MWWRCS:^';$B]?#'Z5(! ECUH1.#EB\/-5'Z:J?QI-#KY5%-Y^:!G\BC'.&,S
M0V7H4\WH9/+ I[0VQ#:()&8G):KQH']R]MRGFN+E@Y[A5^8"#?!3LRBN8(X_
M%6@-5B&8[ ]Z8E.3]^5*1!E\$1-_\(6)HR51XCGBPU5D\8<8K*TIV .8MF\D
M5X'LP;2LT.*?-U6245(#^<%A@>01B[ I]_Y#7H?7& :(L3>C&0>0<T3/K3:Y
M1"JN%= />I.[R3TAV.F3R>3\@<_J^W31+*+33R2,G^[N/^C4E2X#G\U;(SZS
MJW36,,JEN*PH][#.X9>7Z3*.:HRGB!7=%:<)-GGP"4B,8IK*[XGY-KJ"'C68
MKT@Y:?!,EB:3-$-)/[5H,C_)N+K[T-.P$"B* "7<U%-"+JMF@MVN'&1;S+>5
MYXQ1.L%]W\$0'_3B!W3<J$3.FEN*__MG/'X)X.:3SPAN/MF FQMP\R8!$095
M=:^)5PG\<-*4%]$Y2 H,HI4@N\-BE\C]'[)T#1,YNY/7+%%^/HX/GNXIIWT?
MB<5=F6\Z\04@P:W+DIVC-N6;2'?$,0G79F:P/D*+N7A=?N+-9#@;#ARX5Z?&
MS'II<%!WF0HQ7Y:D"ZR1D)(V1=[""^%(*M%O*HTH]KBAM'Z;29#UM(,4+4FF
MVHOY"D<_A V'A&>W,?'8,($$<M'!/IF)+]G -L@?MKOBA!,VCE3"QLLDS4";
M_30(T>,';CP/SV]TDJP6;:Z-S41_^$3;PA(G(!A6GPC?W'O(4QHDL@F;W0VA
M\FM_$DN5I;41\YU0>1\8[T+>U]W5SS?$=6M6T:4CZN6#Q;CI\0&Z@OYXLZUJ
M&YXQM5/4?%9ACTJV=LL(]SOHA[XQ3:C7S2&;K#J%9JI>8I"U[WW8&T82-D<4
M1IEDGPSQ-0_ZAG+S^CK-$?KM8:?@^G/,T5T;3A):"%"<7,#FQ)0%'2[<'R%-
MV9=B.J&F7-1,0)VM.#R3(ZQ9@C9<3DX%V=9#1(JZPASVL2]S5EJGP'(7J8Q9
MF@UGRN+FD8CKJA6KW'K*CZU#) 1+492V%SH^O?3O)#M"BYN:@U<?]@YD[QCO
MDC.B5[*'O,>BDV]40J>0+DFZ.H'9K:3>#0%_[RSW\@H$9037K4VLD@ET^*]?
MD;02>F NJH(IAY3X["FS.NR_#WJ))/:^N^D=/8%.$>O0,W3D99B6[XO94'/"
M V#30T@%@>MQ"9HIJB14'Q')9; M^&]L$Y9L+0#,8>-* #:#3?%:VL2E;A\%
M*I.T>)'_=&ZA)RX4G"KS23T7U>F-P^-N#H^GG]'A\73C\-@X/&XCX9X<#$DX
M^&8CX>[5RMWGS70V/L3T2%"C/YDI^+"CB/UAZL=5.A:/2E2M'"#6L;\V4VKE
MTXT, IXXX/&&..#CYIT\NJ.=?;=!>PR=;CWY +!P!3.N[1X/**E:A"=2U,KR
M>V%VY70*>HVG)/,%-5S:*F++;#FY<^19I!1UIDY4Q]67&H0V<=GA"U@&FTJF
M5^G[:.OK;:(AJWRU<\L&YWY YEL'CE@'91_N[&_ [('==O! =QOIZ$@VL+7_
M[78$8ZHO/_6F.]ALNM:FNX3)B\Z27M9F7%17#!"?(Q(\^TQ/RO_!WAY.^:E7
M=<]^?J/*V ;<-EMA2GA0U]#FAW.U/T)#B7L#3+R2&1(W)4:[:UG3W?UWK#?2
M7<R_[,=@TOH*)#WH\\.>/ ?XKL&-.0C'@L>)X\'493=QHZMR2_W*ED#*Q[^>
MC2V;8"YQTD0V,3555=A0Z&TO!=?@TBRPX5 L!79=3W<F/;W1&](F1UI+"XH5
MFMY/A5MB_[O=[[[[=_OP +5-<'L)SXUF-WW0>[++===?M2(62N_0.\SJ@?>M
M)5R)BVGQEDDZ&RIGX0P%=\%;M2*@0X+C %N-V5(G)BNN^7BX][O(2*P0:=>6
M@Q+)+Y=<]!$(4<5KF!6[@R\-TZ++M/3,26PG!'9?6-MJ!LH2:J[8)GRIM9/D
M*DDSIFA"@I(-)GPW3/CKSX@)?[W!A#>8\"U$)3$F#=0%=XQ*J_:MF6A'.L@4
M;$S*DQ":EVRSS6#)D2CDMM17/$C?K/(Z*X4X$/,6@\7R[^$>H*7"R+(4"YM)
M$8Y6 -E#O@I5<8R^G.2@FCMS?L%RI$M0TNPO7R?E.T/>9%=_N^:O-O-J9Z?_
M[,AV]>ST"WJXTF2'53C]+5+#*$LKR3C\O2DL%Z5,?\!N"+?T[PT&PQ<@=SH:
M,FLTQTDU2WZ/#H7=B[L>?/535DS6?G-&Y=_MGA MR'%'2\E :ZQVU/+*4G*Z
MF0$-JX"A/&CSL]>2Z .KTR!N]J;4%:V'QK<)Q$6EV##BPYI?Y:I-U0SX,!SE
M_^D95&>NL"ZNN6VS\L5U!X@V-ZS2-V\-)'<?I(-?+&%Z2P8F N[W.#K>'>WR
MPMM*'+5M+KD0DL& W)+CA$!*,7]D,IN58I$^^?H@.@/K\S)Z\D/5N%FB%*UI
MDLE0ZV+Y#'YI=D1#W#\ =='/%BK>]>4/7T$#/SH&^K,&[(YH_^N]O3AZ531I
M=95FH$#\[=?HR=[!WH$O]^IM^[6C>,B[I0,K#)2K;Q?X:YNM\K%%JSNAI0ZU
M5J%JGN*5.5FG9#*WZL4XP_;#:CHFNBS7)HA3K?S?L5FTR9$Y0D-3GRCEY>"!
M)Q+]_9>0*TU\2G-1<'Q@-G,KSPS.(2'\LI&9O*>C$(+UVE1&R'RYX$+UO:]'
MV-4'*8J[HQ12@<)0([7AH<CT*H6 KME/!.<(#E_BR:%[WN28Q$FWW))3G!L\
M_K44N<=WX=>=PH-6.5RGU_:/(T')@"$E/''/LZ) T7,1O=H]V8VV)@2D!8/%
M(H>$\7[W_>-UI0)A;S_Y?N\@6@X]L4T\Z+P)<?+?G!_^UW/L&O[CO[M%'_4L
M?X;Y;74GJ0(S&DFR!S8,]KI_LEN61/L-B/S->0B5EN.^=50YJ&FW9K(13M+\
M7?0&C479"F0(N,"NHKP R?-/E[0K]"9TP?.PT9$%RN.\R:<.]>>7X+?<IVW)
MA"B(%&M*(>CI3.8\<-9T.EX5KLNV:!<O//IQ$:7GQ&#8;:(XSY.T%.--JM(3
M*[5[0S@M5>O\,]N,61H2+N0%2=**J/#1F&+E^*(H9O@>N,]L/4GO;J:W.<IR
M!&2%*ZRG ABMB'84L =EH/A5H/_14(WH ^8]=+AB3R&?8U]2&2%P'WGWN=6N
M+P$&_N8SPL#?;&#@#0Q\@X)SI\"9GO N9T+T!.,\9,5Q72&1]ESW375]#4JY
M629(,V9#D_#RHL;6^J@S4U.@M,=B;-WE=A[U5KH-LJ6L$[A8E(?\AO H<4N'
MU\ 0S-.V_]:,A'5AK-C-"L7_Q4H\!X_CZ&#O8"]VF@@KU.IW4BXD_?R#06X9
M*B?J^(3F:9[D4])D]!*U1G9<7%&UG^B !K?O!U<9>.\L')WHTKH]6VV"?X9A
M[7;$Q(.",'Y-%"B</R_574 SJ8B&E-!G&^Z G_8J2]W)HF%<IR!F2S-KIOT5
M:& Q8M6QH$.NF]22^V42D8;'-86@3="Y!@,>NKW:LL5!J3$^/9I/F(/@QO*]
M.GO;0A'3WT4:)[FI4,E,*1(O!TEB=S#,G^M+<G,6KHO9(WW_IJ?EE3-7+94)
M;UJU=@BN]7$S[:$J1AT.8M8HL*QXF$ ?]*'QH!)U00W^81>G"\&R?JAM3;6J
MGI1HF7X/VF_PM\^W%T2[#M[YP^3'T>GYT>&K<71T!..;_/C9WW_R]O3PYQ&Z
M\HY?1&>C5^.;>O$Y9CKZ#\00GK7>Q!\.V2?VC9&\LD==EI/&9R_0H.U!??3C
MP>X^]Z_[OW F)0 .#^-N]*8;%!?[ZG9\XTF-Z-]4Y!]>O5)-S.]Q&R,=II7!
MH]:UXK0#]GA1U3-H6X+(5SWQ6G+$Z-J!:62W6APH(*2\T1U=&0R@Z&.]J? H
M4V\H *RHF546%4CZN;ZA8F'E(TY9&]T&/?L+T?11F&MP&;7#VR217/U8A\Z2
MM&GQK/B,B/X(MYZHM$Y@24_TF_@@G7?1WH\JA ]GPULG 2:C+\\P3G\W.@\B
M__INZ/:D4"EW']WGA+,B0-R-QN&TV/*\M#GLQM,U>./H*DU@ODOCW5T$HDW9
MXPMOGUX:XKT8CLW[L-F7/6;W8*>KK15&[4-B9U$[&IZG#UJ0N-,?PJ;6SB8\
MS*IN"O=9BUQ(MS[9MK_A5(L@IV,W>HN2H@(UJ9J+92+W,U(/Y<[H[147_DT5
MOHH>/-A]' <"28KA34&$V)?;4MWPIO%/9Y%%B7DX'-./@J4*)(>$LS98*R,3
MH3%8.?K&G4<?O)0<$/GBU&14:O*XP!)/[:*%00LBW6#AJ(2J/:$;?/!N^."W
MGQ$?_':##_YKX(-_D-K5TK%Z=#%4NP[$-R;_ 67K!0L125C^T]7_3ST[H2D8
MSLK!-\,:*MQ:0QKJ&R&[37VQTU [';YXD18+?<62A1 D)[:NP\#%_/V?OZ'^
MU,7[YJ"S>/O?KEF\='#Q$CBG%\A\M4QST0;L4AV"( ,-O6T>#"=4ONA+I[P'
M9_]?:ZG6K=54148:1$D9C^V'Z-JJZH?HS51.I$6M)891+)@;G5?9%)S:,V^]
M@;5;[J[#@Z2<LR?P2M27PQ&@/O?M#$N%UQ) W^'\N@?;+EST'5KU?[&MN&XO
M=OUEM]\0&E\6X_T.*#/J1=U&[[*/;?:X"AH\883?@@$A\N_?_9>]W?UOX_N%
M46[V^B?8ZU>WV>H'FZV^V>K_ZEM]>*=W%76*JW6<TBV5W*'#&FGQWG"$^=*\
MJLN&,:,884_;/#OR,9M7XK(\YDF]N$S-')U]B#I#%]X0A$0& W_UDIW1L%/E
MJ\W.^ 0[8_B^U^K;6M7-G^;;:FK8T&;Q/L'B#:_>C7E2(:YYES#(!V#"W14J
MF7PX5++6![ .+=&B6^[CT//2"J[>P"E_")S2Z_2Z@_(V6;7<8]*@U;4\Q<:
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M;P7CF!=<V'5*EB9#,D."NQ3@4$M2&6X+OR>?( R? %XW-W$(6;-7 *?ZPKB
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MZFK.P$#/Y@7FCBN$JRA7*EEEJYWC0A?O2N6Z"&?7=CL[ !0=;_R-IG8]74)
M=*Q DY&$]=QJA5%/9'$C?$YHP0JC$^6D0C<0K2$]]@[L5^LB6ZVI>1:XTTE!
MI*[ IIK+UB,H!$;?Y//DJBA)MH$NDK*J\VD2TFY),1>[S[0.((J!1U$]XC>Q
MSCR+Q\C4C"S-&MKUG ,*RE6Z"(X.F9VEOQQ%Q%NG,,*OO4F%E!'HFD/R<,[R
M SV@F7)F:5.O;$2(%NT2<'#S070BH59'.% -^ 2&I[U+7N\GH"<P0;@ Y5 L
M$#'OF?6P<TYQLF_HT?! "5O:+#:?BSTCU*RRPR$TE44+Z"AH$LC2!:EL'F[L
MQ>R[$1;]<8P]IV%T'],DOP@?Y9//Z:-\LO%1;GR4=]+EWJW5Y1+8%-&I$2R<
M%;KC N3^A WP)=)!."OH%DH54BR"L,P=TJ%,(76)^\#R=@/LM/@$^%"HP?00
M<+1-,<N=X_M&T2,+8Y,0$A"W+B:1XF^-1#*A3TQ^Y=Y0VEF]3)<!K#(0WR:N
MJC6*@\ 0'=I?"7#!&59>1SBW):JU0="-"P'LH-M!JQ/D]+ERAA5KN'XXWDT'
M7_CIP@@@9%.%2_.F;8*V.B=0H[K5>_5V;SO<7;$8X]!RL"$F7!>D$XSF3 S,
MCK(?<I?IGK4!D'& ;##9AJ<\+QAO@KFIV5/GH X_M>3,*_(=]%J9.@V_=)'T
MK![8MP8QA?81ER^%Y,%2O)!P.E17[1# VBUGEAI'4=Z Y4(@I1^AY640SVU[
MTAT8Y%Q\W27HVWARGKTVN>:T!UYW#%/K\EIWVL?--!#1^';W;'<@N5]\,,12
MW,>($=!=J4DBIY3_TR*SZ$2AK#HAI[*E9UTFCOOQ-1AJ_-@EHK\W$A&WAF8)
M,7 3$P;:D.//Y\4E%[!-+FBDPU*18V$W-!F?YN;,UF;1N<632_-6!A\S.S"_
MMJ588A6>5SH07UM"5,CD2P$TV071B%Z#OXAOQ=$4NSO6WZ2V2[<S.[;9?+UL
M!>ATGW9Q*A[/L08E#82)OOJF)/Q:SXZU!W$=FY+./X=H"V=21ZJRX T^5HD
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M1MK-0Q]\5V@T#&6J; 3AW03A<BVQ)9P] A :O&AD\]Q2'+*Q1!:\I[> ?4D
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M'',J#?-'D6KK*HIX_BR=8'47CX!G-1H.;;DQP )E$6D+:\>$-U!0,,OQ0W&
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M#UMDP[T$;D'O.%5Q'AWL[1T(*E:J+,G^ZAR,RPV]LY?A2P<C=7-&54C2;?O
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MBL/-*XD1OS'C3F_+9-_*%\E5DF8V6:O6V8:^_KEUEU$M\GD&,]-.7JZ+"ZX
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M9Q0^)1A96&-?F"GSI#[>CZ.#O8.#S=Z^V]Z^N%CKKC6PNFCSVO"E?I=K7K0
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M\&NPH')OH8A'@CZ\AFO/MDT9 UU-@C5_Y$(>\!K>\E4NBT#XG2TEND5_08O
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M:ZY2!]NQ938F>]3.MF\_>)FH6-8V6&"Q,CVE1%5.M4G[1J0V+G8AK:R^W=>
M.FHEU4PI?;V>XSL-#D>Q2&9<R@E6@S&&-HI6M<.%A)V;#';/"=US^-H]L,14
MO@?HV606'=Y01*>^(XQN>OA]L^:"" E$::V"+'ENS,P6W?+!QUC(QD[947]
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MZ8"P6^JV_;1,HL%%YVN>@*('?>6 UB+/V/W4GP4LKZ0%X2FP<S_4:UXL&MC
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M+ZEN\;P%H79^ZR-&>/,M]-4NLZJBHM&E,[?WD;"<Z0!F7PD[6^U&1QS:)T%
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MT[0, NFZRTM9SJ[$Q#HL*N$+YSA9AS90QS;Y$J3N]HJ%W'TYKIXY?)K;+/.
M:+VN5W'G-T&3'[P1):TG8)4"5 Y1^IRU!]OK);QUY"KX@'0=6L-@ HSCTF0!
M:@O**VDDIX J(E/N$,1/R!&.+U3 DBQCI=]H'>TJ7,_J:%5"&:*H$88CE/Z+
M1615X9=<^&K;9W7.U?$?Z"(1A4WP])EK)+6+(7PR!/E[-V973!4)RFKY#;(
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M8!;_S+)9^TLZ.>*'^ZYWSBZ?20YKB4BA8HD S,A32KH4^1@.M.Q;=T84@[%
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M]Q@_O6I5+^R%;3* 6(%S5(.'H8TRI%4?NF%7V5CX-GC0/K5-Y?][\/_G^0W
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M>D_;21\IS''+I:T,^0\$[2)0ZY1AP<V<?.N,FU-;W79[0!D$]JYR8Q&R"]Z
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M\A 08 =U6="FY_=][N@F9TRHR K!LRRM_(3&KDXY+DEM(^-[@3W2/KA'\$<
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MJBERBA _.,LND-;X9Y+#WN:X2CL, 5(<1":C6_ZN\'>S5"&]S+-<:5L@&F?
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M8<\W4I4Q]@VBKQRYY:ZD0Q#.NT#AWU.I(:35DK;-@:U@ZVQL(ZECM#"85[A
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MF6(1&?]P33(VWJYZH4<WJS]RPKG,7;4)S[7@$*Y=;IEE$R*F$BDZ,\:OS]3
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M4*L GP(FUAL2-&]H>^ P4U'.>5V24;6JHSR2M%N]NY!X.8T5Q^TA[::R*_$
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M^7"->VP_[2@L"+,PV,AC_8SK7!T9':B?6MPHIB;M?$N;3X_)1I,!KO/7=.^
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MK6E(5D.+NG(1L.KW:4K-EHF_BT7<U?E$SR"3@@9T-7NRN#$.UR].2.D)NFM
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M/J;U&]>B=H3)F7S28M&B.)EICW4:L\<GQ?KRTXP$"RD9V!E$28JS)L:]%GM
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M>!!;>M">2 >L=2YA,QX^HYLW^^V0NP5O?;M/X;KF=%<)?2K:'#;5W(565W*
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M@UN%ET2\W:6%:*5!;<@^&E\-@G6O9#\,+/+$,$X2UK6[]?SY#[@;S_$?C:W
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MX,-4B49S+8-$G:;2)-;'6'#V;5Y7Q!AL).*8XXS '^A?@S://T*128YM]^'
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MJ@DA0:3LD (##:?#^"NAK8QX', !_-$H'#2J+'K_A]2&EQ5:K#C8QNIG#4_
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MIGQF]MA(:4 DYB"9: BS!ZF5TVH;FZ! --C?_6:3_H%Q/+J\T KPW&]^-&>
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MUG;8J+R3$SA_:W,/[;(9#-9,=2YBG3BE0IR7'"BO=<1X\6Y'SCKJ!AX3B\>
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M 'M2GX+E"DK"OW1+7'=>89+Z57PA0B6W'I<4NC1#&Q_+THO3WU!+ P04
M" "Q12U5M-VPK=L$  !.+0  %    &YB>2TR,#(R,#DP.5]D968N>&ULS5I=
M;^(X%'U?:?]#)OL<0F"Z.Z!A1H@R([3M%!5&N]J7E4DN8(UCLXY3X-^O'3Y*
MA]@QM(GR B$^N3[G^NOFM!\_;V+B/ %/,*,]-V@T70=HR"),%SWW^\3K3P:C
MD>LD M$($4:AYU+F?O[TZR\?WWG>5Z# D8#(F6V=Z3*E$?!;%H,S9EP@XGA.
MQP_:?JO9:CFM;G#3;=XX_7O/4X\33']TU<<,)>!(&C3)?O;<I1"KKN^OU^O&
M9L9)@_&%#-%L^P>TNX>KUD@<'S@%W_B[QB/T+/2ZG6&#3J?C9ZU':(+S@#)H
MX/]]?S<)EQ C#U.5DU!Q27 WR6[>L1")+)&%$APM0OWR#C!/W?*"EM<.&ILD
M<H^)0SSDC, CS)W]Y??'T7DF,!5^A&-_C_$1(9)P%F')8:XE>DB?ZO]&]?S;
MR9-BNY+3(,'QBH#KOY92Q&*$J1=#/ -^);G<&&],$\= U2KQ=IU=RU03YFW)
M+F4T'J8S\([]7<G7$*FT_,(<I42\/L$OXVCH'KC^3%3U1&?;1LCB;/]J=IH=
M/V,JU[T V8F00QBFV87<'#WYC<56[@MSQN-L&WBI0 ;S#H$RIA?'T2B0.C'%
M"G@G?^ZQBFD96G8<8"- [O4G^Q%AX=EX)8?Q3B!L+-B3'P%6_0?_O5>7WNYR
M-VJ _QUFG=Z^6!8$S8#T7%WSC@U1VR[C)RFIEDW^3"N%U>U^E$;/(S-%,P(Y
M#(N@U;*44Q-&<JHE=DS/X"6RO8,%(KOQ[&]P'D$-HH(,3F47AHR=-E? 9@P<
MLVA(HUNY:QAHY>)*7ZN/L,")X(B*;RC.HV>"E<YN)*MJOF(\F]X3M>T.6$H%
MWPY8I"=K]53IW+]@ M_2T]KJC.@YI'164[091>JDFN-=V5U L0!?.M]^%'%(
MDOV7VN$"+5<#MBJ> WGYP*=LK3_^M,BJ.&8KXH&/.7O"NW<Q(U$-O"JV8R;+
M+?(/7AF7O E<(E,UB'T.2,,MK[G,,UD&)>,EH_I]1P<ID=5?' M9^ Y8'*=T
MOXGDU0M&7(G\)HS@4+X)T,6]G.@<(Y)#3@\JD=F8@\H&R%67U2WJ[8$_S.>Y
M(UL,KH[I*$E2X!?QU3Y2YLA#F,I)MPU:LRD6N>\#.DB)K*8<*2-QLHUG+&\J
MYK97D*7A)EPBN@!-G6B"E7Y6#&/@"YF4KYRMQ5+.JQ6B6^UA8427R+4O)WJD
M)OL7@A8Y['+;2\_=0';($1G)E;?Y$_19T^!T_)X-ECX/'<;ENNZY3?E49CUU
M0\(2B'JNX.EQFNQ=K>MMQ3EGL?GEDQ79(K*+(A'!FXMXZ81<I2+?3CFHJ6)0
M#*;GLZ)"?X59F ?/JJ[3M;_)J("-&)+L_.FY"2S4Q<6Z3SQ^H\YS=X9=XCE5
M.#'S_B[P.FGGEHN%G%9MY1BL&@M=[=KI*O9X+&2]KZFL"]P@"Y4W-56ILY(L
M)/U>4TE6UI.%OC]JJJ_0KK+0]J'>VG0FEX6R3KV5&5TQF[/ZK4KADO09G#0;
M=?4K1?1>G(V>^M4B9B?/1E/]ZA +"]!&6/TJD2+[T$95_2H/6\O11EW]BI#+
M#$H;C?4K1,SVIHVF^A4@!G_41E#]ZHYB9]7F9;JN]8:%&6LCKWX%A\'-M1%4
MOXK#P@8^\1O]G[3)L#\^'>^K#_6ONO+._U!+ P04    " "Q12U54=E<'OH%
M  "K/   %    &YB>2TR,#(R,#DP.5]L86(N>&ULS9MM;^HV%,??3]IW\-B;
M36J:0M=)5&VO4&_O%5J?5*@V[6J:0F+ 6N+#'-/"MY_M\!2P0T*QLS<ED)/S
M/_S/+[&=T*M/LR1&;YBE!.AUHWEZUD"8AA 1.KINO/:\3N^VVVV@E <T"F*@
M^+I!H?'IYOOOKG[PO*^88A9P'*'!'/7'4QIA]AD2C)Z!\2!&'FK[S7._==9J
MH=9E\^+R[ )U'CQ/'AX3^L^E_#,(4HQ$&315;Z\;8\XGE[[__OY^.ANP^!38
M2*0X._>7T8U%N-P;\=4!F\$7?K9S%;J3^OU<Q3;;[;:O]JY"4Z(+%$F;_A\/
M][UPC)/ (U1Z$LI:4G*9J@_O(0RX,G+O5T#&"/G.6X9Y\B.OV?+.FZ>S-&JL
MC&,0XQ<\1/+U]:5K5&S[,L*G>"3;=!\,<"PJ5BG&# _UQ\6,Y0Z35;1E%<U?
M914_ZK+Q^42PD9)D$N.&_\$ZGS$C$-W1(Q>L3VNA\AX/&+=1^V[BHU;?!W'6
M'K?NW93'K5A<NO"1*]Y)>=2*'_&1R=A.>*QJ#RB3[Y98JK98QMR+K4683%=P
M$55JBTOV1EH\XUB,0!M7R1C"G?+3Y4B1XO!T!&]^A(D<H9K__B(WO6Q352_>
M_GU'.>%S,:@%A"[E5+G7#=/NK)I8#@; MK]E<0HOWG2KE V[]C*<PI2%V3 I
ME.10CJGWVFO<9%KH6Z;VUY6_+B9?9H<MG0M8N*>.180?@A@/)SS_'88,D@*K
M8)\'V5<2$LK((S;V7IP]<:;;F9%4TUM#1,7V;F6QW6$EAY9]EHINNVPR#4JX
M8:W7GR&<)ICR+AT"2]0<35QM<)?C1-?X,N$5*2A*:1N)I3;:$$??I#Q2^FX!
M*64N5'7-)3K]8!#C<MCD0C^.C$I7#RY*NG92\GZ:*=$899V0OA HH&)S]X$D
MR!2NNG^"I%HM_<XY!?LLL-[7U:KQLYAM%S18&W=@IW.YW+4\DQ6SAPA)X5JZ
MK[<12OMCC8=LUO*"1R3E+*#\,4AT.!2%';0RR*=RLT(X06M5)&5K6"D8+(2R
MWE@&H4M#8!-@:KSI<<'A+4PI9_-;B,Q<E#KJ($P*,[NB)E?$"5)E(&!H40J2
MM=2 4CG7X4 [+8/VA<3X<9H,,#-2M1MR$$+K-*YXD8HHDZP!"XUM4,8/RPWO
M![-N) 8Y,B39\X0]W=\3?Q *AIRNN!#R**]?'R7[[(7*OEGFIQ-%PN)T\2(7
MS$TC.P6Q!W&CR>>*F87F:@.I.QQ/M(X!I\A6J.27&U9NQ>83Z\.[^1ZW,?(C
MG*RS.:=$2LNIB12OCQ"-G3H^3#ZYH4--?Y[8,X,WDCWR+FRJ(?PCG&RE= [+
M:B*[K* ^8DSNZK IM,T-.\^0\B#^DTP*ET5%P1_A)I?0.369.A+R=2U\"GW5
M$5-@F#5>Y,6MPW!@($2WNR(3FREL4Z#&%2GFON=:IV"?!?:>L(KVQ,]CH.;E
MJRFDZC/6K336'[)*/:0$ZUB7&%V#,G98Z_?OC'".Z2TDR90NEC^ZQZN%<14[
MK\UEN_T+4917=8I L8=0VAQK,/0@)B'AA(X>Q!R$D2#6D& .JHC!;B+;#*P5
MT5+2*0 %UD$Y3ZRU_IEAB1P6]:M'=O)'6>QI.-2. /N#*Z)@3F@;":'LA1O2
M*--&2MPI'"5,A6INN8*EFZ93S"HA8SSD8^#LI'6.3U;!_X8BL\]ZEO88:&_D
MP>%4#'SS9FO0)US[2QU32-519RN-;4*4"((A:K9^&OR,EO)NQQV3=5#&$VM-
M[[- _L]*;YX,0#?3T.ZOV.Y<#NN]SL10IN:TQ7JO8*\)UL_HNUDX%AYAPR\O
MBL(./+,W4UF?42XTT5+4_0\O"AV$LM98OK%XEV V$@A^9?#.QV+$F01T;KRS
M6!A]T*U%;497]Q:7XBA31POY&FXM%AL+%1VSQDQ'3$4B.1WY$@<C#27:_16Y
MR.6P3<)*#$DUIXW7>P5[3;!\0;@5HBR(NV*B.?L-FR\%AKB#+@);N5R=_@M9
MI'21$*[AQ#?9"*7]V>%AXTO<BZV;]4<D^S]8\<E_4$L#!!0    ( +%%+56K
M)@,>=P0  .(M   4    ;F)Y+3(P,C(P.3 Y7W!R92YX;6S=6EV/XC84?:_4
M_Y"FSR&$V6D7M.P*,;,K5&8'#:Q:]:5RD@M8Z\34,0/\^UZ;CV5$G'BD!FG\
M0CY\8A\?7\<WQWSXM,V8]PRBH#SO^U&K[7N0)SRE^:+O?YL&@^EP-/*]0I(\
M)8SGT/=S[G_Z^/-/'WX)@B^0@R 24B_>>;/E.D]!W/$,O D7DC O\+IA=!-V
MVIV.U^E%M[WVK3=X" +U.*/Y]Y[ZB4D!'M+("WW9]Y=2KGIAN-EL6MM8L!87
M"ZRB?1,>T?X!KDI3>7K@''P;[@M/T(NJ-S<:&W6[W5"7GJ %+0-BI5'XU\-X
MFBPA(P'-E2:)XE+07J%OCGE"I!:RM@N>$:&N@B,L4+>"J!/<1*UMD?HGX01G
M\ 1S3QV_/8U>M)C'NU;",RU[N]ONA@H4(ET)&>0R2'FRUB<XI@$>J=QA=^9<
M9)H]]D@WL10PQ]&.=\&Q(D7AUU?7(W<KC)J"9BL&?GCJP4I @0]IZ!AO'-"*
M:Q.]V;. K00,TC,A&4]>]%>U7!R#J8"DM>#/80I4M1_]^TZ=!OM3K09>_G.O
M&\6X)_34'",QL+YO*MZS82I>N#@3Y7]@,X8%8?LV!UM:E! R(!KD='<8H]&/
M<9F1F$$)N3KH=5EB8,(( ZU,1AOX%=C.L(D*=N?%5V S 4%Y>I^G=S@_*VB5
MXAKDMP_W)UC00@J2RZ\D*Z-7!6N<W0@77K'B0H?25+W@AGR=2[$;\M1,UNJI
MQKE_I@R^KK,8A)'H):1Q5C.R':5J39C3_<I<0[$&WSC?09KBJE@<#NIM$AFY
M5F"OQ7.(IX]BQC?F9<^(O!9'/2,>Q43P9[I/URJ)&N#78COAF-BPO^FJ<LI7
M@1MDJ@9Q(( 8N)45-YGG8*5LLL1/$N.D-D$:9/6GH!)3S"'/LG5^>(F4)0^5
MN ;Y33FC"97X>?> @2XH827DS* &F4T$*#7PZU/G]3.5IXO'^;QT9.O!UV,Z
M*HHUB%?Q-3[2Y,A#LL:@VT6=>$9E:>YM@C3(:B:(\AJFNRSF9:%86GX%E>ZW
MR9+D"S#DB56PQM>*^PS$ D7Y(OA&+C&N5B3?&1>+2G2#7 <8Z*D*]L^,+$K8
ME98WKMT0&Q2$C7#F;?\ LVH&G(G?N9DQ$(G'!<[LOM_V/2S!^2T@'>^;,/H^
MVM;0/+ Q[5WU$L8+2/N^%.M3=!&17%@D+RLZ(,(5$<H629:4I<>GYX)GU28
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M?(?Y4TX;S'_V/?S-T.<QHQ7R2K%]?OFK#83BQ[3 ZAFF *?(RW\&?A:G[X
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M7PG^ 7#/H\G$3Q)469' F$"GU[F7R\Y-Y[;#+B;3()J!DO4-D<.F4?8IZM2
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MVS>37I:VB*A%-0 FMZ]7R@X"+=&1N*6XJ$0]HS]#([HB3IOI<7/DA6:1%2X
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MP@QF0K<W%PU+Q%! &:_OR.TF(O^6F,L!A*RHC.T%BL=O2T"L] 7Z"9E<*3R
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MZE7*XP0&M],%03<S?*-U8FTUE.DGN5,J@8,H(&ZDRG-VOEG"P=J[NT+>W:8
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M[*\-+,<=\S2/SU>#EKH&E.O!0A(L"U>$T<Z*J65%H:/3/JT.+0WI554]+>U
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M&IH=RRIP#3I!KP/R- D5WQ_"UC;WWB39M"'RCH*M+3T/O;[*62 ^@\Z5%*_
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M 0 -              "  0    !E>%\T,C(R,3(N:'1M4$L! A0#%     @
ML44M578XJX]:1@  ])X!  T              ( !.TT  &5X7S0R,C(Q,RYH
M=&U02P$"% ,4    " "Q12U5HJJBT(1&  !YK@$ #0              @ '
MDP  97A?-#(R,C$T+FAT;5!+ 0(4 Q0    ( +%%+54QN(U2)T8  ""2 0 -
M              "  6_:  !E>%\T,C(R,34N:'1M4$L! A0#%     @ L44M
M56$1/4J?1@  (98!  T              ( !P2 ! &5X7S0R,C(Q-BYH=&U0
M2P$"% ,4    " "Q12U5<>G T=Q&  #&G $ #0              @ &+9P$
M97A?-#(R,C$W+FAT;5!+ 0(4 Q0    ( +%%+55WGQ&H!$<  ,.> 0 -
M          "  9*N 0!E>%\T,C(R,3@N:'1M4$L! A0#%     @ L44M5:*@
M9]':-P  ]SP!  T              ( !P?4! &5X7S0R,C(Q.2YH=&U02P$"
M% ,4    " "Q12U5\N@UJ; V  !W- $ #0              @ '&+0( 97A?
M-#(R,C(P+FAT;5!+ 0(4 Q0    ( +%%+568<KAVWJT  &H0!  -
M      "  :%D @!E>%\T,C(R,C$N:'1M4$L! A0#%     @ L44M57*O*^=V
M5@  "'$"  T              ( !JA(# &5X7S0R,C(R,BYH=&U02P$"% ,4
M    " "Q12U5<G.-P^(&   9'0  #0              @ %+:0, 97A?-#(R
M,C(S+FAT;5!+ 0(4 Q0    ( +%%+548@1%AO@\  !]7   -
M  "  5AP P!E>%\T,C(R,C0N:'1M4$L! A0#%     @ L44M50>K^ [D$
M=F0   T              ( !08 # &5X7S0R,C(R-2YH=&U02P$"% ,4
M" "Q12U5UL20ZM01  "!4   #0              @ %0D0, 97A?-#(R,C(V
M+FAT;5!+ 0(4 Q0    ( +%%+57M5[36=@,  "<.   0              "
M 4^C P!N8GDM,C R,C Y,#DN>'-D4$L! A0#%     @ L44M5;3=L*W;!
M3BT  !0              ( !\Z8# &YB>2TR,#(R,#DP.5]D968N>&UL4$L!
M A0#%     @ L44M55'97![Z!0  JSP  !0              ( ! *P# &YB
M>2TR,#(R,#DP.5]L86(N>&UL4$L! A0#%     @ L44M5:LF QYW!   XBT
M !0              ( !++(# &YB>2TR,#(R,#DP.5]P<F4N>&UL4$L! A0#
M%     @ L44M5?^VY9?T,0  85,! !(              ( !U;8# &YB>3(P
C,C(P.3 Y7SAK+FAT;5!+!08     %  4 +D$  #YZ ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
